[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"\"}":3,"_public_publisher_byId_ebaab0e5-f88a-47b8-809b-fd5227189687":656,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"totalCitation\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:ebaab0e5-f88a-47b8-809b-fd5227189687,\"}":736},{"meta":4,"data":6},{"total":5},"117",[7,60,176,207,299,413,445,480,543,572],{"id":8,"createTime":9,"updateTime":10,"relativeEntities":11,"slug":12,"properties":13,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":29,"subjectFields":30,"manageAffiliations":31,"indexDatabases":32,"url":33,"thumbnailPath":34,"statistic":35,"gsStatistic":26,"type":26,"analyzePriority":26},"5a09599f-54d1-44c3-8f16-3847ac552024","2023-08-17T04:28:50.832+00:00","2025-10-13T23:58:52.517+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Truy%E1%BB%81n-nhi%E1%BB%85m-Vi%E1%BB%87t-Nam",{"country":14,"issn":16,"introduce":18,"title":21},{"VOID":15},"VN",{"VOID":17},"08667829",{"EN":19,"VI":20},"{\"ops\":[{\"insert\":\"Vietnam Journal of Infectious Diseases is a social - professional forum of the Vietnam Society for Infectious Diseases, whose responsibility is to introduce the researches, the scientific advances in Vietnam and from the world; to contribute to the improvement of knowledges for health care staffs about clinic, treatment, guideline, prevention, epidemiology for infectious diseases, HIV\u002FAIDS and community health care; to provide, exchange and publish scientific information to the public accurately and promptly.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Vietnam Journal of Infectious Diseases publishes in the whole country; serves the professional work for researchers, clinical staffs, administrators, undergraduate and postgraduate students who are working and studying in the infections, tropical diseases and HIV\u002FAIDS from central to local levels, also organizations and individuals in the world who are interested in infectious and tropical diseases and prevention for HIV\u002FAIDS.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Editor in Chief:\"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"insert\":\"Prof. Dr. Nguyen Van Kinh. - Chairman of Editorial Board\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"Prof. Dr. Nguyen Van Mui.\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Headquarter:\"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Address:\"},{\"insert\":\" Level 6, National Hospital for Tropical Diseases, No. 78 Giai Phong Street, Dong Da District, Hanoi city, Vietnam.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Tel:\"},{\"insert\":\" \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:02435765464\"},\"insert\":\"02435765464\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913552672\"},\"insert\":\"0913552672\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913228072\"},\"insert\":\"0913228072\"},{\"insert\":\".\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Email\"},{\"insert\":\": \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Findex\u002Fadmin\u002Fcontexts\u002Fmailto:tungphamvan52@gmail.com\"},\"insert\":\"tungphamvan52@gmail.com\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Fmailto:tapchitruyennhiem@gmail.com\"},\"insert\":\"tapchitruyennhiem@gmail.com\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Bank account:\"},{\"insert\":\" 0021000275119, Vietcombank Hanoi Branch. Transaction office No. 7, 402 Tran Khat Chan, Hai Ba Trung District, Hanoi city, Vietnam.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}","{\"ops\":[{\"insert\":\"Tạp chí Truyền nhiễm Việt Nam là cơ quan ngôn luận của Hội Truyền nhiễm Việt Nam, chịu sự lãnh đạo, chỉ đạo trực tiếp của Thường vụ Ban Chấp hành Hội Truyền nhiễm Việt Nam; sự kiểm tra, giám sát về nghiệp vụ báo chí của các cơ quan chức năng quản lý báo chí thuộc Bộ Thông tin và Truyền thông và Ban Tuyên giáo Trung ương Đảng.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Tạp chí có trách nhiệm giới thiệu các công trình nghiên cứu khoa học, những tiến bộ khoa học trên thế giới và trong nước, góp phần nâng cao kiến thức khoa học cho cán bộ y tế về lâm sàng, điều trị, hướng dẫn, dự phòng, dịch tễ học các bệnh truyền nhiễm, HIV\u002FAIDS và chăm sóc sức khỏe cộng đồng; cung cấp, trao đổi, phổ biến các thông tin khoa học tới công chúng chính xác và kịp thời.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Tạp chí xuất bản 03 tháng\u002F01 kỳ và được phát hành qua Bưu điện và tự phát hành trong phạm vi toàn quốc.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Lãnh đạo Tạp chí: \"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"insert\":\"Tổng Biên tập: ThS.BSCKII Nguyễn Trung Cấp\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"Phó Tổng Biên tập:\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"            TS.BSCKII Phạm Ngọc Thạch\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Trụ sở tòa soạn:\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Địa chỉ: Tầng 6, Bệnh viện Bệnh Nhiệt đới Trung ương, 78 đường Giải Phóng, phường Phương Mai, quận Đống Đa, thành phố Hà Nội.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Điện thoại:\"},{\"insert\":\" \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:02435765464\"},\"insert\":\"02435765464\"},{\"insert\":\" - \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913228072\"},\"insert\":\"0913228072\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Email\"},{\"insert\":\": \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Findex\u002Fadmin\u002Fcontexts\u002Fmailto:tungphamvan52@gmail.com\"},\"insert\":\"tungphamvan52@gmail.com\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Fmailto:tapchitruyennhiem@gmail.com\"},\"insert\":\"tapchitruyennhiem@gmail.com\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Tài khoản:\"},{\"insert\":\" Số 0021000275119 Ngân hàng Ngoại thương Việt Nam, chi nhánh Hà Nội (Vietcombank Hà Nội). Phòng giao dịch số 7, 402 Trần Khát Chân, quận Hai Bà Trưng, Thành phố Hà Nội.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}",{"EN":22,"VI":23},"Vietnam Journal of Infectious Diseases","Tạp chí Truyền nhiễm Việt Nam","PUBLISHER","VERIFIED",null,"Admin update database","PENDING",51,[],[],[],"https:\u002F\u002Ftruyennhiemvietnam.vn\u002Findex.php\u002Fvjid","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F5a09599f-54d1-44c3-8f16-3847ac552024\u002Fadb0e52bf25e0de580fd4289519cb8bf.jpg",{"impactFactor":36,"impactFactorByYear":37,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":41,"totalPublicationByYear":42,"totalCitation":48,"totalCitationByYear":49,"totalCitationPerPublication":54,"totalCitationPerPublicationByYear":55,"hindexLast5Year":59,"hindex":59},0,{"2022":38,"2023":39,"2024":40},0.01,0.03,0.13,315,{"2020":43,"2021":44,"2022":45,"2023":46,"2024":47},63,58,57,65,72,43,{"2020":50,"2021":51,"2022":52,"2023":53},8,15,9,11,0.14,{"2020":40,"2021":56,"2022":57,"2023":58},0.26,0.16,0.17,3,{"id":61,"createTime":62,"updateTime":63,"relativeEntities":64,"slug":65,"properties":66,"entityType":24,"verifyStatus":25,"verifyTime":78,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":79,"subjectFields":80,"manageAffiliations":81,"indexDatabases":136,"url":137,"thumbnailPath":26,"statistic":138,"gsStatistic":155,"type":175,"analyzePriority":26},"25b6bd10-676c-40c0-8dc3-356d1679a284","2023-05-19T02:22:33.430+00:00","2026-06-18T23:33:57.141+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Y-D%C6%B0%E1%BB%A3c-h%E1%BB%8Dc-C%E1%BA%A7n-Th%C6%A1",{"country":67,"issn":68,"introduce":70,"title":73,"gsId":76},{"VOID":15},{"VOID":69},"23541210",{"EN":71,"VI":72},"\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">04\u002F10\u002F2015 Ministry of Information and Communications allowed Can Tho journal of medicine and pharmacy to operate (102 \u002FGP-BTTTT)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">07\u002F16\u002F2015 Can Tho journal of medicine and pharmacy is internationally recognized: ISSN 2354-1210\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">In 2016, The journal has been included in the list of medical science journals by The State Council for professorship which is awarded a work score of 0-0.5 points for a published article.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Can Tho Journal of Medicine and Pharmacy welcome original works that haven’t been submitted or published in other medical journals. Posts must contain content related to one of the journal’s categories.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The content published\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The journal is divided into 3 categories:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Scientific research article: are valuable scientific works, which have been researched and accepted.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Overview of medicine, biology and pharmacy: serving the objective of continuing training in the fields of medicine, biology and pharmacy; to systematize classical and modern knowledge.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Update information on new knowledge about medicine, biology, pharmacy in the country and in the world.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Scope\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Publication and introduction of scientific research in the fields:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Medicine (internal medicine, surgery, pediatrics, obstetrics and gynecology, odonto-stomatology, laboratory, oncology, traditional medicine, nursing).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Biology (genetics, biotechnology).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Pharmacology (pharmaceutics, drug quality analysis-control, synthetic pharmaceutical chemistry, biochemistry, pharmacognosy, botany, clinical pharmacy).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- To enhance the quality of undergraduate, postgraduate education, scientifically researching and meet the necessary treatment in hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Introducing the updated domestic and oversea information about science technology to promote scientific research and exchanging technology in local, other universities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Exchanging pharmaceutical and medical information for social health developing in the Mekong Delta and Vietnam.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The object\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Postgraduate students, student of Can Tho University of Medicine and Pharmacy, scientists from schools, research institutes, hospitals, health centers, pharmaceutical companies of the Mekong Delta; other provinces and regions in Vietnam and other country.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Address\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Headquarters of Can Tho Journal of Medicine and Pharmacy, located Scientific Research and International Cooperation Office: 179 Nguyen Van Cu Street, An Khanh Ward, Ninh Kieu District, Can Tho City, Vietnam.\u003C\u002Fspan>\u003C\u002Fp>","\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Ngày 16\u002F7\u002F2015, Tạp chí Y Dược học Cần Thơ được cấp chỉ số quốc tế: ISSN 2354-1210.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 4\u002F2016, Tạp chí đã được Hội đồng Giáo sư ngành Y đưa vào danh sách các tạp chí khoa học Y học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Năm 2020 Tạp chí Y Dược học Cần Thơ đã được phê duyệt vào danh mục của các Hội đồng Giáo sư ngành Dược học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ ra 12 số\u002Fnăm, 180-200 trang\u002Fsố.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 12\u002F2022 Tạp chí Y Dược học Cần Thơ là thành viên của hệ thống Crossref và từ tháng 01\u002F2023 tạp chí thực hiện bình duyệt online kín 2 chiều nhằm tăng tính minh bạch, tin cậy của các công trình nghiên cứu khoa học và đảm bảo tốt nhất chất lượng khoa học của bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ, mục đích và phạm vi của tạp chí\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ và mục đích hoạt động của tạp chí: xuất bản nhằm mục đích phổ biến kết quả từ các đề tài nghiên cứu khoa học; giao lưu trao đổi khoa học, chia sẻ kinh nghiệm, học tập, đồng thời cập nhật thông tin khoa học mới trong các lĩnh vực y, sinh, dược học trong và ngoài nước.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phạm vi của tạp chí: Tạp chí xuất bản được chia thành 3 chuyên mục: (i) Bài báo nghiên cứu khoa học là kết quả công trình nghiên cứu khoa học có giá trị đã được triển khai nghiên cứu, (ii) Bài tổng quan y, sinh, dược học: phục vụ mục tiêu đào tạo liên tục trong lĩnh vực y, sinh, dược học; nhằm hệ thống hóa những kiến thức kinh điển và hiện đại; (iii) Thông tin cập nhật kiến thức mới về y, sinh, dược học trong nước và trên thế giới.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Chính sách truy cập mở\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ áp dụng chính sách truy cập mở đối với các bài báo đã xuất bản đến với độc giả, nhằm mở rộng cơ hội tiếp cận các kết quả nghiên cứu chất lượng cao và tăng cường trao đổi kiến thức. Tạp chí đăng tải trực tuyến (miễn phí) toàn văn các bài báo được công bố trên website của Tạp chí (https:\u002F\u002Ftapchi.ctump.edu.vn).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đạo đức xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ cam kết tuân thủ đạo đức xuất bản phù hợp với các hướng dẫn và tiêu chuẩn của the Committee on Publication Ethics (COPE), tuân thủ các nguyên tắc của COPE’s Core Practices, Best Practices Guidelines for Journal Editors và Guidelines on Good Publication Practices.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Bản thảo bài báo chỉ được chấp nhận khi được tác giả chịu trách nhiệm chính cam kết các nội dung sau: Các nội dung của bản thảo chưa được đăng tải toàn bộ hoặc một phần ở các tạp chí khác; Tất cả các tác giả đều có đóng góp một cách đáng kể vào quá trình nghiên cứu hoặc chuẩn bị bản thảo và cùng chịu trách nhiệm về các nội dung của bản thảo; Tuân thủ các biện pháp đảm bảo đạo đức nghiên cứu (ví dụ thỏa thuận đồng ý tham gia nghiên cứu).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Cam kết bảo mật\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí cam kết thực hiện và tuân thủ các quy định của luật và các văn bản hướng dẫn liên quan đến bảo mật thông tin cá nhân trên không gian mạng. Các thông tin mà người dùng (tác giả, độc giả, biên tập viên, người phản biện) nhập vào các biểu mẫu trên Hệ thống Quản lý xuất bản trực tuyến của tạp chí chỉ được sử dụng vào các mục đích đã được tuyên bố rõ ràng và sẽ không được cung cấp cho bất kỳ bên thứ ba nào khác, hay dùng vào bất kỳ mục đích nào khác.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phí gửi bài\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng bài: 1.000.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng nhanh: 1.500.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với tác giả là cán bộ viên chức thuộc Trường Đại học Y Dược Cần Thơ thì được hỗ trợ 50% lệ phí gửi đăng bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với sinh viên thực hiện đề tài nghiên cứu khoa học cấp trường được hỗ trợ 100% lệ phí đăng bài ( Tác giả gửi đính kèm “ Quyết định về việc giao tổ chức thực hiện đề tài nghiên cứu khoa học cấp Trường của sinh viên”).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Hình thức nộp lệ phí:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Tiền mặt:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Nộp trực tiếp tại Phòng Tài chính - Kế toán, Trường Đại học Y Dược Cần Thơ, số 179 Nguyễn Văn Cừ, P. An Khánh, Q. Ninh Kiều, thành phố Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Chuyển khoản:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tên Tài khoản: Trường ĐHYD Cần Thơ, Số TK: 0111000115668, tại ngân hàng Vietcombank chi nhánh Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Thời gian: Áp dụng từ ngày 01\u002F02\u002F2023.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">* Phí gửi bài không được hoàn trả khi bài viết bị từ chối hoặc tác giả xin rút bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Quy trình phản biện bài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ thực hiện quy trình phản biện kín hai chiều nghiêm ngặt. Danh tính của những người phản biện không được tiết lộ cho các tác giả và ngược lại. Quy trình thẩm định bài báo đăng gồm các bước sau:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tiếp nhận bản thảo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tác giả liên hệ gửi bản thảo đến Tạp chí qua hệ thống trực tuyến tại website: https:\u002F\u002Ftapchi.ctump.edu.vn. Hướng dẫn về cách đăng ký, gửi bài và chuẩn bị bản thảo được cung cấp trên website của Tạp chí.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sàng lọc sơ bộ\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sau khi Tòa soạn nhận được bài báo của tác giả, Ban Thư ký sẽ tiến hành kiểm tra sơ bộ bài báo (các yêu cầu về nội dung và hình thức). Những bài báo không đúng quy cách hoặc có nội dung không phù hợp hoặc vi phạm bản quyền sẽ bị từ chối (Ban Thư ký thông báo phản hồi đến tác giả trong vòng 1 tuần). Những bài báo đủ điều kiện, được Ban Thư ký tòa soạn chuyển đến Ban Biên tập có cùng chuyên môn với nội dung bài báo để đề xuất người phản biện. Thời gian kể từ khi Ban Biên tập nhận bài báo đến khi đề xuất người phản biện bài báo chậm nhất là 5 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Vòng phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký gửi bài và yêu cầu phản biện đến 02 phản biện độc lập.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Các phản biện gởi nhận xét cho Ban Thư ký. Thời gian từ khi gửi bài cho phản biện đến khi nhận ý kiến của phản biện tối đa là 20 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xử ký kết quả phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Nếu ý kiến đồng ý cho đăng và không cần chỉnh sửa, Ban Thư ký tiếp tục đăng bài theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Nếu ý kiến đồng ý đăng và cần chỉnh sửa, Ban Thư ký sẽ thông tin đến tác giả chỉnh sửa theo yêu cầu của người phản biện. Thời gian chỉnh sửa và gửi lại kéo dài không quá 2 tuần, từ khi tác giả bài báo nhận được thông tin (Quá trình này có thể lặp lại tối đa 2 lần\u002F1 bài báo). Khi có sự thống nhất, đồng ý của người phản biện; bài báo được tiếp tục đăng theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Những bài báo có chất lượng không đạt yêu cầu, cả 2 phản biện không đồng ý cho đăng sẽ bị Tòa soạn từ chối đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký tổng hợp các bản thảo đã được tác giả hoàn thiện sau thẩm định trình Ban Biên tập xem xét, Tổng Biên tập phê duyệt, quyết định bài đăng theo các tiêu chí: sự phù hợp nội dung với tôn chỉ và mục đích, thể loại bài viết (ưu tiên các bài có bài có nghiên cứu chuyên sâu, hàm lượng khoa học cao), đóng góp mới bài báo, bài báo được ưu tiên đăng trong số gần nhất của Tạp chí theo thứ tự: tính thời sự, chất lượng bài báo và thời gian gửi bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Ban Biên tập và Ban Thư ký biên tập bản thảo, chế bản, đọc rà soát lỗi. Thời gian hoàn thành từ 10-15 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Ban Thư ký có trách nhiệm thông báo cho tác giả bài báo (bằng e-mail) về tình hình phê duyệt bài báo, thời gian, số kỳ, tập xuất bản bài báo theo qui định.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">4. Danh sách bài báo theo số Tạp chí được in ấn và phát hành trong năm định kỳ được công bố chính thức trên website: https:\u002F\u002Ftapchi.ctump.edu.vn\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>",{"EN":74,"VI":75},"Cantho Journal of Medicine and Pharmacy","Tạp chí Y Dược học Cần Thơ",{"VOID":77},"wcQ1uqwAAAAJ","2023-05-30T08:17:21.868+00:00",32,[],[82],{"id":83,"createTime":84,"updateTime":85,"relativeEntities":86,"slug":87,"properties":88,"entityType":98,"verifyStatus":25,"verifyTime":99,"verifyNote":26,"syncStatus":28,"languages":100,"translateLanguages":26,"viewCount":103,"url":104,"parentIds":105,"statistic":106},"6413896b-eca9-442b-a73f-182a58a0ce40","2023-06-12T14:59:13.446+00:00","2026-06-19T02:29:32.871+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Y-D%C6%B0%E1%BB%A3c-C%E1%BA%A7n-Th%C6%A1",{"country":89,"title":90,"address":93,"abbreviation":96},{"VOID":15},{"EN":91,"VI":92},"Can Tho University of Medicine and Pharmacy","Trường Đại học Y Dược Cần Thơ",{"VI":94,"EN":95},"Số 179, đường Nguyễn Văn Cừ, phường An Khánh, quận Ninh Kiều, thành phố Cần Thơ, Việt Nam","No 179, Nguyen Van Cu street, An Khanh ward, Ninh Kieu district, Can Tho city, Vietnam",{"VOID":97},"ctump","AFFILIATION","2023-08-01T14:07:27.977+00:00",[101,102],"VI","EN",12,"http:\u002F\u002Fwww.ctump.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":107,"i10Index":111,"i10IndexLast5Year":59,"totalPublication":112,"totalPublicationByYear":113,"totalCitation":122,"totalCitationByYear":123,"totalCitationPerPublication":128,"totalCitationPerPublicationByYear":129,"hindexLast5Year":135,"hindex":135},{"2022":108,"2023":109,"2024":110,"2025":38},0.1,0.05,0.07,4,1489,{"2013":114,"2014":115,"2015":115,"2016":111,"2017":115,"2018":59,"2019":114,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120,"2025":121,"2026":111},2,1,10,84,281,680,260,156,313,{"2013":59,"2014":114,"2018":124,"2021":125,"2022":126,"2023":127},17,36,123,132,0.21,{"2013":130,"2014":114,"2018":131,"2021":132,"2022":133,"2023":134},1.5,5.67,0.43,0.44,0.19,6,[],"https:\u002F\u002Ftapchi.ctump.edu.vn\u002Findex.php\u002Fctump",{"impactFactor":36,"impactFactorByYear":139,"i10Index":114,"i10IndexLast5Year":114,"totalPublication":140,"totalPublicationByYear":141,"totalCitation":147,"totalCitationByYear":148,"totalCitationPerPublication":151,"totalCitationPerPublicationByYear":152,"hindexLast5Year":135,"hindex":135},{"2022":38,"2023":36,"2024":39,"2025":38},1956,{"0":114,"2019":114,"2020":50,"2021":142,"2022":143,"2023":144,"2024":145,"2025":146},76,403,789,305,371,524,{"0":114,"2019":135,"2021":124,"2022":149,"2023":150,"2024":111,"2025":114},287,206,0.27,{"0":115,"2019":59,"2021":153,"2022":154,"2023":56,"2024":38,"2025":38},0.22,0.71,{"impactFactor":26,"impactFactorByYear":26,"i10Index":114,"i10IndexLast5Year":114,"totalPublication":156,"totalPublicationByYear":157,"totalCitation":163,"totalCitationByYear":164,"totalCitationPerPublication":169,"totalCitationPerPublicationByYear":170,"hindexLast5Year":135,"hindex":135},461,{"0":158,"2019":114,"2021":159,"2022":160,"2023":161,"2024":158,"2025":162},7,37,296,107,5,419,{"2021":59,"2022":59,"2023":165,"2024":166,"2025":167,"2026":168},71,126,171,41,0.91,{"2021":171,"2022":38,"2023":172,"2024":173,"2025":174},0.08,0.66,18,34.2,"JOURNAL",{"id":177,"createTime":178,"updateTime":179,"relativeEntities":180,"slug":181,"properties":182,"entityType":24,"verifyStatus":25,"verifyTime":193,"verifyNote":26,"syncStatus":28,"languages":194,"translateLanguages":26,"viewCount":36,"subjectFields":195,"manageAffiliations":196,"indexDatabases":197,"url":198,"thumbnailPath":26,"statistic":26,"gsStatistic":199,"type":175,"analyzePriority":26},"f8d0bf97-8d89-482e-b58c-2fc481a0b79b","2025-10-27T06:27:08.591+00:00","2026-06-18T23:33:41.667+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Khoa-h%E1%BB%8Dc-v%C3%A0-C%C3%B4ng-ngh%E1%BB%87-nhi%E1%BB%87t-%C4%91%E1%BB%9Bi",{"country":183,"introduce":184,"gsId":186,"title":188,"issn":191},{"VOID":15},{"EN":185},"\u003Cp style=\"text-align:justify;\">     Journal of Tropical Science and Engineering (JTSE) is a multidisciplinary scientific journal, licensed to operate as a print journal in 2012 and an electronic journal in 2024 (License No.1479\u002FGP-BTTTT dated August 20, 2012 and No.91\u002FGP-BTTTT dated April 9, 2024 issued by the Ministry of Information and Communications of Vietnam). The JTSE is headquartered in Hanoi.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">        The JTSE is published every 3 months (4 issues\u002Fyear), publishing research results and overview articles in 3 groups of fields: Tropical Ecology and Environment; Chemistry and Material Sciences; Biomedicine and Pharmacy. In 2022, the JTSE registered the international identifier Digital Object Identifier (DOI): 10.58334\u002Fvrtc.jtst and assigned DOI codes to all articles of the journal. The members of the Editorial Board of the JTSE are prestigious scientists and leading scientists from Vietnam and many countries in the world. The JTSE has been recognized by the Vietnam State Council for Professorship to score scientific articles in Chemistry, Medicine and Biology with scores ranging from 0-0.75 points.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">      Currently, the JTSE is building and perfecting a set of criteria and making efforts to join the List of prestigious  international journals with a roadmap to enter Scopus and SCIE in the coming time.\u003C\u002Fp>",{"VOID":187},"MS2_GJQAAAAJ",{"VI":189,"EN":190},"Tạp chí Khoa học và Công nghệ nhiệt đới","Journal of Tropical Science and Engineering",{"VOID":192},"08667535","2025-10-27T06:27:25.058+00:00",[101,102],[],[],[],"https:\u002F\u002Ftapchikhcnnd.com.vn",{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":200,"totalPublicationByYear":201,"totalCitation":161,"totalCitationByYear":203,"totalCitationPerPublication":153,"totalCitationPerPublicationByYear":205,"hindexLast5Year":114,"hindex":114},481,{"0":115,"2020":115,"2021":115,"2022":114,"2024":115,"2025":202,"2026":115},474,{"2017":114,"2018":115,"2019":111,"2020":162,"2021":162,"2022":116,"2023":50,"2024":162,"2025":204,"2026":52},52,{"2020":162,"2021":162,"2022":162,"2024":162,"2025":206,"2026":52},0.11,{"id":208,"createTime":209,"updateTime":210,"relativeEntities":211,"slug":212,"properties":213,"entityType":24,"verifyStatus":25,"verifyTime":221,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":222,"subjectFields":223,"manageAffiliations":224,"indexDatabases":225,"url":226,"thumbnailPath":26,"statistic":227,"gsStatistic":276,"type":175,"analyzePriority":26},"a3d1e82a-57e2-40f9-940e-f5fa8b9ef64a","2023-06-01T07:11:26.039+00:00","2026-06-18T23:33:28.573+00:00",[],"VNU-Journal-of-Science-Earth-and-Environmental-Sciences",{"issn":214,"title":216,"country":218,"gsId":219},{"VOID":215},"26159279",{"EN":217},"VNU Journal of Science: Earth and Environmental Sciences",{"VOID":15},{"VOID":220},"UmXD8vEAAAAJ","2023-06-01T07:17:59.210+00:00",27,[],[],[],"https:\u002F\u002Fjs.vnu.edu.vn\u002FEES",{"impactFactor":36,"impactFactorByYear":228,"i10Index":234,"i10IndexLast5Year":36,"totalPublication":235,"totalPublicationByYear":236,"totalCitation":246,"totalCitationByYear":247,"totalCitationPerPublication":261,"totalCitationPerPublicationByYear":262,"hindexLast5Year":103,"hindex":103},{"2010":229,"2012":40,"2013":230,"2014":230,"2015":231,"2016":54,"2017":171,"2018":109,"2019":110,"2020":57,"2021":232,"2022":233,"2023":151,"2024":58},0.02,0.04,0.09,0.31,0.4,19,656,{"2008":237,"2009":238,"2010":239,"2011":238,"2012":240,"2013":241,"2014":239,"2015":242,"2016":243,"2017":244,"2018":245,"2019":165,"2020":125,"2021":168,"2022":125,"2023":222,"2024":111},23,24,22,28,25,20,146,29,78,1038,{"2008":248,"2009":249,"2010":250,"2011":251,"2012":252,"2013":253,"2014":254,"2015":255,"2016":256,"2017":257,"2018":161,"2019":258,"2020":259,"2021":29,"2022":260},119,64,66,86,38,73,59,31,129,39,97,53,26,1.58,{"2008":263,"2009":264,"2010":59,"2011":265,"2012":266,"2013":267,"2014":268,"2015":269,"2016":270,"2017":271,"2018":272,"2019":272,"2020":273,"2021":274,"2022":275},5.17,2.67,3.58,1.36,2.92,2.68,1.55,0.88,1.34,1.37,1.47,1.24,0.72,{"impactFactor":26,"impactFactorByYear":26,"i10Index":173,"i10IndexLast5Year":135,"totalPublication":277,"totalPublicationByYear":278,"totalCitation":279,"totalCitationByYear":280,"totalCitationPerPublication":288,"totalCitationPerPublicationByYear":289,"hindexLast5Year":158,"hindex":298},113,{"2007":114,"2008":103,"2009":173,"2010":116,"2011":51,"2012":239,"2013":103,"2014":162,"2015":53,"2016":135},616,{"2009":162,"2010":114,"2011":52,"2012":124,"2013":222,"2014":255,"2015":48,"2016":44,"2017":281,"2018":282,"2019":259,"2020":283,"2021":284,"2022":285,"2023":286,"2024":257,"2025":287,"2026":59},54,60,49,47,34,44,33,5.45,{"2009":290,"2010":291,"2011":292,"2012":293,"2013":294,"2014":295,"2015":296,"2016":297},0.28,0.2,0.6,0.77,2.25,6.2,3.91,9.67,14,{"id":300,"createTime":301,"updateTime":302,"relativeEntities":303,"slug":304,"properties":305,"entityType":24,"verifyStatus":25,"verifyTime":316,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":234,"subjectFields":317,"manageAffiliations":318,"indexDatabases":388,"url":389,"thumbnailPath":390,"statistic":391,"gsStatistic":409,"type":175,"analyzePriority":26},"a7166325-6c9e-4db3-8a59-7c879701a372","2023-07-31T04:28:49.231+00:00","2026-06-18T23:33:22.428+00:00",[],"VNU-Journal-of-Science-Policy-and-Management-Studies",{"country":306,"issn":307,"eissn":309,"title":311,"gsId":314},{"VOID":15},{"VOID":308},"26159295",{"VOID":310},"25881116",{"EN":312,"VI":313},"VNU Journal of Science: Policy and Management Studies","Tạp chí Nghiên cứu Chính sách và Quản lý",{"VOID":315},"xKW2E_cAAAAJ","2023-08-01T03:23:46.688+00:00",[],[319],{"id":320,"createTime":321,"updateTime":322,"relativeEntities":323,"slug":324,"properties":325,"entityType":98,"verifyStatus":25,"verifyTime":335,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":336,"url":337,"parentIds":338,"statistic":339},"12466116-8f60-4b01-8faf-2411483a0977","2023-05-30T09:37:38.472+00:00","2026-06-19T02:14:28.352+00:00",[],"Vietnam-National-University",{"country":326,"title":327,"abbreviation":330,"address":332},{"VOID":15},{"EN":328,"VI":329},"Vietnam National University, Hanoi","Đại học Quốc gia Hà Nội",{"VOID":331},"VNU",{"VI":333,"EN":334},"Số 144 Xuân Thủy, Phường Dịch Vọng Hậu, Quận Cầu Giấy, Hà Nội, Việt Nam","No. 144 Xuan Thuy Street, Dich Vong Hau Ward, Cau Giay District, Hanoi, Vietnam","2023-08-02T13:58:17.029+00:00",16,"http:\u002F\u002Fwww.vnu.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":340,"i10Index":285,"i10IndexLast5Year":162,"totalPublication":344,"totalPublicationByYear":345,"totalCitation":354,"totalCitationByYear":355,"totalCitationPerPublication":368,"totalCitationPerPublicationByYear":369,"hindexLast5Year":336,"hindex":336},{"2014":109,"2015":231,"2016":231,"2017":206,"2018":341,"2019":110,"2020":342,"2021":343,"2022":171,"2023":231,"2024":110,"2025":39},0.06,0.18,0.35,1247,{"2003":115,"2004":115,"2005":114,"2006":59,"2007":111,"2008":162,"2009":59,"2010":50,"2011":124,"2012":336,"2013":260,"2014":244,"2015":250,"2016":281,"2017":346,"2018":347,"2019":348,"2020":349,"2021":350,"2022":351,"2023":352,"2024":353,"2025":255,"2026":50},94,88,83,67,176,185,187,93,1644,{"2004":111,"2005":115,"2006":52,"2007":298,"2008":356,"2009":298,"2010":286,"2011":357,"2012":244,"2013":358,"2014":359,"2015":360,"2016":361,"2017":362,"2018":363,"2019":364,"2020":365,"2021":366,"2022":367,"2023":367,"2024":162},13,81,48,70,151,115,109,259,174,181,121,101,1.32,{"2004":111,"2005":370,"2006":59,"2007":371,"2008":372,"2009":373,"2010":374,"2011":375,"2012":376,"2013":377,"2014":378,"2015":379,"2016":380,"2017":381,"2018":382,"2019":383,"2020":384,"2021":385,"2022":386,"2023":387,"2024":109},0.5,3.5,2.6,4.67,5.5,4.76,1.81,1.85,2.41,2.29,2.13,1.16,2.94,2.1,2.7,0.69,0.55,0.54,[],"https:\u002F\u002Fjs.vnu.edu.vn\u002FPaM","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002Fa7166325-6c9e-4db3-8a59-7c879701a372\u002Fecfe83f4bcc60c7023ae04d8900fe0ac.jpg",{"impactFactor":36,"impactFactorByYear":392,"i10Index":111,"i10IndexLast5Year":36,"totalPublication":394,"totalPublicationByYear":395,"totalCitation":399,"totalCitationByYear":400,"totalCitationPerPublication":293,"totalCitationPerPublicationByYear":403,"hindexLast5Year":158,"hindex":158},{"2018":109,"2019":171,"2020":393,"2021":108,"2022":54,"2023":206,"2024":54},0.23,320,{"2015":50,"2016":239,"2017":286,"2018":396,"2019":397,"2020":159,"2021":398,"2022":168,"2023":79,"2024":255},30,35,40,247,{"2015":115,"2016":242,"2017":401,"2018":222,"2019":402,"2020":79,"2021":239,"2022":50,"2023":116},77,50,{"2015":404,"2016":169,"2017":405,"2018":406,"2019":407,"2020":408,"2021":386,"2022":291,"2023":232},0.12,1.75,0.9,1.43,0.86,{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":103,"totalPublicationByYear":410,"totalCitation":234,"totalCitationByYear":411,"totalCitationPerPublication":261,"totalCitationPerPublicationByYear":412,"hindexLast5Year":114,"hindex":59},{"2015":114,"2016":116},{"2016":115,"2017":114,"2018":114,"2019":59,"2020":114,"2021":59,"2022":114,"2023":114,"2024":115,"2026":115},{"2016":108},{"id":414,"createTime":415,"updateTime":416,"relativeEntities":417,"slug":418,"properties":419,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":238,"subjectFields":428,"manageAffiliations":429,"indexDatabases":430,"url":431,"thumbnailPath":26,"statistic":432,"gsStatistic":438,"type":175,"analyzePriority":26},"16e65a3f-d274-47dd-8691-56d76eb58c3d","2023-05-30T09:10:06.062+00:00","2026-06-18T23:33:17.679+00:00",[],"Vietnam-Journal-of-Otorhinolaryngology-Head-and-Neck-Surgery",{"country":420,"issn":421,"title":423,"gsId":426},{"VOID":15},{"VOID":422},"18593704",{"EN":424,"VI":425},"Vietnam Journal of Otorhinolaryngology - Head and Neck Surgery","Tạp chí Tai Mũi Họng Việt Nam",{"VOID":427},"L78B_eIAAAAJ",[],[],[],"https:\u002F\u002Ftapchitaimuihong.vn\u002Findex.php\u002Ftmh",{"impactFactor":36,"impactFactorByYear":433,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":434,"totalPublicationByYear":435,"totalCitation":111,"totalCitationByYear":436,"totalCitationPerPublication":230,"totalCitationPerPublicationByYear":437,"hindexLast5Year":115,"hindex":115},{"2024":229},95,{"2022":52,"2023":286,"2024":255,"2025":53},{"2023":111},{"2023":231},{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":240,"totalPublicationByYear":439,"totalCitation":234,"totalCitationByYear":440,"totalCitationPerPublication":441,"totalCitationPerPublicationByYear":442,"hindexLast5Year":114,"hindex":114},{"2023":53,"2024":116,"2025":135,"2026":115},{"2024":59,"2025":298,"2026":114},0.68,{"2024":443,"2025":444,"2026":114},0.3,2.33,{"id":446,"createTime":447,"updateTime":448,"relativeEntities":449,"slug":450,"properties":451,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":396,"subjectFields":460,"manageAffiliations":461,"indexDatabases":462,"url":463,"thumbnailPath":464,"statistic":465,"gsStatistic":472,"type":175,"analyzePriority":26},"25988add-c322-4eda-afda-63b1559bb824","2023-04-07T03:49:55.817+00:00","2026-06-18T23:32:23.776+00:00",[],"T%E1%BA%A1p%20ch%C3%AD%20Y%20-%20D%C6%B0%E1%BB%A3c%20h%E1%BB%8Dc%20qu%C3%A2n%20s%E1%BB%B1",{"country":452,"issn":453,"title":455,"gsId":458},{"VOID":15},{"VOID":454},"18590748",{"EN":456,"VI":457},"Journal of Military Pharmaco-medicine","Tạp chí Y - Dược học quân sự",{"VOID":459},"_pmQ8IEAAAAJ",[],[],[],"https:\u002F\u002Fjmpm.vn\u002Findex.php\u002Fjmpm","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F25988add-c322-4eda-afda-63b1559bb824\u002F09c6bc42157cf5ece95edc971ccddb52.jpg",{"impactFactor":36,"impactFactorByYear":466,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":467,"totalPublicationByYear":468,"totalCitation":135,"totalCitationByYear":470,"totalCitationPerPublication":38,"totalCitationPerPublicationByYear":471,"hindexLast5Year":115,"hindex":115},{"2023":229,"2024":38},475,{"2022":168,"2023":365,"2024":469,"2025":124},236,{"2022":114,"2023":111},{"2022":109,"2023":229},{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":277,"totalPublicationByYear":473,"totalCitation":401,"totalCitationByYear":474,"totalCitationPerPublication":441,"totalCitationPerPublicationByYear":475,"hindexLast5Year":59,"hindex":59},{"2015":115,"2018":114,"2019":115,"2020":115,"2021":59,"2022":103,"2023":159,"2024":287,"2025":237},{"2020":115,"2021":115,"2022":115,"2023":52,"2024":237,"2025":79,"2026":116},{"2020":115,"2021":476,"2022":171,"2023":477,"2024":478,"2025":479},0.33,0.24,0.7,1.39,{"id":481,"createTime":482,"updateTime":483,"relativeEntities":484,"slug":485,"properties":486,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":496,"translateLanguages":26,"viewCount":45,"subjectFields":497,"manageAffiliations":498,"indexDatabases":525,"url":526,"thumbnailPath":527,"statistic":528,"gsStatistic":26,"type":26,"analyzePriority":26},"2b8d7b12-2d20-4777-be98-077f44f03c69","2023-09-07T07:40:58.286+00:00","2025-07-13T21:21:00.542+00:00",[],"VNU-Journal-of-Social-Sciences-and-Humanities",{"country":487,"issn":488,"introduce":490,"title":493},{"VOID":15},{"VOID":489},"23541172",{"EN":491,"VI":492},"{\"ops\":[{\"insert\":\"VNU Journal of Social Sciences and Humanities (ISSN 2354-1172) is a double-blind peer-reviewed journal published by University of Social Sciences and Humanities, Vietnam National University, Hanoi, Vietnam, under the publication permit no. 155\u002FGP-BTTTT, issued on 11\"},{\"attributes\":{\"script\":\"super\"},\"insert\":\"th \"},{\"insert\":\"May, 2015 by Ministry of Information and Communications. The journal publishes four Vietnamese issues and two English issues per year.\\nCurrently, there are 35 reputable professors in the editorial board. The main objectives of the journal include: providing an intellectual platform for Vietnamese and international scholars; promoting interdisciplinary studies in social sciences and humanities; becoming the leading journal in social sciences and humanities in Vietnam; being indexed by worldwide databases and having academic recognition internationally in the near future.\\nThe journal is currently indexed by Google Scholar, WorldCat, Open Archives, Cosmos Impact Factor, Advanced Sciences Index, Scientific Indexing Services, CrossRef, EBSCO Information Services and Vietnam National University’s digital archive.\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Journal of Social Sciences and Humanities-Vietnam\"},{\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"ISSN 2354-1172, email: tapchikhxhnv@gmail.com, tckhxhnv@vnu.edu.vn\"},{\"insert\":\"\\n\"}]}","{\"ops\":[{\"insert\":\"Được thành lập ngày 31\u002F8\u002F2015 (giấy phép hoạt động số 155\u002FGP-BVHTT ngày 11 tháng 5 năm 2015 của Bộ Thông tin và Truyền thông, mã số tiêu chuẩn quốc tế ISSN 2354-1172), Tạp chí Khoa học Xã hội và Nhân văn (Journal of Social Sciences and Humanities) là ấn phẩm khoa học chính thức, duy nhất của Trường Đại học Khoa học Xã hội và Nhân văn, ĐHQG Hà Nội, phát triển và kế thừa Chuyên san Khoa học Xã hội và Nhân văn, Tạp chí Khoa học, ĐHQG Hà Nội.\\nTạp chí xuất bản định kỳ (04 số tiếng Việt\u002Fnăm và 02 số tiếng Anh\u002Fnăm), có nhiệm vụ \"},{\"attributes\":{\"italic\":true},\"insert\":\"công bố, giới thiệu các công trình nghiên cứu khoa học khoa học xã hội và nhân văn của các tác giả là các nhà khoa học trong và ngoài nước, phục vụ giảng dạy, học tập và nghiên cứu khoa học\"},{\"insert\":\". Hội đồng biên tập của Tạp chí hiện bao gồm 33 nhà khoa học có uy tín trong nước và quốc tế. Tạp chí tập trung và ưu tiên đăng tải những bài báo theo định hướng của tinh thần cởi mở, sáng tạo, nhanh chóng vươn lên để tiếp cận và sánh ngang với các tạp chí có uy tín hàng đầu của khu vực và trên thế giới. Nội dung chính của Tạp chí bao gồm các Bài nghiên cứu (khoảng 6000 đến 15000 từ), các bài điểm sách, thông tin khoa học (khoảng 300 đến 1500 từ) được trình bày theo đúng cấu trúc và chuẩn mực của một tạp chí khoa học.\\nCác bài viết của Tạp chí hiện đang được trích dẫn bởi Google Scholar, WorldCat, Open Archives, Cosmos Impact Factor, Advanced Sciences Index, Scientific Indexing Services, CrossRef, EBSCO Information Services.\\nMọi thông tin xin liên hệ: \"},{\"attributes\":{\"italic\":true},\"insert\":\"Phòng Tạp chí, 701 - E, Trường Đại học Khoa học Xã hội và Nhân văn, 336 Nguyễn Trãi, Thanh Xuân, Hà Nội. ĐT: 024.35581984; email: tckhxhnv@vnu.edu.vn \"},{\"insert\":\"hoặc \"},{\"attributes\":{\"italic\":true},\"insert\":\"tapchikhxhnv@gmail.com \"},{\"insert\":\"\\n\"}]}",{"EN":494,"VI":495},"VNU Journal of Social Sciences and Humanities","Tạp chí Khoa học Xã hội và Nhân văn",[101,102],[],[499],{"id":500,"createTime":501,"updateTime":502,"relativeEntities":503,"slug":504,"properties":505,"entityType":98,"verifyStatus":25,"verifyTime":509,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":222,"url":26,"parentIds":510,"statistic":511},"8b6e349b-0daf-4895-9c3f-85f30f1bfd42","2023-07-31T12:55:58.430+00:00","2026-06-19T02:30:07.899+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Khoa-h%E1%BB%8Dc-X%C3%A3-h%E1%BB%99i-v%C3%A0-Nh%C3%A2n-v%C4%83n-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-H%C3%A0-N%E1%BB%99i",{"title":506},{"EN":507,"VI":508},"VNU University of Social Sciences and Humanities","Trường Đại học Khoa học Xã hội và Nhân văn, Đại học Quốc gia Hà Nội","2023-08-02T15:28:49.057+00:00",[],{"impactFactor":36,"impactFactorByYear":512,"i10Index":59,"i10IndexLast5Year":115,"totalPublication":514,"totalPublicationByYear":515,"totalCitation":518,"totalCitationByYear":519,"totalCitationPerPublication":520,"totalCitationPerPublicationByYear":521,"hindexLast5Year":162,"hindex":162},{"2016":229,"2017":230,"2018":229,"2021":230,"2022":58,"2023":513,"2024":38},0.15,365,{"2013":115,"2014":158,"2015":125,"2016":252,"2017":44,"2018":516,"2019":286,"2020":396,"2021":259,"2022":517,"2023":396,"2024":115,"2025":59,"2026":115},21,42,169,{"2015":283,"2016":135,"2017":52,"2018":50,"2019":298,"2020":53,"2021":359,"2022":115,"2023":115},0.46,{"2015":266,"2016":57,"2017":57,"2018":522,"2019":523,"2020":524,"2021":368,"2022":229,"2023":39},0.38,0.32,0.37,[],"http:\u002F\u002Fjournal.ussh.vnu.edu.vn\u002Findex.php\u002Fvjossh","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F2b8d7b12-2d20-4777-be98-077f44f03c69\u002F0bd0751202944a4b4165b482e6e623e4.png",{"impactFactor":36,"impactFactorByYear":529,"i10Index":162,"i10IndexLast5Year":115,"totalPublication":530,"totalPublicationByYear":531,"totalCitation":537,"totalCitationByYear":538,"totalCitationPerPublication":343,"totalCitationPerPublicationByYear":540,"hindexLast5Year":135,"hindex":135},{"2016":341,"2017":39,"2018":229,"2019":38,"2020":110,"2021":231,"2022":231,"2023":341,"2024":39},764,{"2015":255,"2016":245,"2017":532,"2018":259,"2019":533,"2020":534,"2021":535,"2022":536,"2023":534,"2024":254,"2025":50},111,106,68,92,89,265,{"2015":539,"2016":241,"2017":168,"2018":51,"2019":349,"2020":260,"2021":244,"2022":298,"2023":114},46,{"2015":541,"2016":523,"2017":524,"2018":290,"2019":542,"2020":522,"2021":523,"2022":57,"2023":39},1.48,0.63,{"id":544,"createTime":545,"updateTime":546,"relativeEntities":547,"slug":548,"properties":549,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":558,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":50,"subjectFields":559,"manageAffiliations":560,"indexDatabases":561,"url":562,"thumbnailPath":563,"statistic":564,"gsStatistic":26,"type":26,"analyzePriority":26},"6ec01bd0-15c0-469a-86ac-41339076ae0a","2023-08-10T07:08:33.153+00:00","2026-01-31T21:19:06.362+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Da-li%E1%BB%85u-h%E1%BB%8Dc-Vi%E1%BB%87t-Nam",{"country":550,"issn":551,"introduce":553,"title":555},{"VOID":15},{"VOID":552},"18594824",{"VI":554},"{\"ops\":[{\"insert\":\"Tạp chí “Da liễu học Việt Nam” (Tiếng Anh: Vietnamese Journal of Dermatology and Venereology) thuộc Hội Da liễu Việt Nam, xuất bản 4 số mỗi năm bằng tiếng Việt hoặc tiếng Anh.\\nTạp chí Da liễu học Việt Nam hoạt động với mục đích, tôn chỉ là phổ biến, trao đổi thông tin trong lĩnh vực chuyên ngành da liễu; đăng tải các công trình nghiên cứu khoa học; chuyển giao công nghệ - kinh tế và khoa học kỹ thuật liên quan đến lĩnh vực da liễu.\\nPhạm vi của tạp chí là tất cả các bài báo khoa học, bài tổng quan, giới thiệu ca lâm sàng, … có liên quan tới chuyên ngành da liễu trong và ngoài nước. Tạp chí công bố các công trình nghiên cứu liên quan đến mô hình bệnh tật, các phương pháp chẩn đoán, điều trị, dự phòng và phục hồi chức năng các bệnh thuộc chuyên ngành da liễu. Ngoài ra, tạp chí còn đăng tải các bài tổng quan, cập nhật thông tin, kiến thức, hướng dẫn chẩn đoán, điều trị trong chuyên ngành da liễu trong nước và quốc tế; đăng tải các bài ca lâm sàng đặc biệt trong chuyên ngành da liễu.\\nTạp chí Da liễu học Việt Nam được biết tới là một tạp chí chuyên ngành có uy tín trong lĩnh vực da liễu. Các bài báo về nghiên cứu khoa học đăng trong Tạp chí được bình duyệt một cách nghiêm ngặt bởi ít nhất 2 chuyên gia. Hội đồng biên tập tạp chí bao gồm các nhà khoa học có uy tín (Giáo sư, Phó Giáo sư, Tiến sĩ, Bác sĩ…) trong chuyên ngành da liễu nhằm đảm bảo chất lượng và tính khách quan, khoa học cho các bài viết đăng trên Tạp chí.\\n\"}]}",{"EN":556,"VI":557},"Vietnamese Journal of Dermatology and Venereology","Tạp chí Da liễu học Việt Nam","Admin Import",[],[],[],"https:\u002F\u002Fvjdv.vn\u002Findex.php\u002Fvjdv","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F6ec01bd0-15c0-469a-86ac-41339076ae0a\u002F3cbc81720e58429dc7b1c4d7ab1935ca.jpg",{"impactFactor":36,"impactFactorByYear":565,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":566,"totalPublicationByYear":567,"totalCitation":116,"totalCitationByYear":570,"totalCitationPerPublication":109,"totalCitationPerPublicationByYear":571,"hindexLast5Year":115,"hindex":115},{"2023":38,"2024":230},182,{"2022":568,"2023":45,"2024":569},69,56,{"2022":52,"2023":115},{"2022":40,"2023":229},{"id":573,"createTime":574,"updateTime":575,"relativeEntities":576,"slug":577,"properties":578,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":587,"translateLanguages":26,"viewCount":283,"subjectFields":588,"manageAffiliations":589,"indexDatabases":647,"url":648,"thumbnailPath":649,"statistic":650,"gsStatistic":26,"type":26,"analyzePriority":26},"19221551-7519-47ff-a892-331d1139c64b","2023-09-12T07:03:05.744+00:00","2026-01-24T20:54:40.144+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Khoa-h%E1%BB%8Dc-S%E1%BB%A9c-kho%E1%BA%BB-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-Th%C3%A0nh-ph%E1%BB%91-H%E1%BB%93-Ch%C3%AD-Minh",{"country":579,"issn":580,"introduce":582,"title":584},{"VOID":15},{"VOID":581},"27349446",{"EN":583},"{\"ops\":[{\"attributes\":{\"bold\":true},\"insert\":\"1. History\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Science and Technology Development Journal\"},{\"insert\":\" (STDJ) (ISSN 2734-9446), Vietnam National University - Ho Chi Minh City (VNU-HCM) was established in 1997. And the first issue was published in January 1998 with ISSN 1859-0128. Since then, STDJ has become the most important scientific forum of scientists from VNU-HCM as well as other universities. The magazine has undergone 20 years of development and has become a bridge for scientific exchanges, as well as enriching reference materials for the faculty, doctoral students, students of VNU-HCM in particular and other universities, institutes...\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Science and Technology Development Journal - Health Sciences (STDJ-HS) is a subjournal of Science and Technology Development Journal since 2020.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\" \"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"2. Focus and Scope\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Publishing articles with contents on healthcare, research projects in the field of health, advanced directions in health education and management. Therefore, STDJ-HS will accept articles from doctors, administrators, teachers, researchers, graduate students and fellows. The authors will be responsible for the accuracy of the data, opinions, opinions and material cited in the article.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Facilitating the exchange of scientific and technological information and act as a bridge between theory and practice in the community of educators, scientists, managers, policy makers and enterprises in and out of the country.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}",{"EN":585,"VI":586},"VNUHCM JOURNAL OF HEALTH SCIENCES","Tạp chí Khoa học Sức khoẻ Đại học Quốc gia Thành phố Hồ Chí Minh",[101,102],[],[590],{"id":591,"createTime":592,"updateTime":593,"relativeEntities":594,"slug":595,"properties":596,"entityType":98,"verifyStatus":25,"verifyTime":606,"verifyNote":26,"syncStatus":28,"languages":607,"translateLanguages":26,"viewCount":608,"url":609,"parentIds":610,"statistic":611},"fc4c2560-868c-4677-acb1-8686bef88727","2023-06-26T04:48:23.774+00:00","2026-06-19T01:46:17.248+00:00",[],"%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-Th%C3%A0nh-ph%E1%BB%91-H%E1%BB%93-Ch%C3%AD-Minh",{"country":597,"title":598,"abbreviation":601,"address":603},{"VOID":15},{"EN":599,"VI":600},"Vietnam National University Ho Chi Minh City","Đại học Quốc gia Thành phố Hồ Chí Minh",{"VOID":602},"VNUHCM",{"VI":604,"EN":605},"khu phố 6, Phường Linh Trung, Thành phố Thủ Đức, Thành phố Hồ Chí Minh, Việt Nam","Quarter 6, Linh Trung Ward, Thu Duc City, Ho Chi Minh City, Vietnam","2023-08-16T14:13:07.134+00:00",[101,102],45,"https:\u002F\u002Fvnuhcm.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":612,"i10Index":285,"i10IndexLast5Year":51,"totalPublication":613,"totalPublicationByYear":614,"totalCitation":624,"totalCitationByYear":625,"totalCitationPerPublication":634,"totalCitationPerPublicationByYear":635,"hindexLast5Year":124,"hindex":124},{"2014":36,"2015":38,"2016":109,"2017":39,"2018":229,"2019":38,"2020":110,"2021":171,"2022":110,"2023":110,"2024":171,"2025":229},3708,{"2005":115,"2006":115,"2007":115,"2008":135,"2009":111,"2010":53,"2011":52,"2012":568,"2013":615,"2014":351,"2015":616,"2016":469,"2017":617,"2018":127,"2019":618,"2020":619,"2021":620,"2022":621,"2023":622,"2024":623,"2025":159,"2026":50},164,266,177,226,603,931,314,246,74,2399,{"2006":115,"2008":50,"2010":162,"2011":242,"2012":222,"2013":43,"2014":626,"2015":627,"2016":628,"2017":629,"2018":258,"2019":630,"2020":631,"2021":632,"2022":633,"2023":353,"2024":115},250,124,157,162,152,385,559,128,0.65,{"2006":115,"2008":636,"2010":637,"2011":638,"2012":639,"2013":522,"2014":640,"2015":641,"2016":642,"2017":643,"2018":644,"2019":642,"2020":645,"2021":292,"2022":646,"2023":522,"2024":38},1.33,0.45,2.22,0.39,1.35,0.47,0.67,0.92,0.73,0.64,0.41,[],"http:\u002F\u002Fstdjhs.scienceandtechnology.com.vn\u002Findex.php\u002Fstdjhs","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F19221551-7519-47ff-a892-331d1139c64b\u002F2e10768b7d1e380c36a25ed0c714dd7e.png",{"impactFactor":36,"impactFactorByYear":651,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":652,"totalPublicationByYear":653,"totalCitation":516,"totalCitationByYear":654,"totalCitationPerPublication":151,"totalCitationPerPublicationByYear":655,"hindexLast5Year":59,"hindex":59},{"2022":57,"2023":108,"2024":39},79,{"2020":116,"2021":240,"2022":239,"2023":52,"2024":162,"2025":162},{"2020":59,"2021":51,"2022":59},{"2020":443,"2021":387,"2022":54},{"code":657,"data":658,"meta":26},"SUCCESS",{"id":659,"createTime":660,"updateTime":661,"relativeEntities":662,"slug":663,"properties":664,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":671,"manageAffiliations":680,"indexDatabases":691,"url":730,"thumbnailPath":26,"statistic":731,"gsStatistic":26,"type":175,"analyzePriority":26},"ebaab0e5-f88a-47b8-809b-fd5227189687","2024-04-11T06:23:15.548+00:00","2025-11-21T10:05:04.956+00:00",[],"Current-Atherosclerosis-Reports",{"issn":665,"eissn":667,"title":669},{"VOID":666},"1534-6242",{"VOID":668},"1523-3804",{"EN":670},"Current Atherosclerosis Reports",[672],{"id":673,"createTime":674,"updateTime":675,"relativeEntities":676,"label":677,"description":679,"parentId":26,"standard":26,"scholarHubFieldId":26},"2e748c70-3f53-41a9-99c9-1e3e45a3dc6d","2023-05-29T10:24:06.277+00:00","2023-11-21T08:07:05.812+00:00",[],{"EN":678},"Cardiology and Cardiovascular Medicine",{},[681],{"id":682,"createTime":683,"updateTime":684,"relativeEntities":685,"slug":686,"properties":687,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":111,"url":26,"parentIds":690,"statistic":26},"aeebfe70-bb47-4404-91bd-6d44079a5c1d","2023-05-29T10:26:05.762+00:00","2025-11-21T09:55:14.914+00:00",[],"Current-Medicine-Group",{"title":688},{"EN":689},"Current Medicine Group",[],[692,711],{"id":693,"indexDatabase":694,"url":708,"indexYears":26,"academicFieldIds":709,"indexDatabaseRanking":26},"629aecd0-5d1d-4d70-bd51-ba2b30809f2c",{"id":695,"createTime":696,"updateTime":697,"relativeEntities":698,"label":699,"description":701,"key":704,"publicationTags":705,"standard":26},"a4921856-b128-4d9f-8f1f-e80813d3bbd4","2023-05-22T09:59:31.026+00:00","2025-11-21T10:07:52.153+00:00",[],{"EN":700,"VI":700},"ISI\u002FSCIE - Science Citation Index Expanded",{"VI":702,"EN":703},"Cơ sở dữ liệu SCIE","SCIE database","scie",[706,707],"SCIE","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=1523-3804",[710],"0ddd214e-2317-43ae-8737-4f5747adc536",{"id":712,"indexDatabase":713,"url":725,"indexYears":726,"academicFieldIds":727,"indexDatabaseRanking":729},"0a82bf5e-8290-43c6-8691-de426ab20078",{"id":714,"createTime":715,"updateTime":716,"relativeEntities":717,"label":718,"description":720,"key":722,"publicationTags":723,"standard":26},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":719,"VI":719},"Scopus - Elsevier",{"EN":719,"VI":721},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[724],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F23116","1999-2025",[728],"d44e3b1d-4abe-47f2-b4aa-783c24a9f903","SCOPUS__Q1","https:\u002F\u002Flink.springer.com\u002Fjournal\u002F11883",{"impactFactor":36,"impactFactorByYear":732,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":51,"totalPublicationByYear":733,"totalCitation":36,"totalCitationByYear":734,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":735,"hindexLast5Year":36,"hindex":36},{},{"2002":115,"2003":115,"2004":114,"2006":114,"2007":115,"2011":115,"2012":115,"2013":115,"2017":115,"2019":114,"2020":115,"2023":115},{},{},{"meta":737,"data":739},{"total":738},"1343",[740,1107,1349,1623,2021,2559,2828,3412,3955,4360],{"id":741,"createTime":742,"updateTime":742,"relativeEntities":743,"slug":744,"properties":745,"entityType":760,"verifyStatus":25,"verifyTime":761,"verifyNote":762,"syncStatus":28,"languages":763,"translateLanguages":26,"viewCount":36,"primaryUrl":764,"fullTextUrl":26,"authors":765,"publicationType":830,"publisherRelationship":831,"citationCount":867,"citationInfo":868,"publishDate":870,"publishYear":871,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":872,"isForceReanalyzing":1106},"934f8787-a065-4c7f-afdd-297b62cc5453","2024-11-28T14:53:27.410+00:00",[],"Unprocessed-Red-and-Processed-Meats-and-Risk-of-Coronary-Artery-Disease-and-Type-2-Diabetes-An-Updated-Review-of-the-Evidence",{"mag":746,"keywords":748,"pmc":749,"openalex":751,"abstract":753,"title":754,"pm":756,"doi":758},{"VOID":747},"2034819178",{},{"VOID":750},"3483430",{"VOID":752},"W2034819178",{},{"EN":755},"Unprocessed Red and Processed Meats and Risk of Coronary Artery Disease and Type 2 Diabetes – An Updated Review of the Evidence",{"VOID":757},"23001745",{"VOID":759},"10.1007\u002Fs11883-012-0282-8","PUBLICATION","2024-11-28T14:53:27.409+00:00","Auto Verify",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11883-012-0282-8",[766,787,808],{"id":767,"sortIndex":115,"researcher":26,"roles":768,"affiliations":769,"properties":780},"5e2a20b4-083e-4eaa-a331-13c4e040aa35",[],[770],{"id":771,"sortIndex":36,"affiliation":772,"properties":26},"ea4022f1-a8d8-43fa-8a4e-302dff30b010",{"id":773,"createTime":774,"updateTime":774,"relativeEntities":775,"slug":776,"properties":777,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"883e4e40-60b3-435c-a0d9-1219ed1dd6c1","2024-11-28T14:53:27.439+00:00",[],"Department-of-Internal-Medicine-General-Hospital-of-Kalamata-Kalamata-Greece",{"title":778},{"EN":779},"Department of Internal Medicine, General Hospital of Kalamata, Kalamata, Greece",{"openalex":781,"orcid":783,"title":785},{"VOID":782},"A5038956440",{"VOID":784},"https:\u002F\u002Forcid.org\u002F0000-0003-1359-180X",{"EN":786},"George Michas",{"id":788,"sortIndex":114,"researcher":26,"roles":789,"affiliations":790,"properties":801},"eeb11c5b-2947-4274-814e-34f3d77364e8",[],[791],{"id":792,"sortIndex":36,"affiliation":793,"properties":26},"e6900437-43b6-44f4-855c-dee22e280e3d",{"id":794,"createTime":795,"updateTime":795,"relativeEntities":796,"slug":797,"properties":798,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"6657da35-0f5a-41a3-a096-f87ba49f92b2","2024-11-28T14:53:27.454+00:00",[],"Departments-of-Epidemiology-and-Nutrition-Harvard-School-of-Public-Health-665-Huntington-Ave-Bldg-2-319-Boston-MA-02115-USA",{"title":799},{"EN":800},"Departments of Epidemiology and Nutrition, Harvard School of Public Health, 665 Huntington Ave Bldg 2-319, Boston, MA, 02115, USA",{"openalex":802,"orcid":804,"title":806},{"VOID":803},"A5064987258",{"VOID":805},"https:\u002F\u002Forcid.org\u002F0000-0001-7958-9492",{"EN":807},"Dariush Mozaffarian",{"id":809,"sortIndex":36,"researcher":26,"roles":810,"affiliations":811,"properties":823},"0e0f1123-173d-4f6c-b6a0-bad5520364cc",[],[812],{"id":813,"sortIndex":36,"affiliation":814,"properties":26},"73aac01d-26b6-46e1-b49c-fabd27405ced",{"id":815,"createTime":816,"updateTime":817,"relativeEntities":818,"slug":819,"properties":820,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"508a7d4c-d6c9-4aa0-86ab-4312b0fd3ee2","2024-02-13T23:25:35.619+00:00","2025-02-03T23:32:25.130+00:00",[],"Department-of-Epidemiology-Harvard-School-of-Public-Health-Boston-MA-USA-",{"title":821},{"VI":822},"Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA;",{"openalex":824,"orcid":826,"title":828},{"VOID":825},"A5009187711",{"VOID":827},"https:\u002F\u002Forcid.org\u002F0000-0002-3983-1632",{"EN":829},"Renata Micha","ARTICLE",{"url":26,"publisher":832,"properties":860},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":833,"slug":663,"properties":834,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":838,"manageAffiliations":839,"indexDatabases":840,"url":730,"thumbnailPath":26,"statistic":855,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":835,"eissn":836,"title":837},{"VOID":666},{"VOID":668},{"EN":670},[],[],[841,848],{"id":712,"indexDatabase":842,"url":725,"indexYears":726,"academicFieldIds":847,"indexDatabaseRanking":729},{"id":714,"createTime":715,"updateTime":716,"relativeEntities":843,"label":844,"description":845,"key":722,"publicationTags":846,"standard":26},[],{"EN":719,"VI":719},{"EN":719,"VI":721},[724],[728],{"id":693,"indexDatabase":849,"url":708,"indexYears":26,"academicFieldIds":854,"indexDatabaseRanking":26},{"id":695,"createTime":696,"updateTime":697,"relativeEntities":850,"label":851,"description":852,"key":704,"publicationTags":853,"standard":26},[],{"EN":700,"VI":700},{"VI":702,"EN":703},[706,707],[710],{"impactFactor":36,"impactFactorByYear":856,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":51,"totalPublicationByYear":857,"totalCitation":36,"totalCitationByYear":858,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":859,"hindexLast5Year":36,"hindex":36},{},{"2002":115,"2003":115,"2004":114,"2006":114,"2007":115,"2011":115,"2012":115,"2013":115,"2017":115,"2019":114,"2020":115,"2023":115},{},{},{"volume":861,"pages":863,"issue":865},{"VOID":862},"14",{"VOID":864},"515-524",{"VOID":866},"6",449,{"total":867,"publishYear":26,"statisticByYear":869},{"2013":356,"2014":516,"2015":260,"2016":159,"2017":257,"2018":517,"2019":539,"2020":257,"2021":45,"2022":358,"2023":286,"2024":397},"2012-12-01",2012,[873,877,881,885,889,892,896,899,902,905,909,913,917,921,924,928,932,936,940,944,948,952,956,960,964,968,972,976,980,984,988,992,996,1000,1004,1008,1012,1016,1020,1024,1028,1031,1035,1039,1042,1045,1049,1053,1057,1061,1065,1069,1073,1077,1081,1085,1089,1093,1096,1099,1102],{"id":26,"text":874,"url":26,"identifiers":875},"•• Micha R, Wallace SK, Mozaffarian D. Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. Circulation. 2010;121(21):2271–83. The first systematic review and meta-analysis that assessed relationships between unprocessed red and processed meat consumption and risk of incident coronary heart disease, stroke, and type 2 diabetes. This meta-analysis provided evidence that the effects of meat consumption on cardiometabolic outcomes might vary depending on the extent of processing i.e., whether or not the meat is fresh (unprocessed) or has been processed and preserved for long-term storage, typically by adding high amounts of salt, as well as other preservatives such as nitrates.",{"doi":876},"10.1161\u002FCIRCULATIONAHA.109.924977",{"id":26,"text":878,"url":26,"identifiers":879},"Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047–67.",{"doi":880},"10.1016\u002Fj.jacc.2011.06.063",{"id":26,"text":882,"url":26,"identifiers":883},"Turesky RJ, Le Marchand L. Metabolism and biomarkers of heterocyclic aromatic amines in molecular epidemiology studies: lessons learned from aromatic amines. Chem Res Toxicol. 2011;24(8):1169–214.",{"doi":884},"10.1021\u002Ftx200135s",{"id":26,"text":886,"url":26,"identifiers":887},"Mozaffarian D. Chapter 48: Nutrition and Cardiovascular Diseases, in Braunwald's Heart Disease: a Textbook of Cardiovascular Medicine. 2012: Philadelphia.",{"doi":888},"10.1016\u002FB978-1-4377-0398-6.00048-2",{"id":26,"text":890,"url":26,"identifiers":891},"Institute of Medicine of the National Academies, Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. 2010.",{},{"id":26,"text":893,"url":26,"identifiers":894},"Micha R, Kalantarian S, Wirojratana P, et al. Estimating the global and regional burden of suboptimal nutrition on chronic disease: methods and inputs to the analysis. Eur J Clin Nutr. 2012;66(1):119–29.",{"doi":895},"10.1038\u002Fejcn.2011.147",{"id":26,"text":897,"url":26,"identifiers":898},"World Health Organization, Diet, nutrition and the prevention of chronic diseases: report of a joint WHO\u002FFAO expert consultation, in World Health Organ Tech Rep Ser. 916: i–viii. 2003: Geneva. p. 1–149.",{},{"id":26,"text":900,"url":26,"identifiers":901},"Hill AB. The Environment and Disease: association or Causation? Proc R Soc Med. 1965;58:295–300.",{},{"id":26,"text":903,"url":26,"identifiers":904},"World Cancer Research Fund\u002F American Institute for Cancer Research, Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. 2007: Washington DC: AICR.",{},{"id":26,"text":906,"url":26,"identifiers":907},"Whiteman D, Muir J, Jones L, et al. Dietary questions as determinants of mortality: the OXCHECK experience. Public Health Nutr. 1999;2(4):477–87.",{"doi":908},"10.1017\u002FS136898009900066X",{"id":26,"text":910,"url":26,"identifiers":911},"Ascherio A, Willett WC, Rimm EB, et al. Dietary iron intake and risk of coronary disease among men. Circulation. 1994;89(3):969–74.",{"doi":912},"10.1161\u002F01.CIR.89.3.969",{"id":26,"text":914,"url":26,"identifiers":915},"Burke V, Zhao Y, Lee AH, et al. Health-related behaviours as predictors of mortality and morbidity in Australian Aborigines. Prev Med. 2007;44(2):135–42.",{"doi":916},"10.1016\u002Fj.ypmed.2006.09.008",{"id":26,"text":918,"url":26,"identifiers":919},"Martinez-Gonzalez MA, Fernandez-Jarne E, Serrano-Martinez M, et al. Mediterranean diet and reduction in the risk of a first acute myocardial infarction: an operational healthy dietary score. Eur J Nutr. 2002;41(4):153–60.",{"doi":920},"10.1007\u002Fs00394-002-0370-6",{"id":26,"text":922,"url":26,"identifiers":923},"Liu J, Stampfer MJ, Hu FB, et al. Dietary iron and red meat intake and risk of coronary heart disease in postmenopausal women. Am J Epidemiol. 2003;157:S100.",{},{"id":26,"text":925,"url":26,"identifiers":926},"Sinha R, Cross AJ, Graubard BI, et al. Meat intake and mortality: a prospective study of over half a million people. Arch Intern Med. 2009;169(6):562–71.",{"doi":927},"10.1001\u002Farchinternmed.2009.6",{"id":26,"text":929,"url":26,"identifiers":930},"• Bernstein AM, Sun Q, Hu FB, et al. Major dietary protein sources and risk of coronary heart disease in women. Circulation. 2010;122(9):876–83. Bernstein and colleagues evaluated the association between unprocessed red and processed meat consumption and incidence of coronary heart disease in the Nurse’s Health Study cohort.",{"doi":931},"10.1161\u002FCIRCULATIONAHA.109.915165",{"id":26,"text":933,"url":26,"identifiers":934},"• Pan A, Sun Q, Bernstein AM, et al. Red meat consumption and mortality: results from 2 prospective cohort studies. Arch Intern Med. 2012;172(7):555–63. Pan and colleagues evaluated the Nurse’s Health Study and the Health Professionals Follow-up Study cohort to assess the associations between unprocessed red and processed meat consumption and risk of CVD death.",{"doi":935},"10.1001\u002Farchinternmed.2011.2287",{"id":26,"text":937,"url":26,"identifiers":938},"• Pan A, Sun Q, Bernstein AM, et al. Red meat consumption and risk of type 2 diabetes: 3 cohorts of US adults and an updated meta-analysis. Am J Clin Nutr. 2011;94(4):1088–96. An updated meta-analysis, using the methods reported in our meta-analysis [1], which evaluated the relationship between unprocessed red and processed meat consumption and incident type 2 diabetes, including our previously identified studies plus updated findings from three Harvard cohorts [19–21].",{"doi":939},"10.3945\u002Fajcn.111.018978",{"id":26,"text":941,"url":26,"identifiers":942},"Fung TT, Schulze M, Manson JE, et al. Dietary patterns, meat intake, and the risk of type 2 diabetes in women. Arch Intern Med. 2004;164(20):2235–40.",{"doi":943},"10.1001\u002Farchinte.164.20.2235",{"id":26,"text":945,"url":26,"identifiers":946},"Schulze MB, Manson JE, Willett WC, et al. Processed meat intake and incidence of Type 2 diabetes in younger and middle-aged women. Diabetologia. 2003;46(11):1465–73.",{"doi":947},"10.1007\u002Fs00125-003-1220-7",{"id":26,"text":949,"url":26,"identifiers":950},"van Dam RM, Willett WC, Rimm EB, et al. Dietary fat and meat intake in relation to risk of type 2 diabetes in men. Diabetes Care. 2002;25(3):417–24.",{"doi":951},"10.2337\u002Fdiacare.25.3.417",{"id":26,"text":953,"url":26,"identifiers":954},"Song Y, Manson JE, Buring JE, et al. A prospective study of red meat consumption and type 2 diabetes in middle-aged and elderly women: the women's health study. Diabetes Care. 2004;27(9):2108–15.",{"doi":955},"10.2337\u002Fdiacare.27.9.2108",{"id":26,"text":957,"url":26,"identifiers":958},"Villegas R, Shu XO, Gao YT, et al. The association of meat intake and the risk of type 2 diabetes may be modified by body weight. Int J Med Sci. 2006;3(4):152–9.",{"doi":959},"10.7150\u002Fijms.3.152",{"id":26,"text":961,"url":26,"identifiers":962},"• Fretts AM, Howard BV, McKnight B, et al. Associations of processed meat and unprocessed red meat intake with incident diabetes: the Strong Heart Family Study. Am J Clin Nutr. 2012;95(3):752–8. Fretts and colleagues evaluated relationships between unprocessed red and processed meat consumption and incident diabetes in the Strong Heart Family Study cohort, in a population of American Indians characterized by relative high rates of obesity and diabetes.",{"doi":963},"10.3945\u002Fajcn.111.029942",{"id":26,"text":965,"url":26,"identifiers":966},"Jakobsen MU, O'Reilly EJ, Heitmann BL, et al. Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. Am J Clin Nutr. 2009;89(5):1425–32.",{"doi":967},"10.3945\u002Fajcn.2008.27124",{"id":26,"text":969,"url":26,"identifiers":970},"Meyer KA, Kushi LH, Jacobs Jr DR, et al. Dietary fat and incidence of type 2 diabetes in older Iowa women. Diabetes Care. 2001;24(9):1528–35.",{"doi":971},"10.2337\u002Fdiacare.24.9.1528",{"id":26,"text":973,"url":26,"identifiers":974},"Micha R, Mozaffarian D. Saturated fat and cardiometabolic risk factors, coronary heart disease, stroke, and diabetes: a fresh look at the evidence. Lipids. 2010;45(10):893–905.",{"doi":975},"10.1007\u002Fs11745-010-3393-4",{"id":26,"text":977,"url":26,"identifiers":978},"Feskens EJ, Virtanen SM, Rasanen L, et al. Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care. 1995;18(8):1104–12.",{"doi":979},"10.2337\u002Fdiacare.18.8.1104",{"id":26,"text":981,"url":26,"identifiers":982},"Galgani JE, Uauy RD, Aguirre CA, et al. Effect of the dietary fat quality on insulin sensitivity. Br J Nutr. 2008;100(3):471–9.",{"doi":983},"10.1017\u002FS0007114508894408",{"id":26,"text":985,"url":26,"identifiers":986},"Riserus U, Willett WC, Hu FB. Dietary fats and prevention of type 2 diabetes. Prog Lipid Res. 2009;48(1):44–51.",{"doi":987},"10.1016\u002Fj.plipres.2008.10.002",{"id":26,"text":989,"url":26,"identifiers":990},"de Oliveira Otto MC, Mozaffarian D, Kromhout D, et al. Dietary intake of saturated fat by food source and incident cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. Am J Clin Nutr. 2012;96(2):397–404.",{"doi":991},"10.3945\u002Fajcn.112.037770",{"id":26,"text":993,"url":26,"identifiers":994},"Djousse L, Gaziano JM. Dietary cholesterol and coronary artery disease: a systematic review. Curr Atheroscler Rep. 2009;11(6):418–22.",{"doi":995},"10.1007\u002Fs11883-009-0063-1",{"id":26,"text":997,"url":26,"identifiers":998},"Salmeron J, Hu FB, Manson JE, et al. Dietary fat intake and risk of type 2 diabetes in women. Am J Clin Nutr. 2001;73(6):1019–26.",{"doi":999},"10.1093\u002Fajcn\u002F73.6.1019",{"id":26,"text":1001,"url":26,"identifiers":1002},"Siri-Tarino PW, Sun Q, Hu FB, et al. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am J Clin Nutr. 2010;91(3):535–46.",{"doi":1003},"10.3945\u002Fajcn.2009.27725",{"id":26,"text":1005,"url":26,"identifiers":1006},"Djousse L, Gaziano JM, Buring JE, et al. Egg consumption and risk of type 2 diabetes in men and women. Diabetes Care. 2009;32(2):295–300.",{"doi":1007},"10.2337\u002Fdc08-1271",{"id":26,"text":1009,"url":26,"identifiers":1010},"Rajpathak S, Ma J, Manson J, et al. Iron intake and the risk of type 2 diabetes in women: a prospective cohort study. Diabetes Care. 2006;29(6):1370–6.",{"doi":1011},"10.2337\u002Fdc06-0119",{"id":26,"text":1013,"url":26,"identifiers":1014},"Lee DH, Folsom AR, Jacobs Jr DR. Dietary iron intake and Type 2 diabetes incidence in postmenopausal women: the Iowa Women's Health Study. Diabetologia. 2004;47(2):185–94.",{"doi":1015},"10.1007\u002Fs00125-003-1307-1",{"id":26,"text":1017,"url":26,"identifiers":1018},"Zhao Z, Li S, Liu G, et al. Body iron stores and heme-iron intake in relation to risk of type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2012;7(7):e41641.",{"doi":1019},"10.1371\u002Fjournal.pone.0041641",{"id":26,"text":1021,"url":26,"identifiers":1022},"Sacks FM, Campos H. Dietary therapy in hypertension. N Engl J Med. 2010;362(22):2102–12.",{"doi":1023},"10.1056\u002FNEJMct0911013",{"id":26,"text":1025,"url":26,"identifiers":1026},"He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens. 2002;16(11):761–70.",{"doi":1027},"10.1038\u002Fsj.jhh.1001459",{"id":26,"text":1029,"url":26,"identifiers":1030},"Singh G.M., Danaei G., Farzadfar F., et al., Effect sizes for cardiovascular disease and diabetes outcomes of metabolic risk factors for population-based comparative risk assessment (CRA). Int J Cardiol, 2012. Under Review.",{},{"id":26,"text":1032,"url":26,"identifiers":1033},"Forstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med. 2008;5(6):338–49.",{"doi":1034},"10.1038\u002Fncpcardio1211",{"id":26,"text":1036,"url":26,"identifiers":1037},"McGrowder D, Ragoobirsingh D, Dasgupta T. Effects of S-nitroso-N-acetyl-penicillamine administration on glucose tolerance and plasma levels of insulin and glucagon in the dog. Nitric Oxide. 2001;5(4):402–12.",{"doi":1038},"10.1006\u002Fniox.2001.0360",{"id":26,"text":1040,"url":26,"identifiers":1041},"Portha B, Giroix MH, Cros JC, et al. Diabetogenic effect of N-nitrosomethylurea and N-nitrosomethylurethane in the adult rat. Ann Nutr Aliment. 1980;34(5–6):1143–51.",{},{"id":26,"text":1043,"url":26,"identifiers":1044},"Gajdosik A., Gajdosikova A , Stefek M., et al., Streptozotocin-induced experimental diabetes in male Wistar rats. Gen Physiol Biophys, 1999. 18 Spec No: p. 54–62.",{},{"id":26,"text":1046,"url":26,"identifiers":1047},"Virtanen SM, Jaakkola L, Rasanen L, et al. Nitrate and nitrite intake and the risk for type 1 diabetes in Finnish children. Childhood Diabetes in Finland Study Group. Diabet Med. 1994;11(7):656–62.",{"doi":1048},"10.1111\u002Fj.1464-5491.1994.tb00328.x",{"id":26,"text":1050,"url":26,"identifiers":1051},"Parslow RC, McKinney PA, Law GR, et al. Incidence of childhood diabetes mellitus in Yorkshire, northern England, is associated with nitrate in drinking water: an ecological analysis. Diabetologia. 1997;40(5):550–6.",{"doi":1052},"10.1007\u002Fs001250050714",{"id":26,"text":1054,"url":26,"identifiers":1055},"Kleinbongard P, Dejam A, Lauer T, et al. Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med. 2006;40(2):295–302.",{"doi":1056},"10.1016\u002Fj.freeradbiomed.2005.08.025",{"id":26,"text":1058,"url":26,"identifiers":1059},"Pereira EC, Ferderbar S, Bertolami MC, et al. Biomarkers of oxidative stress and endothelial dysfunction in glucose intolerance and diabetes mellitus. Clin Biochem. 2008;41(18):1454–60.",{"doi":1060},"10.1016\u002Fj.clinbiochem.2008.08.074",{"id":26,"text":1062,"url":26,"identifiers":1063},"Binkova B, Smerhovsky Z, Strejc P, et al. DNA-adducts and atherosclerosis: a study of accidental and sudden death males in the Czech Republic. Mutat Res. 2002;501(1–2):115–28.",{"doi":1064},"10.1016\u002FS0027-5107(02)00019-2",{"id":26,"text":1066,"url":26,"identifiers":1067},"Lakshmi VM, Schut HA, Zenser TV. 2-Nitrosoamino-3-methylimidazo[4,5-f]quinoline activated by the inflammatory response forms nucleotide adducts. Food Chem Toxicol. 2005;43(11):1607–17.",{"doi":1068},"10.1016\u002Fj.fct.2005.05.002",{"id":26,"text":1070,"url":26,"identifiers":1071},"Bogen KT, Keating GA. U.S. dietary exposures to heterocyclic amines. J Expo Anal Environ Epidemiol. 2001;11(3):155–68.",{"doi":1072},"10.1038\u002Fsj.jea.7500158",{"id":26,"text":1074,"url":26,"identifiers":1075},"Anderson RN, Rosenberg HM. Disease classification: measuring the effect of the Tenth Revision of the International Classification of Diseases on cause-of-death data in the United States. Stat Med. 2003;22(9):1551–70.",{"doi":1076},"10.1002\u002Fsim.1511",{"id":26,"text":1078,"url":26,"identifiers":1079},"Mozaffarian D. Meat intake and mortality: evidence for harm, no effect, or benefit? Arch Intern Med. 2009;169(16):1537–8. author reply 1539.",{"doi":1080},"10.1001\u002Farchinternmed.2009.277",{"id":26,"text":1082,"url":26,"identifiers":1083},"Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86(3):803–11.",{"doi":1084},"10.1161\u002F01.CIR.86.3.803",{"id":26,"text":1086,"url":26,"identifiers":1087},"Kontogianni MD, Panagiotakos DB, Pitsavos C, et al. Relationship between meat intake and the development of acute coronary syndromes: the CARDIO2000 case-control study. Eur J Clin Nutr. 2008;62(2):171–7.",{"doi":1088},"10.1038\u002Fsj.ejcn.1602713",{"id":26,"text":1090,"url":26,"identifiers":1091},"Tavani A, Bertuzzi M, Gallus S, et al. Risk factors for non-fatal acute myocardial infarction in Italian women. Prev Med. 2004;39(1):128–34.",{"doi":1092},"10.1016\u002Fj.ypmed.2004.01.010",{"id":26,"text":1094,"url":26,"identifiers":1095},"Dietary Guidelines Advisory Committee. 2010 Dietary Guidelines For Americans. 2010 [cited Jan 31, 2011]; Available from: http:\u002F\u002Fwww.cnpp.usda.gov\u002FPublications\u002FDietaryGuidelines\u002F2010\u002FPolicyDoc\u002FPolicyDoc.pdf .",{},{"id":26,"text":1097,"url":26,"identifiers":1098},"Steinfeld H., Gerber P.,Wassenaar T., et al. Livestock's Long Shadow: Environmental Issues and Options, FAO, Editor. 2006: Rome.",{},{"id":26,"text":1100,"url":26,"identifiers":1101},"Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. [cited; Available from: http:\u002F\u002Fwww.cdc.gov.nchs\u002Fnhanes.htm .",{},{"id":26,"text":1103,"url":26,"identifiers":1104},"Griesenbeck JS, Steck MD, Huber Jr JC, et al. Development of estimates of dietary nitrates, nitrites, and nitrosamines for use with the Short Willet Food Frequency Questionnaire. Nutr J. 2009;8:16.",{"doi":1105},"10.1186\u002F1475-2891-8-16",false,{"id":1108,"createTime":1109,"updateTime":1110,"relativeEntities":1111,"slug":1112,"properties":1113,"entityType":760,"verifyStatus":25,"verifyTime":1110,"verifyNote":762,"syncStatus":28,"languages":1126,"translateLanguages":26,"viewCount":36,"primaryUrl":1127,"fullTextUrl":26,"authors":1128,"publicationType":830,"publisherRelationship":1169,"citationCount":1198,"citationInfo":1199,"publishDate":1201,"publishYear":1202,"citationAnalyzeStatus":1203,"lastCitationAnalyze":1204,"indexDatabases":26,"openAccess":26,"references":1205,"isForceReanalyzing":1106},"837b82e8-c972-4d58-8c76-7489192e9db8","2024-04-11T22:35:54.989+00:00","2024-12-21T03:09:38.103+00:00",[],"Diabetes-and-cardiovascular-disease",{"mag":1114,"keywords":1116,"openalex":1117,"abstract":1119,"title":1120,"pm":1122,"doi":1124},{"VOID":1115},"3022958147",{},{"VOID":1118},"W3022958147",{},{"EN":1121},"Diabetes and cardiovascular disease",{"VOID":1123},"11122781",{"VOID":1125},"10.1007\u002Fs11883-000-0046-8",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11883-000-0046-8",[1129,1150],{"id":1130,"sortIndex":115,"researcher":26,"roles":1131,"affiliations":1132,"properties":1143},"5a89703a-59d2-489e-a2e6-1ff443e3d368",[],[1133],{"id":26,"sortIndex":36,"affiliation":1134,"properties":26},{"id":1135,"createTime":1136,"updateTime":1137,"relativeEntities":1138,"slug":1139,"properties":1140,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"3e68c56b-789b-4df5-9551-0e6b63e8ed2b","2024-01-25T20:10:54.367+00:00","2024-10-11T07:34:53.640+00:00",[],"Medstar-Research-Institute-Washington-DC-USA",{"title":1141},{"VI":1142},"Medstar Research Institute, Washington, DC USA",{"openalex":1144,"orcid":1146,"title":1148},{"VOID":1145},"A5082131619",{"VOID":1147},"https:\u002F\u002Forcid.org\u002F0000-0002-4692-3201",{"EN":1149},"Michelle F. Magee",{"id":1151,"sortIndex":36,"researcher":26,"roles":1152,"affiliations":1153,"properties":1164},"9d53cf20-fc8f-41fe-bcd6-27ad894b8677",[],[1154],{"id":26,"sortIndex":36,"affiliation":1155,"properties":26},{"id":1156,"createTime":1157,"updateTime":1158,"relativeEntities":1159,"slug":1160,"properties":1161,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"21066382-9da2-4c91-9183-f9a44290884f","2024-04-11T22:35:54.998+00:00","2024-09-11T20:13:39.675+00:00",[],"MedStar-Research-Institute-108-Irving-Street-NW-Annex-5-Washington-DC-20010-USA-",{"title":1162},{"EN":1163},"MedStar Research Institute, 108 Irving Street, NW, Annex 5, Washington, DC 20010, USA.",{"openalex":1165,"title":1167},{"VOID":1166},"A5018436834",{"EN":1168},"Barbara V. Howard",{"url":26,"publisher":1170,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":1171,"slug":663,"properties":1172,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1176,"manageAffiliations":1177,"indexDatabases":1178,"url":730,"thumbnailPath":26,"statistic":1193,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":1173,"eissn":1174,"title":1175},{"VOID":666},{"VOID":668},{"EN":670},[],[],[1179,1186],{"id":712,"indexDatabase":1180,"url":725,"indexYears":726,"academicFieldIds":1185,"indexDatabaseRanking":729},{"id":714,"createTime":715,"updateTime":716,"relativeEntities":1181,"label":1182,"description":1183,"key":722,"publicationTags":1184,"standard":26},[],{"EN":719,"VI":719},{"EN":719,"VI":721},[724],[728],{"id":693,"indexDatabase":1187,"url":708,"indexYears":26,"academicFieldIds":1192,"indexDatabaseRanking":26},{"id":695,"createTime":696,"updateTime":697,"relativeEntities":1188,"label":1189,"description":1190,"key":704,"publicationTags":1191,"standard":26},[],{"EN":700,"VI":700},{"VI":702,"EN":703},[706,707],[710],{"impactFactor":36,"impactFactorByYear":1194,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":51,"totalPublicationByYear":1195,"totalCitation":36,"totalCitationByYear":1196,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":1197,"hindexLast5Year":36,"hindex":36},{},{"2002":115,"2003":115,"2004":114,"2006":114,"2007":115,"2011":115,"2012":115,"2013":115,"2017":115,"2019":114,"2020":115,"2023":115},{},{},430,{"total":1198,"publishYear":26,"statisticByYear":1200},{"2012":517,"2013":287,"2014":241,"2015":242,"2016":158,"2017":162,"2018":115,"2019":114,"2020":111,"2021":115,"2022":59,"2023":114},"2000-11-01",2000,"ERROR_IN_ANALYZE_CITATION","2024-04-12T03:26:32.466+00:00",[1206,1209,1212,1216,1219,1223,1226,1229,1233,1237,1241,1245,1249,1253,1256,1260,1264,1267,1271,1274,1278,1282,1286,1290,1293,1297,1301,1305,1309,1313,1317,1321,1325,1329,1333,1337,1341,1345],{"id":26,"text":1207,"url":26,"identifiers":1208},"Diabetes in America, edn 2. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Diabetes Data Group; 1995.",{},{"id":26,"text":1210,"url":26,"identifiers":1211},"Howard BV, Magee MF: Macrovascular complications of diabetes mellitus. In Diabetes Mellitus, edn 2. Edited by LeRoith D, Taylor SI, Olefsky JM. Philadelphia: Lippincott-Raven, 2000:957–962.",{},{"id":26,"text":1213,"url":26,"identifiers":1214},"Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229–234.",{"doi":1215},"10.1056\u002FNEJM199807233390404",{"id":26,"text":1217,"url":26,"identifiers":1218},"Sievers ML, Fisher JR: Diseases of North American Indians. In Biocultural Aspects of Disease. Edited by Rothschild HR. New York: Academic Press; 1981:191–252.",{},{"id":26,"text":1220,"url":26,"identifiers":1221},"Howard BV, Lee ET, Cowan LD, et al.: Coronary heart disease prevalence and its relation to risk factors in American Indians: the Strong Heart Study. Am J Epidemiol 1995, 142:254–268.",{"doi":1222},"10.1093\u002Foxfordjournals.aje.a117632",{"id":26,"text":1224,"url":26,"identifiers":1225},"Indian Health Service: IHS Chart Series Book, June 1984. Washington DC, U.S. Government Printing Office, US Dept. of Health & Human Services; 1984.",{},{"id":26,"text":1227,"url":26,"identifiers":1228},"US Congress: Office of Technology Assessment. Indian Health Care. OTA-H-290. Washington, DC: US Government Printing Office; April, 1986.",{},{"id":26,"text":1230,"url":26,"identifiers":1231},"Lee ET, Cowan LD, Welty TK, et al.: All-cause mortality and cardiovascular disease mortality in three American Indian populations, aged 45–74 years, 1984–1988: The Strong Heart Study. Am J Epidemiol, 1998, 147:995–1008.",{"doi":1232},"10.1093\u002Foxfordjournals.aje.a009406",{"id":26,"text":1234,"url":26,"identifiers":1235},"Howard BV, Lee ET, Cowan LD, et al.: Rising tide of cardiovascular disease in American Indians: the Strong Heart study. Circulation 1999, 99:2389–2395.",{"doi":1236},"10.1161\u002F01.CIR.99.18.2389",{"id":26,"text":1238,"url":26,"identifiers":1239},"Chambless LE, Heiss G, Folsom AR, et al.: Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) study, 1987 to 1993. Am J Epidemiol 1997, 146:483–494.",{"doi":1240},"10.1093\u002Foxfordjournals.aje.a009302",{"id":26,"text":1242,"url":26,"identifiers":1243},"Howard BV, Cowan LD, Go O, et al.: Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. Diabetes Care 1998, 21:1258–1265.",{"doi":1244},"10.2337\u002Fdiacare.21.8.1258",{"id":26,"text":1246,"url":26,"identifiers":1247},"Howard BV, Lee ET, Cowan LD, et al.: LDL cholesterol is a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: the Strong Heart study. Atheroscler Thromb Vasc Biol 2000, 20:830–835.",{"doi":1248},"10.1161\u002F01.ATV.20.3.830",{"id":26,"text":1250,"url":26,"identifiers":1251},"Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434–444.",{"doi":1252},"10.2337\u002Fdiacare.16.2.434",{"id":26,"text":1254,"url":26,"identifiers":1255},"Haffner SM, Cassells HB: Type 2 diabetes and coronary heart disease. Role of dyslipidemia and insulin resistance. Practical Diabetology 1998:6–9.",{},{"id":26,"text":1257,"url":26,"identifiers":1258},"Goldberg RB: Cardiovascular disease in diabetic patients. Med Clin North Am 2000, 34:81–93.",{"doi":1259},"10.1016\u002FS0025-7125(05)70208-X",{"id":26,"text":1261,"url":26,"identifiers":1262},"Borch-Johnsen K, Kreiner S: Proteinuria: value as predictor of cardiovascular mortality in insulin-dependent diabetes mellitus. BMJ 1987, 294:1651–1654.",{"doi":1263},"10.1136\u002Fbmj.294.6588.1651",{"id":26,"text":1265,"url":26,"identifiers":1266},"Parving HH, Gall MA, Neilson FS: Dyslipidaemia and cardiovascular disease in non-insulin-dependent diabetic patients with and without diabetic nephropathy. J Intern Med 1994, 736:89–94.",{},{"id":26,"text":1268,"url":26,"identifiers":1269},"Savage S, Estacio RO, Jeffers B, Schrier RW: Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care 1996, 19:1243–1248.",{"doi":1270},"10.2337\u002Fdiacare.19.11.1243",{"id":26,"text":1272,"url":26,"identifiers":1273},"Rahmaniyan M, Robbins DC, Roman MJ: Albuminuria (UA) is independently associated with larger left ventricular (LV) mass in NIDDM: the Strong Heart Study (SHS). Diabetes 1998, 47:A9.",{},{"id":26,"text":1275,"url":26,"identifiers":1276},"Lydakis C, Lip GY: Microalbuminuria and cardiovascular risk. QJM 1998, 91:381–391.",{"doi":1277},"10.1093\u002Fqjmed\u002F91.6.381",{"id":26,"text":1279,"url":26,"identifiers":1280},"McCarty MF: Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses 1999, 52:465–477.",{"doi":1281},"10.1054\u002Fmehy.1997.0684",{"id":26,"text":1283,"url":26,"identifiers":1284},"Duh E, Aiello LP: Vascular endothelial growth factor and diabetes: The agonist versus antagonist paradox. Diabetes 1999, 48:1899–1906.",{"doi":1285},"10.2337\u002Fdiabetes.48.10.1899",{"id":26,"text":1287,"url":26,"identifiers":1288},"de Luis DA, Lahera M, Canton R, et al.: Association of Helicobacter pylori infection with cardiovascular and cerebrovascular disease in diabetic patients. Diabetes Care 1998, 21:1129–1132.",{"doi":1289},"10.2337\u002Fdiacare.21.7.1129",{"id":26,"text":1291,"url":26,"identifiers":1292},"Kenny SJ, Aubert RF, Geiss LS: Prevalence and incidence of non-insulin-dependent diabetes. In Diabetes in America, edn 2. Edited by Harris MI, Cowie CC, Stern MP, et al. Washington, DC: US Government Printing Office; 1995:47–68 (NIH Publ. No. 95-1468).",{},{"id":26,"text":1294,"url":26,"identifiers":1295},"Harris MI, Hadden WC, Knowler WC, Bennett PH: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20–74 yr. Diabetes 1987, 36:523–534.",{"doi":1296},"10.2337\u002Fdiab.36.4.523",{"id":26,"text":1298,"url":26,"identifiers":1299},"Kannel WB, McGee DL: Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979, 2:120–126.",{"doi":1300},"10.2337\u002Fdiacare.2.2.120",{"id":26,"text":1302,"url":26,"identifiers":1303},"Kannel WB, Wilson PWF: Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995, 155:57–61.",{"doi":1304},"10.1001\u002Farchinte.1995.00430010063008",{"id":26,"text":1306,"url":26,"identifiers":1307},"Heyden S, Heiss G, Bartel AG, Hames CG: Sex differences in coronary mortality among diabetics in Evans County, Georgia. J Chron Dis 1980, 33:265–273.",{"doi":1308},"10.1016\u002F0021-9681(80)90021-1",{"id":26,"text":1310,"url":26,"identifiers":1311},"Pan WH, Cedres LB, Liu K, et al.: Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol 1986, 123:504–516.",{"doi":1312},"10.1093\u002Foxfordjournals.aje.a114266",{"id":26,"text":1314,"url":26,"identifiers":1315},"Elveback LR, Connolly DC, Melton LJ: Coronary heart disease in residents of Rochester, Minnesota: incidence, 1950 through 1982. Mayo Clin Proc 1986, 61:896–900.",{"doi":1316},"10.1016\u002FS0025-6196(12)62612-3",{"id":26,"text":1318,"url":26,"identifiers":1319},"DeStefano F, Ford ES, Newman J, et al.: Risk factors of coronary heart disease mortality among persons with diabetes. Ann Epidemiol 1993, 3:27–34.",{"doi":1320},"10.1016\u002F1047-2797(93)90006-P",{"id":26,"text":1322,"url":26,"identifiers":1323},"Sprafka JM, Pankow J, McGovern PG, French LR: Mortality among type 2 diabetic individuals and associated risk factors: the Three City study. Diabet Med 1993, 10:627–632.",{"doi":1324},"10.1111\u002Fj.1464-5491.1993.tb00135.x",{"id":26,"text":1326,"url":26,"identifiers":1327},"Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL: Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? the Rancho Bernardo study. JAMA 1991, 265:627–631.",{"doi":1328},"10.1001\u002Fjama.1991.03460050081025",{"id":26,"text":1330,"url":26,"identifiers":1331},"Rewers M, Shetterly SM, Baxter J, et al.: Prevalence of coronary heart disease in subjects with normal and impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a biethnic Colorado population: the San Luis Valley Diabetes study. Am J Epidemiol 1992, 135:1321–1330.",{"doi":1332},"10.1093\u002Foxfordjournals.aje.a116243",{"id":26,"text":1334,"url":26,"identifiers":1335},"Matthews KA, Meilahn E, Kuller LH, et al.: Menopause and risk factors for coronary heart disease. N Engl J Med 1989, 321:641–646.",{"doi":1336},"10.1056\u002FNEJM198909073211004",{"id":26,"text":1338,"url":26,"identifiers":1339},"Wahl PW, Walden CE, Knopp RH, et al.: Lipid and lipoprotein triglyceride and cholesterol interrelationships: effects of sex, hormone use, and hyperlipidemia. Metabolism 1984, 33:502–508.",{"doi":1340},"10.1016\u002F0026-0495(84)90003-9",{"id":26,"text":1342,"url":26,"identifiers":1343},"Knopp RH, Zhu X, Bonet B: Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women. Atherosclerosis 1995, 110:S83-S91.",{"doi":1344},"10.1016\u002F0021-9150(94)05379-W",{"id":26,"text":1346,"url":26,"identifiers":1347},"Peiris AN, Aiman EJ, Drucker WD, Kissebah AH: The relative contributions of hepatic and peripheral tissue to insulin resistance in hyperandrogenic women. J Clin Endocrin Metab 1989, 68:715–720.",{"doi":1348},"10.1210\u002Fjcem-68-4-715",{"id":1350,"createTime":1351,"updateTime":1351,"relativeEntities":1352,"slug":1353,"properties":1354,"entityType":760,"verifyStatus":25,"verifyTime":1351,"verifyNote":762,"syncStatus":28,"languages":1367,"translateLanguages":26,"viewCount":36,"primaryUrl":1368,"fullTextUrl":26,"authors":1369,"publicationType":830,"publisherRelationship":1408,"citationCount":1442,"citationInfo":1443,"publishDate":1445,"publishYear":1446,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":1447,"isForceReanalyzing":1106},"d17f0e4c-2cc3-446a-90f9-923326c8e01d","2024-09-24T09:02:27.525+00:00",[],"Omega-3-fatty-acids-and-inflammation",{"mag":1355,"keywords":1357,"openalex":1358,"abstract":1360,"title":1361,"pm":1363,"doi":1365},{"VOID":1356},"1967514197",{},{"VOID":1359},"W1967514197",{},{"EN":1362},"Omega-3 fatty acids and inflammation",{"VOID":1364},"15485592",{"VOID":1366},"10.1007\u002Fs11883-004-0087-5",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11883-004-0087-5",[1370,1391],{"id":1371,"sortIndex":115,"researcher":26,"roles":1372,"affiliations":1373,"properties":1384},"2bf80aee-105c-4cfa-84ec-b57500ef40bb",[],[1374],{"id":1375,"sortIndex":36,"affiliation":1376,"properties":26},"4cff4805-9bc0-4686-a6ef-9d47948f12ae",{"id":1377,"createTime":1378,"updateTime":1378,"relativeEntities":1379,"slug":1380,"properties":1381,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"79a8ff59-6f6e-432f-ab0d-ae10787b7f96","2024-09-24T09:02:27.542+00:00",[],"School-of-Medicine-and-Pharmacology-Royal-Perth-Hospital-Unit-The-University-of-Western-Australia-Medical-Research-Foundation-Building-Box-X-2213-GPO-6847-Perth-Western-Australia-Australia",{"title":1382},{"EN":1383},"School of Medicine and Pharmacology - Royal Perth Hospital Unit, The University of Western Australia, Medical Research Foundation Building, Box X 2213 GPO, 6847, Perth, Western Australia, Australia",{"openalex":1385,"orcid":1387,"title":1389},{"VOID":1386},"A5024230104",{"VOID":1388},"https:\u002F\u002Forcid.org\u002F0000-0003-4853-7360",{"EN":1390},"Lawrence J. Beilin",{"id":1392,"sortIndex":36,"researcher":26,"roles":1393,"affiliations":1394,"properties":1401},"2320620c-6e7b-480b-b248-66a22e38f6f2",[],[1395],{"id":1396,"sortIndex":36,"affiliation":1397,"properties":26},"0487ed9e-50df-4cec-a814-c72beff66b15",{"id":1377,"createTime":1378,"updateTime":1378,"relativeEntities":1398,"slug":1380,"properties":1399,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1400},{"EN":1383},{"openalex":1402,"orcid":1404,"title":1406},{"VOID":1403},"A5045012584",{"VOID":1405},"https:\u002F\u002Forcid.org\u002F0000-0002-5264-9229",{"EN":1407},"Trevor A. Mori",{"url":26,"publisher":1409,"properties":1437},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":1410,"slug":663,"properties":1411,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1415,"manageAffiliations":1416,"indexDatabases":1417,"url":730,"thumbnailPath":26,"statistic":1432,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":1412,"eissn":1413,"title":1414},{"VOID":666},{"VOID":668},{"EN":670},[],[],[1418,1425],{"id":712,"indexDatabase":1419,"url":725,"indexYears":726,"academicFieldIds":1424,"indexDatabaseRanking":729},{"id":714,"createTime":715,"updateTime":716,"relativeEntities":1420,"label":1421,"description":1422,"key":722,"publicationTags":1423,"standard":26},[],{"EN":719,"VI":719},{"EN":719,"VI":721},[724],[728],{"id":693,"indexDatabase":1426,"url":708,"indexYears":26,"academicFieldIds":1431,"indexDatabaseRanking":26},{"id":695,"createTime":696,"updateTime":697,"relativeEntities":1427,"label":1428,"description":1429,"key":704,"publicationTags":1430,"standard":26},[],{"EN":700,"VI":700},{"VI":702,"EN":703},[706,707],[710],{"impactFactor":36,"impactFactorByYear":1433,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":51,"totalPublicationByYear":1434,"totalCitation":36,"totalCitationByYear":1435,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":1436,"hindexLast5Year":36,"hindex":36},{},{"2002":115,"2003":115,"2004":114,"2006":114,"2007":115,"2011":115,"2012":115,"2013":115,"2017":115,"2019":114,"2020":115,"2023":115},{},{},{"volume":1438,"pages":1439,"issue":1441},{"VOID":866},{"VOID":1440},"461-467",{"VOID":866},397,{"total":1442,"publishYear":26,"statisticByYear":1444},{"2012":241,"2013":239,"2014":124,"2015":237,"2016":173,"2017":298,"2018":173,"2019":336,"2020":298,"2021":242,"2022":298,"2023":50,"2024":135},"2004-11-01",2004,[1448,1451,1455,1459,1463,1467,1471,1474,1478,1482,1486,1488,1492,1496,1500,1504,1508,1512,1516,1520,1524,1528,1532,1536,1540,1544,1548,1552,1556,1560,1564,1568,1572,1576,1580,1584,1588,1592,1595,1599,1603,1607,1611,1615,1619],{"id":26,"text":1449,"url":26,"identifiers":1450},"Mori TA, Beilin LJ: n-3 Fatty acids, blood lipids and cardiovascular risk reduction. Curr Opin Lipidol 2001, 12:1211–1217.",{},{"id":26,"text":1452,"url":26,"identifiers":1453},"Calder PC: Polyunsaturated fatty acids, inflammation, and immunity. Lipids 2001, 36:1007–1024.",{"doi":1454},"10.1007\u002Fs11745-001-0812-7",{"id":26,"text":1456,"url":26,"identifiers":1457},"Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340:115–126.",{"doi":1458},"10.1056\u002FNEJM199901143400207",{"id":26,"text":1460,"url":26,"identifiers":1461},"Browning LM: n-3 Polyunsaturated fatty acids, inflammation and obesity-related disease. Proc Nutrition Soc 2003, 62:447–453.",{"doi":1462},"10.1079\u002FPNS2003252",{"id":26,"text":1464,"url":26,"identifiers":1465},"Simopoulos AP: Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002, 21:495–505.",{"doi":1466},"10.1080\u002F07315724.2002.10719248",{"id":26,"text":1468,"url":26,"identifiers":1469},"Gil A: Polyunsaturated fatty acids and inflammatory diseases. Biomed Pharmacother 2002, 56:388–396.",{"doi":1470},"10.1016\u002FS0753-3322(02)00256-1",{"id":26,"text":1472,"url":26,"identifiers":1473},"Sakr HM, Dunham EW: Mechanism of arachidonic acid-induced vasoconstriction in the intact rat kidney: possible involvement of thromboxane A2. J Pharmacol Exp Ther 1982, 221:614–622.",{},{"id":26,"text":1475,"url":26,"identifiers":1476},"De Caterina R, Endres S, Kristensen SD, Schmidt EB: n-3 fatty acids and renal diseases. Am J Kidney Dis 1994, 24:397–415.",{"doi":1477},"10.1016\u002FS0272-6386(12)80896-1",{"id":26,"text":1479,"url":26,"identifiers":1480},"Mori TA, Beilin LJ, Burke V, et al.: Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 1997, 17:279–286.",{"doi":1481},"10.1161\u002F01.ATV.17.2.279",{"id":26,"text":1483,"url":26,"identifiers":1484},"Harbige LS: Fatty acids, the immune response, and autoimmunity: a question of n-6 essentiality and the balance between n-6 and n-3. Lipids 2003, 38:323–341.",{"doi":1485},"10.1007\u002Fs11745-003-1067-z",{"id":26,"text":1279,"url":26,"identifiers":1487},{"doi":1281},{"id":26,"text":1489,"url":26,"identifiers":1490},"Madsen T, Skou HA, Hansen VE, et al.: C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. Am J Cardiol 2001, 88:1139–1142.",{"doi":1491},"10.1016\u002FS0002-9149(01)02049-5",{"id":26,"text":1493,"url":26,"identifiers":1494},"Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973–979.",{"doi":1495},"10.1056\u002FNEJM199704033361401",{"id":26,"text":1497,"url":26,"identifiers":1498},"Dunstan JA, Mori TA, Barden A, et al.: The effects of omega-3 polyunsaturated fatty acid supplementation in pregnancy on maternal and fetal erythrocyte fatty acid composition. Eur J Clin Nutr 2004, 58:429–437.",{"doi":1499},"10.1038\u002Fsj.ejcn.1601825",{"id":26,"text":1501,"url":26,"identifiers":1502},"Dunstan JA, Mori TA, Barden A, et al.: Maternal fish oil supplementation in pregnancy reduces interleukin-13 levels in cord blood of infants at high risk of atopy. Clin Exper Allergy 2003, 33:442–448.",{"doi":1503},"10.1046\u002Fj.1365-2222.2003.01590.x",{"id":26,"text":1505,"url":26,"identifiers":1506},"Dunstan JA, Mori TA, Barden A, et al.: Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: a randomised controlled trial. J Allergy Clin Immunol 2003, 112:1178–1184.",{"doi":1507},"10.1016\u002Fj.jaci.2003.09.009",{"id":26,"text":1509,"url":26,"identifiers":1510},"Fox PL, DiCorleto PE: Fish oils inhibit endothelial cell production of platelet-derived growth factor-like protein. Science 1988, 241:453–456.",{"doi":1511},"10.1126\u002Fscience.3393911",{"id":26,"text":1513,"url":26,"identifiers":1514},"Chandrasekar B, Troyer DA, Venkatraman JT, Fernandes G: Dietary omega-3 lipids delay the onset and progression of autoimmune lupus nephritis by inhibiting transforming growth factor beta mRNA and protein expression. J Autoimmunity 1995, 8:381–393.",{"doi":1515},"10.1006\u002Fjaut.1995.0030",{"id":26,"text":1517,"url":26,"identifiers":1518},"Nakayama M, Fukuda N, Watanabe Y, et al.: Low dose of eicosapentaenoic acid inhibits the exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats through suppression of transforming growth factor-beta. J Hypertens 1999, 17:1421–1430.",{"doi":1519},"10.1097\u002F00004872-199917100-00009",{"id":26,"text":1521,"url":26,"identifiers":1522},"Grande JP, Walker HJ, Holub BJ, et al.: Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo. Kidney Int 2000, 57:1027–1040.",{"doi":1523},"10.1046\u002Fj.1523-1755.2000.00930.x",{"id":26,"text":1525,"url":26,"identifiers":1526},"Grimble RF, Howell WM, O’Reilly G, et al.: The ability of fish oil to suppress tumor necrosis factor alpha production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor alpha production. Am J Clin Nutr 2002, 76:454–459.",{"doi":1527},"10.1093\u002Fajcn\u002F76.2.454",{"id":26,"text":1529,"url":26,"identifiers":1530},"Chan DC, Watts GF, Barrett PH, et al.: Effect of atorvastatin and fish oil on plasma high sensitive C-reactive protein concentrations in individuals with visceral obesity. Clin Chem 2002, 48:877–883.",{"doi":1531},"10.1093\u002Fclinchem\u002F48.6.877",{"id":26,"text":1533,"url":26,"identifiers":1534},"Nenseter MS, Drevon CA: Dietary polyunsaturates and peroxidation of low density lipoprotein. Curr Opin Lipidol 1996, 7:8–13.",{"doi":1535},"10.1097\u002F00041433-199602000-00003",{"id":26,"text":1537,"url":26,"identifiers":1538},"Steinberg D, Parthasarathy S, Carew TE, et al.: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915–924.",{"doi":1539},"10.1056\u002FNEJM198901053200122",{"id":26,"text":1541,"url":26,"identifiers":1542},"Liu J, Yeo HC, Doniger SJ, Ames BN: Assay of aldehydes from lipid peroxidation: gas chromatography-mass spectrometry compared to thiobarbituric acid. Anal Biochem 1997, 245:161–166.",{"doi":1543},"10.1006\u002Fabio.1996.9990",{"id":26,"text":1545,"url":26,"identifiers":1546},"Lawson JA, Rokach J, Fitzgerland GA: Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem 1999, 274:24441–24444.",{"doi":1547},"10.1074\u002Fjbc.274.35.24441",{"id":26,"text":1549,"url":26,"identifiers":1550},"Leitinger N, Huber J, Rizza C, et al.: The isoprostane 8-iso-PGF2a stimulates endothelial cells to bind monocytes: differences from thromboxane-mediated endothelial activation. FASEB J 2001, 15:1254–1256.",{"doi":1551},"10.1096\u002Ffj.00-0498fje",{"id":26,"text":1553,"url":26,"identifiers":1554},"Mori TA, Dunstan DW, Burke V, et al.: Effects of dietary fish and exercise training on urinary F2-isoprostane excretion in non-insulin dependent diabetic patients. Metabolism 1999, 48:1402–1408.",{"doi":1555},"10.1016\u002FS0026-0495(99)90150-6",{"id":26,"text":1557,"url":26,"identifiers":1558},"Barden AE, Mori TA, Dunstan JA, et al.: Fish oil supplementation in pregnancy lowers F2-isoprostanes in neonates at high risk of atopy. Free Rad Res 2004, 38:233–239.",{"doi":1559},"10.1080\u002F10715760310001656722",{"id":26,"text":1561,"url":26,"identifiers":1562},"Quaggiotto P, Leitch JW, Falconer J, et al.: Plasma F2alpha isoprostane levels are lowered in pigs fed an (n-3) polyunsaturated fatty acid supplemented diet following occlusion of the left anterior descending coronary artery. Nutr Res 2000, 20(5):675–684.",{"doi":1563},"10.1016\u002FS0271-5317(00)00157-3",{"id":26,"text":1565,"url":26,"identifiers":1566},"Higdon JV, Liu JK, Du SH, et al.: Supplementation of postmenopausal women with fish oil rich in eicosapentaenoic acid and docosahexaenoic acid is not associated with greater in vivo lipid peroxidation compared with oils rich in oleate and linoleate as assessed by plasma malondialdehyde and F2-isoprostanes. Am J Clin Nutr 2000, 72:714–722.",{"doi":1567},"10.1093\u002Fajcn\u002F72.3.714",{"id":26,"text":1569,"url":26,"identifiers":1570},"Mori TA, Puddey IB, Burke V, et al.: Effect of n-3 fatty acids on oxidative stress in humans: GCMS measurement of urinary F2-isoprostane excretion. Redox Rep 2000, 5:45–46.",{"doi":1571},"10.1179\u002Frer.2000.5.1.45",{"id":26,"text":1573,"url":26,"identifiers":1574},"Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD, Beilin LJ: Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers, in treated-hypertensive Type 2 diabetic subjects. Free Rad Biol Med 2003, 35:772–781.",{"doi":1575},"10.1016\u002FS0891-5849(03)00407-6",{"id":26,"text":1577,"url":26,"identifiers":1578},"Fisher M, Levine PH, Weiner BH, et al.: Dietary n-3 fatty acid supplementation reduces superoxide production and chemiluminescence in a monocyte-enriched preparation of leukocytes. Am J Clin Nutr 1990, 51:804–808.",{"doi":1579},"10.1093\u002Fajcn\u002F51.5.804",{"id":26,"text":1581,"url":26,"identifiers":1582},"Takahashi M, Tsuboyama-Kasaoka N, Nakatani T, et al.: Fish oil feeding alters liver gene expressions to defend against PPAR alpha activation and ROS production. Am J Physiol Gastrointest Liver Physiol 2002, 282:G338-G348.",{"doi":1583},"10.1152\u002Fajpgi.00376.2001",{"id":26,"text":1585,"url":26,"identifiers":1586},"Hansen JB, Olsen JO, Wilsgard L, Osterud B: Effects of dietary supplementation with cod liver oil on monocyte thromboplastin synthesis, coagulation and fibrinolysis. J Intern Med Suppl 1989, 225:133–139.",{"doi":1587},"10.1111\u002Fj.1365-2796.1989.tb01447.x",{"id":26,"text":1589,"url":26,"identifiers":1590},"Baumann KH, Hessel F, Larass I, et al.: Dietary omega-3, omega-6, and omega-9 unsaturated fatty acids and growth factor and cytokine gene expression in unstimulated and stimulated monocytes. A randomized volunteer study. Arterioscler Thromb Vasc Biol 1999, 19:59–66.",{"doi":1591},"10.1161\u002F01.ATV.19.1.59",{"id":26,"text":1593,"url":26,"identifiers":1594},"Shimokawa H, Vanhoutte PM: Dietary omega 3 fatty acids and endothelium-dependent relaxations in porcine coronary arteries. Am J Physiol 1989, 256(4 Pt 2):H968-H973.",{},{"id":26,"text":1596,"url":26,"identifiers":1597},"De Caterina R, Zampolli A: n-3 Fatty acids: antiatherosclerotic effects. Lipids 2001, 36(Suppl):S69-S78.",{"doi":1598},"10.1007\u002Fs11745-001-0685-9",{"id":26,"text":1600,"url":26,"identifiers":1601},"Beilin LJ, Mori TA: Dietary n-3 fatty acids. In Lifestyle Modification for the Prevention and Treatment of Hypertension. Edited by PK Whelton, He J, Louis GT. New York: Marcel Dekker; 2003:275–300.",{"doi":1602},"10.1201\u002Fb14224-13",{"id":26,"text":1604,"url":26,"identifiers":1605},"Mori TA, Watts GF, Burke V, et al.: Differential effects of eicosapentaenoic acid and docosahexaenoic acid on forearm vascular reactivity of the microcirculation in hyperlipidaemic, overweight men. Circulation 2000, 102:1264–1269.",{"doi":1606},"10.1161\u002F01.CIR.102.11.1264",{"id":26,"text":1608,"url":26,"identifiers":1609},"Suzuki T, Fukuo K, Suhara T, et al.: Eicosapentaenoic acid protects endothelial cells against anoikis through restoration of cFLIP. Hypertension 2003, 42:342–348.",{"doi":1610},"10.1161\u002F01.HYP.0000084602.06114.AD",{"id":26,"text":1612,"url":26,"identifiers":1613},"Diep QN, Touyz RM, Schiffrin EL: Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension 2000, 36:851–855.",{"doi":1614},"10.1161\u002F01.HYP.36.5.851",{"id":26,"text":1616,"url":26,"identifiers":1617},"Meydani SN, Lichtenstein AH, Cornwall S, et al.: Immunologic effects of national cholesterol education panel step-2 diets with and without fish-derived N-3 fatty acid enrichment. J Clin Invest 1993, 92:105–113.",{"doi":1618},"10.1172\u002FJCI116537",{"id":26,"text":1620,"url":26,"identifiers":1621},"Calder PC, Zurier RB: Polyunsaturated fatty acids and rheumatoid arthritis. Curr Opin Clin Nutr Metab Care 2001, 4:115–121.",{"doi":1622},"10.1097\u002F00075197-200103000-00006",{"id":1624,"createTime":1625,"updateTime":1626,"relativeEntities":1627,"slug":1628,"properties":1629,"entityType":760,"verifyStatus":25,"verifyTime":1626,"verifyNote":762,"syncStatus":28,"languages":1642,"translateLanguages":26,"viewCount":36,"primaryUrl":1643,"fullTextUrl":26,"authors":1644,"publicationType":830,"publisherRelationship":1699,"citationCount":1728,"citationInfo":1729,"publishDate":1731,"publishYear":1732,"citationAnalyzeStatus":1203,"lastCitationAnalyze":1733,"indexDatabases":26,"openAccess":26,"references":1734,"isForceReanalyzing":1106},"21a38ba3-496f-4832-9529-73e7b8f97f0c","2024-04-14T13:38:55.989+00:00","2025-01-04T08:24:43.061+00:00",[],"Dietary-intake-of-fruits-and-vegetables-and-risk-of-cardiovascular-disease",{"mag":1630,"keywords":1632,"openalex":1633,"abstract":1635,"title":1636,"pm":1638,"doi":1640},{"VOID":1631},"2069154878",{},{"VOID":1634},"W2069154878",{},{"EN":1637},"Dietary intake of fruits and vegetables and risk of cardiovascular disease",{"VOID":1639},"14525683",{"VOID":1641},"10.1007\u002Fs11883-003-0040-z",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11883-003-0040-z",[1645,1665,1685],{"id":1646,"sortIndex":36,"researcher":26,"roles":1647,"affiliations":1648,"properties":1658},"33f4791a-87b1-44ad-b78a-75f3146243db",[],[1649],{"id":26,"sortIndex":36,"affiliation":1650,"properties":26},{"id":1651,"createTime":1652,"updateTime":1652,"relativeEntities":1653,"slug":1654,"properties":1655,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"5cfc236b-3edf-4f2f-a3df-6f37337b40ba","2024-04-14T13:38:56.000+00:00",[],"Division-of-Preventive-Medicine-Harvard-Medical-School-Brigham-and-Women-s-Hospital-900-Commonwealth-Avenue-Boston-MA-02215-USA-",{"title":1656},{"EN":1657},"Division of Preventive Medicine, Harvard Medical School & Brigham and Women's Hospital, 900 Commonwealth Avenue, Boston, MA 02215, USA.",{"openalex":1659,"orcid":1661,"title":1663},{"VOID":1660},"A5049612047",{"VOID":1662},"https:\u002F\u002Forcid.org\u002F0000-0002-8958-1352",{"EN":1664},"Lydia A. Bazzano",{"id":1666,"sortIndex":114,"researcher":26,"roles":1667,"affiliations":1668,"properties":1678},"ac638c8a-a335-4f3c-8390-c1c6771e7b33",[],[1669],{"id":26,"sortIndex":36,"affiliation":1670,"properties":26},{"id":1671,"createTime":1672,"updateTime":1672,"relativeEntities":1673,"slug":1674,"properties":1675,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"d62862d9-7b12-4d21-b1c9-09ee4c761393","2024-04-14T13:38:56.018+00:00",[],"Division-of-Preventive-Medicine-Harvard-Medical-School-Brigham-and-Women-s-Hospital-Boston-USA",{"title":1676},{"EN":1677},"Division of Preventive Medicine, Harvard Medical School & Brigham and Women’s Hospital, Boston, USA",{"openalex":1679,"orcid":1681,"title":1683},{"VOID":1680},"A5003794185",{"VOID":1682},"https:\u002F\u002Forcid.org\u002F0000-0003-2098-3844",{"EN":1684},"Simin Liu",{"id":1686,"sortIndex":115,"researcher":26,"roles":1687,"affiliations":1688,"properties":1694},"67d082ef-26ad-4923-98b4-0a28905005d3",[],[1689],{"id":26,"sortIndex":36,"affiliation":1690,"properties":26},{"id":1671,"createTime":1672,"updateTime":1672,"relativeEntities":1691,"slug":1674,"properties":1692,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1693},{"EN":1677},{"openalex":1695,"title":1697},{"VOID":1696},"A5035093638",{"EN":1698},"Mary K. Serdula",{"url":26,"publisher":1700,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":1701,"slug":663,"properties":1702,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1706,"manageAffiliations":1707,"indexDatabases":1708,"url":730,"thumbnailPath":26,"statistic":1723,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":1703,"eissn":1704,"title":1705},{"VOID":666},{"VOID":668},{"EN":670},[],[],[1709,1716],{"id":712,"indexDatabase":1710,"url":725,"indexYears":726,"academicFieldIds":1715,"indexDatabaseRanking":729},{"id":714,"createTime":715,"updateTime":716,"relativeEntities":1711,"label":1712,"description":1713,"key":722,"publicationTags":1714,"standard":26},[],{"EN":719,"VI":719},{"EN":719,"VI":721},[724],[728],{"id":693,"indexDatabase":1717,"url":708,"indexYears":26,"academicFieldIds":1722,"indexDatabaseRanking":26},{"id":695,"createTime":696,"updateTime":697,"relativeEntities":1718,"label":1719,"description":1720,"key":704,"publicationTags":1721,"standard":26},[],{"EN":700,"VI":700},{"VI":702,"EN":703},[706,707],[710],{"impactFactor":36,"impactFactorByYear":1724,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":51,"totalPublicationByYear":1725,"totalCitation":36,"totalCitationByYear":1726,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":1727,"hindexLast5Year":36,"hindex":36},{},{"2002":115,"2003":115,"2004":114,"2006":114,"2007":115,"2011":115,"2012":115,"2013":115,"2017":115,"2019":114,"2020":115,"2023":115},{},{},389,{"total":1728,"publishYear":26,"statisticByYear":1730},{"2012":237,"2013":241,"2014":239,"2015":396,"2016":239,"2017":240,"2018":516,"2019":124,"2020":53,"2021":124,"2022":52,"2023":356,"2024":111},"2003-11-01",2003,"2024-04-15T03:20:50.921+00:00",[1735,1738,1741,1745,1748,1752,1755,1759,1763,1766,1769,1773,1777,1780,1784,1787,1791,1795,1798,1802,1806,1810,1814,1818,1822,1826,1829,1833,1837,1841,1844,1848,1852,1856,1860,1864,1868,1872,1876,1880,1884,1888,1892,1896,1900,1904,1908,1912,1916,1920,1924,1928,1931,1935,1939,1943,1947,1951,1955,1958,1962,1966,1970,1974,1978,1982,1986,1990,1994,1998,2002,2006,2010,2014,2018],{"id":26,"text":1736,"url":26,"identifiers":1737},"American Heart Association: Heart Disease and Stroke Statistics-2003 Update. Dallas, TX: American Heart Association; 2002.",{},{"id":26,"text":1739,"url":26,"identifiers":1740},"Pearson T, Jamison D, Trejo-Gutierrez J: Cardiovascular disease. In Disease Control Priorities in Developing Countries. Edited by Jamison D, Mosley W, Measham A, Bobadilla J: Oxford: Oxford University Press; 1993.",{},{"id":26,"text":1742,"url":26,"identifiers":1743},"Stephen AM, Wald NJ: Trends in individual consumption of dietary fat in the United States, 1920–1984. Am J Clin Nutr 1990, 52:457–469.",{"doi":1744},"10.1093\u002Fajcn\u002F52.3.457",{"id":26,"text":1746,"url":26,"identifiers":1747},"Putnam J, Allshouse J, Kantor L: US per capita food supply trends: more calories, refined carbohydrates, and fats. Food Rev 2002, 25:2–15.",{},{"id":26,"text":1749,"url":26,"identifiers":1750},"Krauss RM, Eckel RH, Howard B, et al.: AHA dietary guidelines: revision 2000: a statement for healthcare professionals from the nutrition committee of the american heart association. Circulation 2000, 102:2284–2299.",{"doi":1751},"10.1161\u002F01.CIR.102.18.2284",{"id":26,"text":1753,"url":26,"identifiers":1754},"U.S. Department of Agriculture: Nutrition and Your Health: Dietary Guidelines for Americans. Washington, DC: US Government Printing Office; 2000.",{},{"id":26,"text":1756,"url":26,"identifiers":1757},"Liu S, Manson J: Dietary carbohydrates, physical inactivity, obesity, and the ‘metabolic syndrome’ as predictors of coronary heart disease. Curr Opin Lipidol 2001, 12:395–404.",{"doi":1758},"10.1097\u002F00041433-200108000-00005",{"id":26,"text":1760,"url":26,"identifiers":1761},"Liu S, Willett WC: Dietary glycemic load and atherothrombotic risk. Curr Atheroscler Rep 2002, 4:454–461.",{"doi":1762},"10.1007\u002Fs11883-002-0050-2",{"id":26,"text":1764,"url":26,"identifiers":1765},"Liu S: Insulin resistance, hyperglycemia and risk of major chronic diseases—a dietary perspective. Proc Nutr Soc Austral 1998, 22:140–150.",{},{"id":26,"text":1767,"url":26,"identifiers":1768},"Willett WC: Nutritional epidemiology. In Modern Epidemiology, edn 2. Edited by Rothman KJ, Greenland S: Philadelphia: Lippincott-Raven Publishers; 1998.",{},{"id":26,"text":1770,"url":26,"identifiers":1771},"Liu S, Manson JE, Stampfer M, et al.: Dietary glycemic load assessed by food frequency questionnaire in relation to plasma high-density lipoprotein cholesterol and fasting triglycerides among postmenopausal women. Am J Clin Nutr 2001, 73:560–566.",{"doi":1772},"10.1093\u002Fajcn\u002F73.3.560",{"id":26,"text":1774,"url":26,"identifiers":1775},"Serdula MK, Byers T, Mokdad AH, et al.: The association between fruit and vegetable intake and chronic disease risk factors. Epidemiology 1996, 7:161–165.",{"doi":1776},"10.1097\u002F00001648-199603000-00010",{"id":26,"text":1778,"url":26,"identifiers":1779},"Liu S, Manson J, Hu F, et al.: Changes in intake of fruits and vegetables in relation to weight and the development of obesity among middle-aged women [abstract]. Circulation 2002, Supplement.",{},{"id":26,"text":1781,"url":26,"identifiers":1782},"Appel LJ, Moore TJ, Obarzanek E, et al.: A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997, 336:1117–1124.",{"doi":1783},"10.1056\u002FNEJM199704173361601",{"id":26,"text":1785,"url":26,"identifiers":1786},"Appel LJ, Champagne CM, Harsha DW, et al.: Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003, 289:2083–2093.",{},{"id":26,"text":1788,"url":26,"identifiers":1789},"Colditz G, Manson J, Stampfer M, et al.: Diet and risk of clinical diabetes in women. Am J Clin Nutr 1992, 55:1018–1023.",{"doi":1790},"10.1093\u002Fajcn\u002F55.5.1018",{"id":26,"text":1792,"url":26,"identifiers":1793},"Mokdad AH, Bowman BA, Ford ES, et al.: The continuing epidemics of obesity and diabetes in the United States. JAMA 2001, 286:1195–1200.",{"doi":1794},"10.1001\u002Fjama.286.10.1195",{"id":26,"text":1796,"url":26,"identifiers":1797},"National Institutes of Health: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the Evidence Report. Obes Res 1998, 6(suppl 2):51S-209S.",{},{"id":26,"text":1799,"url":26,"identifiers":1800},"Kahn HS, Tatham LM, Rodriguez C, et al.: Stable behaviors associated with adults’ 10-year change in body mass index and likelihood of gain at the waist. Am J Public Health 1997, 87:747–754.",{"doi":1801},"10.2105\u002FAJPH.87.5.747",{"id":26,"text":1803,"url":26,"identifiers":1804},"Epstein LH, Gordy CC, Raynor HA, et al.: Increasing fruit and vegetable intake and decreasing fat and sugar intake in families at risk for childhood obesity. Obes Res 2001, 9:171–178.",{"doi":1805},"10.1038\u002Foby.2001.18",{"id":26,"text":1807,"url":26,"identifiers":1808},"Singh RB, Rastogi V, Rastogi SS, et al.: Effect of diet and moderate exercise on central obesity and associated disturbances, myocardial infarction and mortality in patients with and without coronary artery disease. J Am Coll Nutr 1996, 15:592–601.",{"doi":1809},"10.1080\u002F07315724.1996.10718635",{"id":26,"text":1811,"url":26,"identifiers":1812},"Pereira MA, Ludwig DS: Dietary fiber and body-weight regulation. Observations and mechanisms. Pediatr Clin North Am 2001, 48:969–980.",{"doi":1813},"10.1016\u002FS0031-3955(05)70351-5",{"id":26,"text":1815,"url":26,"identifiers":1816},"Liu S, Willett W, Manson J, et al.: Changes in intake of dietary fiber and grain products in relation to changes in weight and the development of obesity among middle-aged women. Am J Clin Nutr 2003, in press.",{"doi":1817},"10.1093\u002Fajcn\u002F78.5.920",{"id":26,"text":1819,"url":26,"identifiers":1820},"Williams DE, Wareham NJ, Cox BD, et al.: Frequent salad vegetable consumption is associated with a reduction in the risk of diabetes mellitus. J Clin Epidemiol 1999, 52:329–335.",{"doi":1821},"10.1016\u002FS0895-4356(99)00006-2",{"id":26,"text":1823,"url":26,"identifiers":1824},"Sargeant LA, Khaw KT, Bingham S, et al.: Fruit and vegetable intake and population glycosylated haemoglobin levels: the EPIC-Norfolk Study. Eur J Clin Nutr 2001, 55:342–348.",{"doi":1825},"10.1038\u002Fsj.ejcn.1601162",{"id":26,"text":1827,"url":26,"identifiers":1828},"Feskens EJ, Virtanen SM, Rasanen L, et al.: Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 1995, 18:1104–1112.",{"doi":979},{"id":26,"text":1830,"url":26,"identifiers":1831},"Ford ES, Mokdad AH: Fruit and vegetable consumption and diabetes mellitus incidence among U.S. adults. Prev Med 2001, 32:33–39.",{"doi":1832},"10.1006\u002Fpmed.2000.0772",{"id":26,"text":1834,"url":26,"identifiers":1835},"Pan X, Cao H, Li Gea: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care 1997, 20:537–544.",{"doi":1836},"10.2337\u002Fdiacare.20.4.537",{"id":26,"text":1838,"url":26,"identifiers":1839},"Meyer KA, Kushi LH, Jacobs DR Jr, et al.: Carbohydrates, dietary fiber, and incident type 2 diabetes in older women. Am J Clin Nutr 2000, 71:921–930.",{"doi":1840},"10.1093\u002Fajcn\u002F71.4.921",{"id":26,"text":1842,"url":26,"identifiers":1843},"Hirayama T: Nutrition and cancer—a large-scale cohort study. Prog Clin Biol Res 1986, 206:299–311.",{},{"id":26,"text":1845,"url":26,"identifiers":1846},"Fraser GE, Sabate J, Beeson WL, Strahan TM: A possible protective effect of nut consumption on risk of coronary heart disease. The Adventist Health Study. Arch Intern Med 1992, 152:1416–1424.",{"doi":1847},"10.1001\u002Farchinte.1992.00400190054010",{"id":26,"text":1849,"url":26,"identifiers":1850},"Knekt P, Reunanen A, Jarvinen R, et al.: Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol 1994, 139:1180–1189.",{"doi":1851},"10.1093\u002Foxfordjournals.aje.a116964",{"id":26,"text":1853,"url":26,"identifiers":1854},"Gillman MW, Cupples LA, Gagnon D, et al.: Protective effect of fruits and vegetables on development of stroke in men. J Am Med Assoc 1995, 273:1113–1117.",{"doi":1855},"10.1001\u002Fjama.1995.03520380049034",{"id":26,"text":1857,"url":26,"identifiers":1858},"Key TJ, Thorogood M, Appleby PN, Burr ML: Dietary habits and mortality in 11,000 vegetarians and health conscious people: results of a 17-year follow-up. BMJ 1996, 313:775–779.",{"doi":1859},"10.1136\u002Fbmj.313.7060.775",{"id":26,"text":1861,"url":26,"identifiers":1862},"Ness AR, Powles JW: Fruit and vegetables, and cardiovascular disease: a review. Int J Epidemiol 1997, 26:1–13.",{"doi":1863},"10.1093\u002Fije\u002F26.1.1",{"id":26,"text":1865,"url":26,"identifiers":1866},"Joshipura KJ, Ascherio A, Manson JE, et al.: Fruit and vegetable intake in relation to risk of ischemic stroke. JAMA 1999, 282:1233–1239.",{"doi":1867},"10.1001\u002Fjama.282.13.1233",{"id":26,"text":1869,"url":26,"identifiers":1870},"Joshipura KJ, Hu FB, Manson JE, et al.: The effect of fruit and vegetable intake on risk for coronary heart disease. Ann Intern Med 2001, 134:1106–1114.",{"doi":1871},"10.7326\u002F0003-4819-134-12-200106190-00010",{"id":26,"text":1873,"url":26,"identifiers":1874},"Liu S, Lee I, Ajani U, et al.: Intake of vegetables rich in carotenoids and risk of coronary heart disease in men: the Physicians’ Health Study. Int J Epidemiology 2001, 30:130–135.",{"doi":1875},"10.1093\u002Fije\u002F30.1.130",{"id":26,"text":1877,"url":26,"identifiers":1878},"Liu S, Manson J, Lee I, et al.: Fruit and vegetable intake and risk of cardiovascular disease: the Women’s Health Study. Am J Clin Nutr 2000, 72:922–928.",{"doi":1879},"10.1093\u002Fajcn\u002F72.4.922",{"id":26,"text":1881,"url":26,"identifiers":1882},"Bazzano LA, He J, Ogden LG, et al.: Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Am J Clin Nutr 2002, 76:93–99.",{"doi":1883},"10.1093\u002Fajcn\u002F76.1.93",{"id":26,"text":1885,"url":26,"identifiers":1886},"Strandhagen E, Hansson PO, Bosaeus I, et al.: High fruit intake may reduce mortality among middle-aged and elderly men. The Study of Men Born in 1913. Eur J Clin Nutr 2000, 54:337–341.",{"doi":1887},"10.1038\u002Fsj.ejcn.1600959",{"id":26,"text":1889,"url":26,"identifiers":1890},"Liu S, Buring J, Sesso H, et al.: A prospective study of dietary fiber intake and risk of cardiovascular disease among women. J Am Coll Card 2002, 39:49–56.",{"doi":1891},"10.1016\u002FS0735-1097(01)01695-3",{"id":26,"text":1893,"url":26,"identifiers":1894},"Pietinen P, Rimm EB, Korhonen P, et al.: Intake of dietary fiber and risk of coronary heart disease in a cohort of Finnish men: The Alpha-tocopherol, Beta-carotene Cancer Prevention Study. Circulation 1996, 94:2720–2727.",{"doi":1895},"10.1161\u002F01.CIR.94.11.2720",{"id":26,"text":1897,"url":26,"identifiers":1898},"Rimm EB, Ascherio A, Giovannucci E, et al.: Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA 1996, 275:447–451.",{"doi":1899},"10.1001\u002Fjama.1996.03530300031036",{"id":26,"text":1901,"url":26,"identifiers":1902},"Liu S: Intake of refined carbohydrates and whole grain foods in relation to risk of type 2 diabetes mellitus and coronary heart disease. J Am Coll Nutr 2002, 21:298–306.",{"doi":1903},"10.1080\u002F07315724.2002.10719227",{"id":26,"text":1905,"url":26,"identifiers":1906},"Ripsin CM, Keenan JM, Jacobs DR Jr, et al.: Oat products and lipid lowering. A meta-analysis. JAMA 1992, 267:3317–3325.",{"doi":1907},"10.1001\u002Fjama.1992.03480240079039",{"id":26,"text":1909,"url":26,"identifiers":1910},"Ludwig DS, Pereira MA, Kroenke CH, et al.: Dietary fiber, weight gain, and cardiovascular disease risk factors in young adults. JAMA 1999, 282:1539–1546.",{"doi":1911},"10.1001\u002Fjama.282.16.1539",{"id":26,"text":1913,"url":26,"identifiers":1914},"Burton-Freeman B: Dietary fiber and energy regulation. J Nutr 2000, 130:272S-275S.",{"doi":1915},"10.1093\u002Fjn\u002F130.2.272S",{"id":26,"text":1917,"url":26,"identifiers":1918},"Whelton PK, He J, Cutler JA, et al.: Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997, 277:1624–1632.",{"doi":1919},"10.1001\u002Fjama.1997.03540440058033",{"id":26,"text":1921,"url":26,"identifiers":1922},"Krishna GG, Miller E, Kapoor S: Increased blood pressure during potassium depletion in normotensive men. N Engl J Med 1989, 320:1177–1182.",{"doi":1923},"10.1056\u002FNEJM198905043201804",{"id":26,"text":1925,"url":26,"identifiers":1926},"Krishna GG, Kapoor SC: Potassium depletion exacerbates essential hypertension. Ann Intern Med 1991, 115:77–83.",{"doi":1927},"10.7326\u002F0003-4819-115-2-77",{"id":26,"text":1929,"url":26,"identifiers":1930},"Xie JX, Sasaki S, Joossens JV, Kesteloot H: The relationship between urinary cations obtained from the INTERSALT study and cerebrovascular mortality. J Hum Hypertens 1992, 6:17–21.",{},{"id":26,"text":1932,"url":26,"identifiers":1933},"Khaw KT, Barrett-Connor E: Dietary potassium and stroke-associated mortality. A 12-year prospective population study. N Engl J Med 1987, 316:235–240.",{"doi":1934},"10.1056\u002FNEJM198701293160502",{"id":26,"text":1936,"url":26,"identifiers":1937},"Ascherio A, Rimm EB, Hernan MA, et al.: Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. Circulation 1998, 98:1198–1204.",{"doi":1938},"10.1161\u002F01.CIR.98.12.1198",{"id":26,"text":1940,"url":26,"identifiers":1941},"Bazzano LA, He J, Ogden LG, et al.: Dietary potassium intake and risk of stroke in US men and women: National Health and Nutrition Examination Survey I epidemiologic follow-up study. Stroke 2001, 32:1473–1480.",{"doi":1942},"10.1161\u002F01.STR.32.7.1473",{"id":26,"text":1944,"url":26,"identifiers":1945},"Stampfer MJ, Malinow MR, et al.: A prospective study of plasma homocyste(e)ine and risk of myocardial infarction in US physicians. JAMA 1992, 268:877–881.",{"doi":1946},"10.1001\u002Fjama.1992.03490070059042",{"id":26,"text":1948,"url":26,"identifiers":1949},"Selhub J, Jacques PF, Bostom AG, et al.: Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995, 332:286–291.",{"doi":1950},"10.1056\u002FNEJM199502023320502",{"id":26,"text":1952,"url":26,"identifiers":1953},"Bostom AG, Shemin D, Lapane KL, et al.: Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 1996, 123:193–202.",{"doi":1954},"10.1016\u002F0021-9150(96)05809-1",{"id":26,"text":1956,"url":26,"identifiers":1957},"Selhub J, Jacques PF, Bostom AG, et al.: Relationship between plasma homocysteine and vitamin status in the Framingham study population. Impact of folic acid fortification. Pub Health Rev 2000, 28:117–145.",{},{"id":26,"text":1959,"url":26,"identifiers":1960},"Giles WH, Kittner SJ, Croft JB, et al.: Serum folate and risk for coronary heart disease: results from a cohort of US adults. Ann Epidemiol 1998, 8:490–496.",{"doi":1961},"10.1016\u002FS1047-2797(98)00027-1",{"id":26,"text":1963,"url":26,"identifiers":1964},"Morrison HI, Schaubel D, Desmeules M, Wigle DT: Serum folate and risk of fatal coronary heart disease. JAMA 1996, 275:1893–1896.",{"doi":1965},"10.1001\u002Fjama.1996.03530480035037",{"id":26,"text":1967,"url":26,"identifiers":1968},"Vermeulen EG, Stehouwer CD, Twisk JW, et al.: Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000, 355:517–522.",{"doi":1969},"10.1016\u002FS0140-6736(99)07391-2",{"id":26,"text":1971,"url":26,"identifiers":1972},"Wilmink HW, Stroes ES, Erkelens WD, et al.: Influence of folic acid on postprandial endothelial dysfunction. Arterioscler Thromb Vasc Biol 2000, 20:185–188.",{"doi":1973},"10.1161\u002F01.ATV.20.1.185",{"id":26,"text":1975,"url":26,"identifiers":1976},"Bazzano LA, He J, Ogden LG, et al.: Dietary intake of folate and risk of stroke in US men and women: NHANES I Epidemiologic Follow-up Study. National Health and Nutrition Examination Survey. Stroke 2002, 33:1183–1188.",{"doi":1977},"10.1161\u002F01.STR.0000014607.90464.88",{"id":26,"text":1979,"url":26,"identifiers":1980},"Salmeron J, Ascherio A, Rimm EB, et al.: Dietary fiber, glycemic load, and risk of NIDDM in men. Diabetes Care 1997, 20:545–550.",{"doi":1981},"10.2337\u002Fdiacare.20.4.545",{"id":26,"text":1983,"url":26,"identifiers":1984},"Salmeron J, Manson JE, Stampfer MJ, et al.: Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women JAMA 1997, 277:472–477.",{"doi":1985},"10.1001\u002Fjama.1997.03540300040031",{"id":26,"text":1987,"url":26,"identifiers":1988},"Liu S, Willett WC, Stampfer MJ, et al.: A prospective study of dietary glycemic load, carbohydrate intake and risk of coronary heart disease in US women. Am J Clin Nutr 2000, 71:1455–1461.",{"doi":1989},"10.1093\u002Fajcn\u002F71.6.1455",{"id":26,"text":1991,"url":26,"identifiers":1992},"Liu S, Manson J, Buring J, et al.: Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr 2002, 75:492–498.",{"doi":1993},"10.1093\u002Fajcn\u002F75.3.492",{"id":26,"text":1995,"url":26,"identifiers":1996},"Ludwig DS: The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA 2002, 287:2414–2423.",{"doi":1997},"10.1001\u002Fjama.287.18.2414",{"id":26,"text":1999,"url":26,"identifiers":2000},"Sargeant LA, Wareham NJ, Bingham S, et al.: Vitamin C and hyperglycemia in the European Prospective Investigation into Cancer-Norfolk (EPIC-Norfolk) study: a population-based study. Diabetes Care 2000, 23:726–732.",{"doi":2001},"10.2337\u002Fdiacare.23.6.726",{"id":26,"text":2003,"url":26,"identifiers":2004},"Jacobs DR, Murtaugh MA: It’s more than an apple a day: an appropriately processed, plant-centered dietary pattern may be good for your health. Am J Clin Nutr 2000, 72:899–900.",{"doi":2005},"10.1093\u002Fajcn\u002F72.4.899",{"id":26,"text":2007,"url":26,"identifiers":2008},"Sesso HD, Liu S, Gaziano JM, Buring JE: Dietary lycopene, tomato-based food products and cardiovascular disease in women. J Nutr 2003, 133:2336–2341.",{"doi":2009},"10.1093\u002Fjn\u002F133.7.2336",{"id":26,"text":2011,"url":26,"identifiers":2012},"Sesso HD, Gaziano JM, Liu S, Buring JE: Flavonoid intake and the risk of cardiovascular disease in women. Am J Clin Nutr 2003, 77:1400–1408.",{"doi":2013},"10.1093\u002Fajcn\u002F77.6.1400",{"id":26,"text":2015,"url":26,"identifiers":2016},"Ylonen K, Alfthan G, Groop L, et al.: Dietary intakes and plasma concentrations of carotenoids and tocopherols in relation to glucose metabolism in subjects at high risk of type 2 diabetes: the Botnia Dietary Study. Am J Clin Nutr 2003, 77:1434–1441.",{"doi":2017},"10.1093\u002Fajcn\u002F77.6.1434",{"id":26,"text":2019,"url":26,"identifiers":2020},"Hill AB: The environment and disease: association or causation? Proc R Soc Med 1965, 58:295–300.",{},{"id":2022,"createTime":2023,"updateTime":2024,"relativeEntities":2025,"slug":2026,"properties":2027,"entityType":760,"verifyStatus":25,"verifyTime":2024,"verifyNote":762,"syncStatus":28,"languages":2042,"translateLanguages":26,"viewCount":36,"primaryUrl":2043,"fullTextUrl":26,"authors":2044,"publicationType":830,"publisherRelationship":2101,"citationCount":2136,"citationInfo":2137,"publishDate":2139,"publishYear":871,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":2140,"isForceReanalyzing":1106},"875ba937-92bc-4aef-a944-4dd809280eef","2024-04-18T16:39:06.019+00:00","2025-02-07T01:37:25.230+00:00",[],"Residual-Cardiovascular-Risk-Despite-Optimal-LDL-Cholesterol-Reduction-with-Statins-The-Evidence-Etiology-and-Therapeutic-Challenges",{"mag":2028,"keywords":2030,"pmc":2031,"openalex":2033,"abstract":2035,"title":2036,"pm":2038,"doi":2040},{"VOID":2029},"2079979713",{},{"VOID":2032},"3697085",{"VOID":2034},"W2079979713",{},{"EN":2037},"Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges",{"VOID":2039},"22102062",{"VOID":2041},"10.1007\u002Fs11883-011-0219-7",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11883-011-0219-7",[2045,2063,2084],{"id":2046,"sortIndex":36,"researcher":26,"roles":2047,"affiliations":2048,"properties":2058},"ab91f8e4-d437-4536-bca6-64e6151561fc",[],[2049],{"id":2050,"sortIndex":36,"affiliation":2051,"properties":26},"203844a7-a242-41ff-943a-c6191d479a27",{"id":2052,"createTime":2053,"updateTime":2053,"relativeEntities":2054,"slug":26,"properties":2055,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"a01e4ee7-b5a7-4f6a-ae65-47e25ff350d1","2023-12-11T21:25:05.955+00:00",[],{"title":2056},{"VI":2057},"Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, USA",{"openalex":2059,"title":2061},{"VOID":2060},"A5047824675",{"EN":2062},"Uchechukwu K.A. Sampson",{"id":2064,"sortIndex":115,"researcher":26,"roles":2065,"affiliations":2066,"properties":2077},"564bb93e-3b8c-4ed3-88e9-60ad809a7b0b",[],[2067],{"id":2068,"sortIndex":36,"affiliation":2069,"properties":26},"d5938a37-b3d8-4d7d-8a48-a5e0e70db5e7",{"id":2070,"createTime":2071,"updateTime":2071,"relativeEntities":2072,"slug":2073,"properties":2074,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"1ea6c4b5-d3e3-4e1c-a820-6624aaa8e3d1","2024-04-16T00:43:31.548+00:00",[],"Department-of-Medicine-Vanderbilt-University-Medical-Center-Nashville-USA-",{"title":2075},{"EN":2076},"Department of Medicine, Vanderbilt University Medical Center, Nashville, USA.",{"openalex":2078,"orcid":2080,"title":2082},{"VOID":2079},"A5067797353",{"VOID":2081},"https:\u002F\u002Forcid.org\u002F0000-0002-8145-8034",{"EN":2083},"Sergio Fazio",{"id":2085,"sortIndex":114,"researcher":26,"roles":2086,"affiliations":2087,"properties":2094},"0d2e7dfb-50ae-4348-87f5-62ce1fe93069",[],[2088],{"id":2089,"sortIndex":36,"affiliation":2090,"properties":26},"0922ba8d-3d93-47de-b652-0fbd5a139174",{"id":2070,"createTime":2071,"updateTime":2071,"relativeEntities":2091,"slug":2073,"properties":2092,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2093},{"EN":2076},{"openalex":2095,"orcid":2097,"title":2099},{"VOID":2096},"A5089000198",{"VOID":2098},"https:\u002F\u002Forcid.org\u002F0000-0002-9277-0453",{"EN":2100},"MacRae F. Linton",{"url":26,"publisher":2102,"properties":2130},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2103,"slug":663,"properties":2104,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":2108,"manageAffiliations":2109,"indexDatabases":2110,"url":730,"thumbnailPath":26,"statistic":2125,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":2105,"eissn":2106,"title":2107},{"VOID":666},{"VOID":668},{"EN":670},[],[],[2111,2118],{"id":712,"indexDatabase":2112,"url":725,"indexYears":726,"academicFieldIds":2117,"indexDatabaseRanking":729},{"id":714,"createTime":715,"updateTime":716,"relativeEntities":2113,"label":2114,"description":2115,"key":722,"publicationTags":2116,"standard":26},[],{"EN":719,"VI":719},{"EN":719,"VI":721},[724],[728],{"id":693,"indexDatabase":2119,"url":708,"indexYears":26,"academicFieldIds":2124,"indexDatabaseRanking":26},{"id":695,"createTime":696,"updateTime":697,"relativeEntities":2120,"label":2121,"description":2122,"key":704,"publicationTags":2123,"standard":26},[],{"EN":700,"VI":700},{"VI":702,"EN":703},[706,707],[710],{"impactFactor":36,"impactFactorByYear":2126,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":51,"totalPublicationByYear":2127,"totalCitation":36,"totalCitationByYear":2128,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":2129,"hindexLast5Year":36,"hindex":36},{},{"2002":115,"2003":115,"2004":114,"2006":114,"2007":115,"2011":115,"2012":115,"2013":115,"2017":115,"2019":114,"2020":115,"2023":115},{},{},{"volume":2131,"pages":2132,"issue":2134},{"VOID":862},{"VOID":2133},"1-10",{"VOID":2135},"1",306,{"total":2136,"publishYear":26,"statisticByYear":2138},{"2012":135,"2013":53,"2014":103,"2015":51,"2016":242,"2017":239,"2018":255,"2019":255,"2020":285,"2021":240,"2022":48,"2023":608,"2024":50},"2012-02-01",[2141,2145,2149,2153,2157,2161,2165,2168,2172,2176,2180,2184,2188,2192,2196,2200,2204,2208,2212,2216,2220,2224,2228,2232,2236,2239,2243,2247,2251,2255,2259,2263,2267,2271,2275,2279,2283,2287,2291,2295,2299,2303,2307,2311,2315,2319,2323,2327,2331,2335,2339,2343,2347,2351,2355,2359,2363,2367,2371,2375,2379,2383,2387,2391,2395,2399,2403,2407,2411,2415,2419,2423,2427,2431,2435,2439,2443,2447,2451,2455,2459,2463,2467,2471,2475,2479,2483,2487,2491,2495,2499,2503,2507,2511,2515,2519,2523,2527,2531,2535,2539,2543,2547,2551,2555],{"id":26,"text":2142,"url":26,"identifiers":2143},"•• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81. This is the strongest available meta-analysis on the value of intensive LDL-C lowering in reducing cardiovascular risk.",{"doi":2144},"10.1016\u002FS0140-6736(10)61350-5",{"id":26,"text":2146,"url":26,"identifiers":2147},"Smith Jr SC, Allen J, Blair SN, et al. AHA\u002FACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2006;47:2130–9.",{"doi":2148},"10.1016\u002Fj.jacc.2006.04.026",{"id":26,"text":2150,"url":26,"identifiers":2151},"Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.",{"doi":2152},"10.1161\u002F01.CIR.0000133317.49796.0E",{"id":26,"text":2154,"url":26,"identifiers":2155},"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.",{"doi":2156},"10.1001\u002Fjama.285.19.2486",{"id":26,"text":2158,"url":26,"identifiers":2159},"Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007;28:2375–414.",{"doi":2160},"10.1093\u002Feurheartj\u002Fehm316",{"id":26,"text":2162,"url":26,"identifiers":2163},"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.",{"doi":2164},"10.1016\u002FS0140-6736(94)90566-5",{"id":26,"text":2166,"url":26,"identifiers":2167},"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349–57.",{},{"id":26,"text":2169,"url":26,"identifiers":2170},"MRC\u002FBHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.",{"doi":2171},"10.1016\u002FS0140-6736(02)09327-3",{"id":26,"text":2173,"url":26,"identifiers":2174},"Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\u002FTexCAPS. Air Force\u002FTexas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–22.",{"doi":2175},"10.1001\u002Fjama.279.20.1615",{"id":26,"text":2177,"url":26,"identifiers":2178},"Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–9.",{"doi":2179},"10.1056\u002FNEJM199610033351401",{"id":26,"text":2181,"url":26,"identifiers":2182},"Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–7.",{"doi":2183},"10.1056\u002FNEJM199511163332001",{"id":26,"text":2185,"url":26,"identifiers":2186},"Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46:1225–8.",{"doi":2187},"10.1016\u002Fj.jacc.2005.07.006",{"id":26,"text":2189,"url":26,"identifiers":2190},"Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.",{"doi":2191},"10.1056\u002FNEJMoa040583",{"id":26,"text":2193,"url":26,"identifiers":2194},"LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35.",{"doi":2195},"10.1056\u002FNEJMoa050461",{"id":26,"text":2197,"url":26,"identifiers":2198},"Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–45.",{"doi":2199},"10.1001\u002Fjama.294.19.2437",{"id":26,"text":2201,"url":26,"identifiers":2202},"de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307–16.",{"doi":2203},"10.1001\u002Fjama.292.11.1307",{"id":26,"text":2205,"url":26,"identifiers":2206},"Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438–45.",{"doi":2207},"10.1016\u002Fj.jacc.2006.04.070",{"id":26,"text":2209,"url":26,"identifiers":2210},"Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.",{"doi":2211},"10.1016\u002FS0140-6736(05)67394-1",{"id":26,"text":2213,"url":26,"identifiers":2214},"• Sazonov V, Beetsch J, Phatak H, et al. Association between dyslipidemia and vascular events in patients treated with statins: report from the UK General Practice Research Database. Atherosclerosis. 2010;208:210–6. This is a retrospective cohort study that demonstrated the association between low HDL-C and\u002For elevated TG and cardiovascular events despite statin treatment for LDL-C reduction.",{"doi":2215},"10.1016\u002Fj.atherosclerosis.2009.07.021",{"id":26,"text":2217,"url":26,"identifiers":2218},"Arsenault BJ, Barter P, DeMicco DA, et al. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. J Am Coll Cardiol. 2011;57:63–9.",{"doi":2219},"10.1016\u002Fj.jacc.2010.06.052",{"id":26,"text":2221,"url":26,"identifiers":2222},"Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–92.",{"doi":2223},"10.1056\u002FNEJMoa011090",{"id":26,"text":2225,"url":26,"identifiers":2226},"Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid- lowering therapy in men with high levels of apolipoprotein B [see comments]. N Engl J Med. 1990;323:1289–98.",{"doi":2227},"10.1056\u002FNEJM199011083231901",{"id":26,"text":2229,"url":26,"identifiers":2230},"Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–8.",{"doi":2231},"10.1056\u002FNEJM199908053410604",{"id":26,"text":2233,"url":26,"identifiers":2234},"Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ. 1991;303:276–82.",{"doi":2235},"10.1136\u002Fbmj.303.6797.276",{"id":26,"text":2237,"url":26,"identifiers":2238},"Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–44.",{"doi":1252},{"id":26,"text":2240,"url":26,"identifiers":2241},"Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 2000;102:1893–900.",{"doi":2242},"10.1161\u002F01.CIR.102.16.1893",{"id":26,"text":2244,"url":26,"identifiers":2245},"Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707–14.",{"doi":2246},"10.1016\u002F0002-9343(77)90874-9",{"id":26,"text":2248,"url":26,"identifiers":2249},"Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15.",{"doi":2250},"10.1161\u002F01.CIR.79.1.8",{"id":26,"text":2252,"url":26,"identifiers":2253},"Genest Jr JJ, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85:2025–33.",{"doi":2254},"10.1161\u002F01.CIR.85.6.2025",{"id":26,"text":2256,"url":26,"identifiers":2257},"Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol. 1991;67:1185–9.",{"doi":2258},"10.1016\u002F0002-9149(91)90924-A",{"id":26,"text":2260,"url":26,"identifiers":2261},"Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124(Suppl):S11–20.",{"doi":2262},"10.1016\u002F0021-9150(96)05852-2",{"id":26,"text":2264,"url":26,"identifiers":2265},"Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104:1108–13.",{"doi":2266},"10.1161\u002Fhc3501.095214",{"id":26,"text":2268,"url":26,"identifiers":2269},"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.",{"doi":2270},"10.1161\u002Fcirc.106.25.3143",{"id":26,"text":2272,"url":26,"identifiers":2273},"Bruckert E, Baccara-Dinet M, McCoy F, Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin. 2005;21:1927–34.",{"doi":2274},"10.1185\u002F030079905X74871",{"id":26,"text":2276,"url":26,"identifiers":2277},"Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–9.",{"doi":2278},"10.1001\u002Fjama.287.3.356",{"id":26,"text":2280,"url":26,"identifiers":2281},"•• Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med. 2010;153:800–8. This is the strongest available meta-analysis showing the persistent relationship between low HDL-C and cardiovascular risk despite statin therapy.",{"doi":2282},"10.7326\u002F0003-4819-153-12-201012210-00006",{"id":26,"text":2284,"url":26,"identifiers":2285},"Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–10.",{"doi":2286},"10.1056\u002FNEJMoa064278",{"id":26,"text":2288,"url":26,"identifiers":2289},"Ray KK, Cannon CP, Cairns R, et al. Prognostic utility of apoB\u002FAI, total cholesterol\u002FHDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2009;29:424–30.",{"doi":2290},"10.1161\u002FATVBAHA.108.181735",{"id":26,"text":2292,"url":26,"identifiers":2293},"Ridker PM, Genest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010;376:333–9.",{"doi":2294},"10.1016\u002FS0140-6736(10)60713-1",{"id":26,"text":2296,"url":26,"identifiers":2297},"Garrison RJ, Kannel WB, Feinleib M, et al. Cigarette smoking and HDL cholesterol: the Framingham offspring study. Atherosclerosis. 1978;30:17–25.",{"doi":2298},"10.1016\u002F0021-9150(78)90149-1",{"id":26,"text":2300,"url":26,"identifiers":2301},"Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med. 2003;37:283–90.",{"doi":2302},"10.1016\u002FS0091-7435(03)00110-5",{"id":26,"text":2304,"url":26,"identifiers":2305},"Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271–6.",{"doi":2306},"10.1111\u002Fj.1365-2796.1989.tb01393.x",{"id":26,"text":2308,"url":26,"identifiers":2309},"Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320–8.",{"doi":2310},"10.1093\u002Fajcn\u002F56.2.320",{"id":26,"text":2312,"url":26,"identifiers":2313},"Ellison RC, Zhang Y, Qureshi MM, et al. Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am Heart J. 2004;147:529–35.",{"doi":2314},"10.1016\u002Fj.ahj.2003.10.033",{"id":26,"text":2316,"url":26,"identifiers":2317},"James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000;356:2119–25.",{"doi":2318},"10.1016\u002FS0140-6736(00)03491-7",{"id":26,"text":2320,"url":26,"identifiers":2321},"Karpe F, Frayn KN. The nicotinic acid receptor–a new mechanism for an old drug. Lancet. 2004;363:1892–4.",{"doi":2322},"10.1016\u002FS0140-6736(04)16359-9",{"id":26,"text":2324,"url":26,"identifiers":2325},"Lichtenstein AH. Dietary fat and cardiovascular disease risk: quantity or quality? J Womens Health (Larchmt). 2003;12:109–14.",{"doi":2326},"10.1089\u002F154099903321576493",{"id":26,"text":2328,"url":26,"identifiers":2329},"Meksawan K, Pendergast DR, Leddy JJ, et al. Effect of low and high fat diets on nutrient intakes and selected cardiovascular risk factors in sedentary men and women. J Am Coll Nutr. 2004;23:131–40.",{"doi":2330},"10.1080\u002F07315724.2004.10719353",{"id":26,"text":2332,"url":26,"identifiers":2333},"Couillard C, Despres JP, Lamarche B, et al. Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Arterioscler Thromb Vasc Biol. 2001;21:1226–32.",{"doi":2334},"10.1161\u002Fhq0701.092137",{"id":26,"text":2336,"url":26,"identifiers":2337},"King AC, Haskell WL, Young DR, et al. Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years. Circulation. 1995;91:2596–604.",{"doi":2338},"10.1161\u002F01.CIR.91.10.2596",{"id":26,"text":2340,"url":26,"identifiers":2341},"Thompson PD. What do muscles have to do with lipoproteins? Circulation. 1990;81:1428–30.",{"doi":2342},"10.1161\u002F01.CIR.81.4.1428",{"id":26,"text":2344,"url":26,"identifiers":2345},"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21–7.",{"doi":2346},"10.1161\u002F01.CIR.102.1.21",{"id":26,"text":2348,"url":26,"identifiers":2349},"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905–10.",{"doi":2350},"10.1016\u002FS0140-6736(00)04209-4",{"id":26,"text":2352,"url":26,"identifiers":2353},"Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61.",{"doi":2354},"10.1016\u002FS0140-6736(05)67667-2",{"id":26,"text":2356,"url":26,"identifiers":2357},"Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641–51.",{"doi":2358},"10.1001\u002Fjama.1988.03410050061031",{"id":26,"text":2360,"url":26,"identifiers":2361},"Jacobson TA, Chin MM, Fromell GJ, et al. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol. 1994;74:149–54.",{"doi":2362},"10.1016\u002F0002-9149(94)90088-4",{"id":26,"text":2364,"url":26,"identifiers":2365},"O’Keefe Jr JH, Harris WS, Nelson J, Windsor SL. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol. 1995;76:480–4.",{"doi":2366},"10.1016\u002FS0002-9149(99)80134-9",{"id":26,"text":2368,"url":26,"identifiers":2369},"Gardner SF, Schneider EF, Granberry MC, Carter IR. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy. 1996;16:419–23.",{"doi":2370},"10.1002\u002Fj.1875-9114.1996.tb02972.x",{"id":26,"text":2372,"url":26,"identifiers":2373},"Capuzzi DM, Morgan JM, Weiss RJ, et al. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol. 2003;91:1304–10.",{"doi":2374},"10.1016\u002FS0002-9149(03)00318-7",{"id":26,"text":2376,"url":26,"identifiers":2377},"Insull Jr W, McGovern ME, Schrott H, et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med. 2004;164:1121–7.",{"doi":2378},"10.1001\u002Farchinte.164.10.1121",{"id":26,"text":2380,"url":26,"identifiers":2381},"Hunninghake DB, McGovern ME, Koren M, et al. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol. 2003;26:112–8.",{"doi":2382},"10.1002\u002Fclc.4960260304",{"id":26,"text":2384,"url":26,"identifiers":2385},"Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–7.",{"doi":2386},"10.1161\u002F01.CIR.0000148955.19792.8D",{"id":26,"text":2388,"url":26,"identifiers":2389},"Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;22:2243–50.",{"doi":2390},"10.1185\u002F030079906X148508",{"id":26,"text":2392,"url":26,"identifiers":2393},"Navab M, Anantharamaiah GM, Reddy ST, Fogelman AM. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med. 2006;3:540–7.",{"doi":2394},"10.1038\u002Fncpcardio0661",{"id":26,"text":2396,"url":26,"identifiers":2397},"Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 2004;109:3215–20.",{"doi":2398},"10.1161\u002F01.CIR.0000134275.90823.87",{"id":26,"text":2400,"url":26,"identifiers":2401},"Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002;105:290–2.",{"doi":2402},"10.1161\u002Fhc0302.103711",{"id":26,"text":2404,"url":26,"identifiers":2405},"Garber DW, Datta G, Chaddha M, et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res. 2001;42:545–52.",{"doi":2406},"10.1016\u002FS0022-2275(20)31163-9",{"id":26,"text":2408,"url":26,"identifiers":2409},"Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292–300.",{"doi":2410},"10.1001\u002Fjama.290.17.2292",{"id":26,"text":2412,"url":26,"identifiers":2413},"Davidson MH. Apolipoprotein A-I therapy promise, challenges, and disappointment. J Am Coll Cardiol. 2011;57:1120–1.",{"doi":2414},"10.1016\u002Fj.jacc.2010.11.025",{"id":26,"text":2416,"url":26,"identifiers":2417},"Schwartz GG, Olsson AG, Ballantyne CM, et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009;158:896–901 e3.",{"doi":2418},"10.1016\u002Fj.ahj.2009.09.017",{"id":26,"text":2420,"url":26,"identifiers":2421},"Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505–15.",{"doi":2422},"10.1056\u002FNEJMoa031766",{"id":26,"text":2424,"url":26,"identifiers":2425},"de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose–response study. Circulation. 2002;105:2159–65.",{"doi":2426},"10.1161\u002F01.CIR.0000015857.31889.7B",{"id":26,"text":2428,"url":26,"identifiers":2429},"Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.",{"doi":2430},"10.1056\u002FNEJMoa0706628",{"id":26,"text":2432,"url":26,"identifiers":2433},"Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 2008;118:2515–22.",{"doi":2434},"10.1161\u002FCIRCULATIONAHA.108.772665",{"id":26,"text":2436,"url":26,"identifiers":2437},"Miyares MA. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors. Ann Pharmacother. 2011;45:84–94.",{"doi":2438},"10.1345\u002Faph.1P446",{"id":26,"text":2440,"url":26,"identifiers":2441},"Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol. 2005;95:254–7.",{"doi":2442},"10.1016\u002Fj.amjcard.2004.09.013",{"id":26,"text":2444,"url":26,"identifiers":2445},"•• Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210:353–61. This is the strongest available meta-analysis on the beneficial effects of nicotinic acid in reducing cardiovascular risk.",{"doi":2446},"10.1016\u002Fj.atherosclerosis.2009.12.023",{"id":26,"text":2448,"url":26,"identifiers":2449},"•• Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127–35. This article provides strong evidence that the functionality of HDL, independent of HDL-C level, has a strong inverse association with atherosclerotic cardiovascular disease.",{"doi":2450},"10.1056\u002FNEJMoa1001689",{"id":26,"text":2452,"url":26,"identifiers":2453},"Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450–8.",{"doi":2454},"10.1161\u002FCIRCULATIONAHA.106.637793",{"id":26,"text":2456,"url":26,"identifiers":2457},"Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51:724–30.",{"doi":2458},"10.1016\u002Fj.jacc.2007.10.038",{"id":26,"text":2460,"url":26,"identifiers":2461},"Sacks FM. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. Am J Cardiol. 2008;102:34L–40L.",{"doi":2462},"10.1016\u002Fj.amjcard.2008.09.073",{"id":26,"text":2464,"url":26,"identifiers":2465},"Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.",{"doi":2466},"10.1056\u002FNEJMoa1001282",{"id":26,"text":2468,"url":26,"identifiers":2469},"Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol. 2008;28:39–46.",{"doi":2470},"10.1161\u002FATVBAHA.107.148817",{"id":26,"text":2472,"url":26,"identifiers":2473},"Elam M, Lovato LC, Ginsberg H. Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective. Curr Opin Lipidol. 2011;22:55–61.",{"doi":2474},"10.1097\u002FMOL.0b013e328341a5a8",{"id":26,"text":2476,"url":26,"identifiers":2477},"Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161:1413–9.",{"doi":2478},"10.1001\u002Farchinte.161.11.1413",{"id":26,"text":2480,"url":26,"identifiers":2481},"Jiang R, Schulze MB, Li T, et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care. 2004;27:1991–7.",{"doi":2482},"10.2337\u002Fdiacare.27.8.1991",{"id":26,"text":2484,"url":26,"identifiers":2485},"Liu J, Sempos C, Donahue RP, et al. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care. 2005;28:1916–21.",{"doi":2486},"10.2337\u002Fdiacare.28.8.1916",{"id":26,"text":2488,"url":26,"identifiers":2489},"Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294:326–33.",{"doi":2490},"10.1001\u002Fjama.294.3.326",{"id":26,"text":2492,"url":26,"identifiers":2493},"Liu J, Sempos CT, Donahue RP, et al. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol. 2006;98:1363–8.",{"doi":2494},"10.1016\u002Fj.amjcard.2006.06.032",{"id":26,"text":2496,"url":26,"identifiers":2497},"Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364:937–52.",{"doi":2498},"10.1016\u002FS0140-6736(04)17018-9",{"id":26,"text":2500,"url":26,"identifiers":2501},"Shepherd J, Betteridge J, Van Gaal L. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin. 2005;21:665–82.",{"doi":2502},"10.1185\u002F030079905X43677",{"id":26,"text":2504,"url":26,"identifiers":2505},"Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–25.",{"doi":2506},"10.1016\u002FS0140-6736(08)60104-X",{"id":26,"text":2508,"url":26,"identifiers":2509},"Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.",{"doi":2510},"10.1056\u002FNEJMoa0807646",{"id":26,"text":2512,"url":26,"identifiers":2513},"•• Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175–82. This article provides clinical trial evidence for the relationship between inflammation, LDL-C, and cardiovascular events in patients with low LDL-C but elevated hs-CRP.",{"doi":2514},"10.1016\u002FS0140-6736(09)60447-5",{"id":26,"text":2516,"url":26,"identifiers":2517},"Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–43.",{"doi":2518},"10.1161\u002Fhc0902.104353",{"id":26,"text":2520,"url":26,"identifiers":2521},"Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost. 2009;7 Suppl 1:332–9.",{"doi":2522},"10.1111\u002Fj.1538-7836.2009.03404.x",{"id":26,"text":2524,"url":26,"identifiers":2525},"Vollmer WM, Sacks FM, Ard J, et al. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med. 2001;135:1019–28.",{"doi":2526},"10.7326\u002F0003-4819-135-12-200112180-00005",{"id":26,"text":2528,"url":26,"identifiers":2529},"Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3–10.",{"doi":2530},"10.1056\u002FNEJM200101043440101",{"id":26,"text":2532,"url":26,"identifiers":2533},"Kelley GA, Kelley KS. Progressive resistance exercise and resting blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2000;35:838–43.",{"doi":2534},"10.1161\u002F01.HYP.35.3.838",{"id":26,"text":2536,"url":26,"identifiers":2537},"Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136:493–503.",{"doi":2538},"10.7326\u002F0003-4819-136-7-200204020-00006",{"id":26,"text":2540,"url":26,"identifiers":2541},"Major outcomes in moderately hypercholesterolemic. hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007.",{"doi":2542},"10.1001\u002Fjama.288.23.2998",{"id":26,"text":2544,"url":26,"identifiers":2545},"Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled tria. Lancet. 2003;361:1149–58.",{"doi":2546},"10.1016\u002FS0140-6736(03)12948-0",{"id":26,"text":2548,"url":26,"identifiers":2549},"Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478–85.",{"doi":2550},"10.2337\u002Fdc05-2415",{"id":26,"text":2552,"url":26,"identifiers":2553},"Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–96.",{"doi":2554},"10.1016\u002FS0140-6736(04)16895-5",{"id":26,"text":2556,"url":26,"identifiers":2557},"Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.",{"doi":2558},"10.1016\u002FS0140-6736(02)11600-X",{"id":2560,"createTime":2561,"updateTime":2561,"relativeEntities":2562,"slug":2563,"properties":2564,"entityType":760,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":2577,"translateLanguages":26,"viewCount":36,"primaryUrl":2578,"fullTextUrl":26,"authors":2579,"publicationType":830,"publisherRelationship":2623,"citationCount":626,"citationInfo":2658,"publishDate":2660,"publishYear":2661,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":2662,"isForceReanalyzing":1106},"953eb082-8210-4767-b6a1-420825594f38","2024-04-16T20:26:16.635+00:00",[],"Effects-of-Eicosapentaenoic-Acid-Versus-Docosahexaenoic-Acid-on-Serum-Lipids-A-Systematic-Review-and-Meta-Analysis",{"mag":2565,"keywords":2567,"openalex":2568,"abstract":2570,"title":2571,"pm":2573,"doi":2575},{"VOID":2566},"2138013532",{},{"VOID":2569},"W2138013532",{},{"EN":2572},"Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis",{"VOID":2574},"21975919",{"VOID":2576},"10.1007\u002Fs11883-011-0210-3",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11883-011-0210-3",[2580,2601],{"id":2581,"sortIndex":115,"researcher":26,"roles":2582,"affiliations":2583,"properties":2594},"c969888c-c48e-4bbb-8a5a-91b614f180dd",[],[2584],{"id":2585,"sortIndex":36,"affiliation":2586,"properties":26},"c5dc33a9-8879-4798-9416-160b4f1f907d",{"id":2587,"createTime":2588,"updateTime":2588,"relativeEntities":2589,"slug":2590,"properties":2591,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"7349244c-7581-40a1-811c-3c4f1cda2550","2024-04-16T20:26:16.693+00:00",[],"Office-of-Health-Promotion-and-Disease-Prevention-Department-of-Medicine-Emory-University-Faculty-Office-Building-49-Jesse-Hill-Jr-Drive-SE-Atlanta-GA-30303-USA",{"title":2592},{"EN":2593},"Office of Health Promotion and Disease Prevention, Department of Medicine, Emory University, Faculty Office Building, 49 Jesse Hill Jr. Drive SE, Atlanta, GA, 30303, USA",{"openalex":2595,"orcid":2597,"title":2599},{"VOID":2596},"A5084230583",{"VOID":2598},"https:\u002F\u002Forcid.org\u002F0000-0002-9926-2179",{"EN":2600},"Terry A. Jacobson",{"id":2602,"sortIndex":36,"researcher":26,"roles":2603,"affiliations":2604,"properties":2616},"77a1c394-d3d4-434a-a131-851c27704d6d",[],[2605],{"id":2606,"sortIndex":36,"affiliation":2607,"properties":26},"f5b20154-75b4-4c02-8991-fd46488ab82d",{"id":2608,"createTime":2609,"updateTime":2610,"relativeEntities":2611,"slug":2612,"properties":2613,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"115bc0a4-8f50-44a0-84e7-62669e4e3f27","2023-12-20T06:01:04.923+00:00","2025-01-07T13:47:10.309+00:00",[],"Department-of-Medicine-Emory-University-School-of-Medicine-Atlanta-Georgia",{"title":2614},{"VI":2615},"Department of Medicine, Emory University School of Medicine, Atlanta, Georgia",{"openalex":2617,"orcid":2619,"title":2621},{"VOID":2618},"A5066422495",{"VOID":2620},"https:\u002F\u002Forcid.org\u002F0000-0001-5093-6040",{"EN":2622},"Melissa Y. Wei",{"url":26,"publisher":2624,"properties":2652},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2625,"slug":663,"properties":2626,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":2630,"manageAffiliations":2631,"indexDatabases":2632,"url":730,"thumbnailPath":26,"statistic":2647,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":2627,"eissn":2628,"title":2629},{"VOID":666},{"VOID":668},{"EN":670},[],[],[2633,2640],{"id":712,"indexDatabase":2634,"url":725,"indexYears":726,"academicFieldIds":2639,"indexDatabaseRanking":729},{"id":714,"createTime":715,"updateTime":716,"relativeEntities":2635,"label":2636,"description":2637,"key":722,"publicationTags":2638,"standard":26},[],{"EN":719,"VI":719},{"EN":719,"VI":721},[724],[728],{"id":693,"indexDatabase":2641,"url":708,"indexYears":26,"academicFieldIds":2646,"indexDatabaseRanking":26},{"id":695,"createTime":696,"updateTime":697,"relativeEntities":2642,"label":2643,"description":2644,"key":704,"publicationTags":2645,"standard":26},[],{"EN":700,"VI":700},{"VI":702,"EN":703},[706,707],[710],{"impactFactor":36,"impactFactorByYear":2648,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":51,"totalPublicationByYear":2649,"totalCitation":36,"totalCitationByYear":2650,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":2651,"hindexLast5Year":36,"hindex":36},{},{"2002":115,"2003":115,"2004":114,"2006":114,"2007":115,"2011":115,"2012":115,"2013":115,"2017":115,"2019":114,"2020":115,"2023":115},{},{},{"volume":2653,"pages":2655,"issue":2657},{"VOID":2654},"13",{"VOID":2656},"474-483",{"VOID":866},{"total":626,"publishYear":26,"statisticByYear":2659},{"2012":53,"2013":173,"2014":222,"2015":238,"2016":240,"2017":244,"2018":234,"2019":238,"2020":124,"2021":173,"2022":103,"2023":336,"2024":162},"2011-12-01",2011,[2663,2667,2671,2675,2679,2683,2687,2691,2695,2699,2703,2707,2711,2715,2719,2723,2727,2731,2735,2739,2743,2747,2751,2755,2759,2763,2767,2771,2775,2779,2783,2787,2791,2795,2799,2803,2807,2811,2814,2818,2821,2824],{"id":26,"text":2664,"url":26,"identifiers":2665},"Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992;85:37–45.",{"doi":2666},"10.1161\u002F01.CIR.85.1.37",{"id":26,"text":2668,"url":26,"identifiers":2669},"Ballantyne CM, Olsson AG, Cook TJ. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001;104:3046–51.",{"doi":2670},"10.1161\u002Fhc5001.100624",{"id":26,"text":2672,"url":26,"identifiers":2673},"Tirosh A, Rudich A, Shochat T. Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med. 2007;147:377–85.",{"doi":2674},"10.7326\u002F0003-4819-147-6-200709180-00007",{"id":26,"text":2676,"url":26,"identifiers":2677},"Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960–2002. JAMA. 2005;294:1773–81.",{"doi":2678},"10.1001\u002Fjama.294.14.1773",{"id":26,"text":2680,"url":26,"identifiers":2681},"Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65(5 Suppl):1645S–54S.",{"doi":2682},"10.1093\u002Fajcn\u002F65.5.1645S",{"id":26,"text":2684,"url":26,"identifiers":2685},"Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747–57.",{"doi":2686},"10.1161\u002F01.CIR.0000038493.65177.94",{"id":26,"text":2688,"url":26,"identifiers":2689},"von Schacky C, Harris WS. Cardiovascular benefits of omega-3 fatty acids. Cardiovasc Res. 2007;73:310–5.",{"doi":2690},"10.1016\u002Fj.cardiores.2006.08.019",{"id":26,"text":2692,"url":26,"identifiers":2693},"•• Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–333. This article discusses the current American Heart Association recommendations for EPA plus DHA supplementation and the clinical evidence and potential mechanisms supporting these recommendations.",{"doi":2694},"10.1161\u002FCIR.0b013e3182160726",{"id":26,"text":2696,"url":26,"identifiers":2697},"Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008;197:12–24.",{"doi":2698},"10.1016\u002Fj.atherosclerosis.2007.11.008",{"id":26,"text":2700,"url":26,"identifiers":2701},"Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA. 1997;94:4318–23.",{"doi":2702},"10.1073\u002Fpnas.94.9.4318",{"id":26,"text":2704,"url":26,"identifiers":2705},"Xu HE, Lambert MH, Montana VG, et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell. 1999;3:397–403.",{"doi":2706},"10.1016\u002FS1097-2765(00)80467-0",{"id":26,"text":2708,"url":26,"identifiers":2709},"Eslick GD, Howe PR, Smith C, et al. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol. 2009;136:4–16.",{"doi":2710},"10.1016\u002Fj.ijcard.2008.03.092",{"id":26,"text":2712,"url":26,"identifiers":2713},"Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g\u002Fd to simvastatin 40 mg\u002Fd in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:1354–67.",{"doi":2714},"10.1016\u002Fj.clinthera.2007.07.018",{"id":26,"text":2716,"url":26,"identifiers":2717},"• Maki KC, Dicklin MR, Davidson MH, et al. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. Am J Cardiol. 2010;105:1409–12. This post-hoc analysis of the COMBOS trial identifies subgroups of participants for which increased LDL occurs with omega-3 fatty acid ethyl ester plus simvastatin therapy.",{"doi":2718},"10.1016\u002Fj.amjcard.2009.12.063",{"id":26,"text":2720,"url":26,"identifiers":2721},"Tanaka K, Ishikawa Y, Yokoyama M, et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke. 2008;39:2052–8.",{"doi":2722},"10.1161\u002FSTROKEAHA.107.509455",{"id":26,"text":2724,"url":26,"identifiers":2725},"Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med. 1999;18:321–59.",{"doi":2726},"10.1002\u002F(SICI)1097-0258(19990215)18:3\u003C321::AID-SIM28>3.0.CO;2-P",{"id":26,"text":2728,"url":26,"identifiers":2729},"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.",{"doi":2730},"10.1016\u002F0197-2456(86)90046-2",{"id":26,"text":2732,"url":26,"identifiers":2733},"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.",{"doi":2734},"10.1002\u002Fsim.1186",{"id":26,"text":2736,"url":26,"identifiers":2737},"Jacobson T, Soni P, Glickstein S, et al. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol: a critical review [abstract]. J Clin Lipidol. 2011;5:200–1.",{"doi":2738},"10.1016\u002Fj.jacl.2011.03.010",{"id":26,"text":2740,"url":26,"identifiers":2741},"Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol. 1999;10:2177–84.",{"doi":2742},"10.1681\u002FASN.V10102177",{"id":26,"text":2744,"url":26,"identifiers":2745},"Satoh N, Shimatsu A, Kotani K, et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care. 2007;30:144–6.",{"doi":2746},"10.2337\u002Fdc06-1179",{"id":26,"text":2748,"url":26,"identifiers":2749},"Egert S, Kannenberg F, Somoza V, et al. Dietary alphalinolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. J Nutr. 2009;139:861–8.",{"doi":2750},"10.3945\u002Fjn.108.103861",{"id":26,"text":2752,"url":26,"identifiers":2753},"Kurabayashi T, Okada M, Tanaka K. Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women. Obstet Gynecol. 2000;96:521–8.",{"doi":2754},"10.1016\u002FS0029-7844(00)00988-1",{"id":26,"text":2756,"url":26,"identifiers":2757},"Grimsgaard S, Bonaa KH, Hansen JB, et al. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr. 1997;66:649–59.",{"doi":2758},"10.1093\u002Fajcn\u002F66.3.649",{"id":26,"text":2760,"url":26,"identifiers":2761},"Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res. 2003;44:455–63.",{"doi":2762},"10.1194\u002Fjlr.M200282-JLR200",{"id":26,"text":2764,"url":26,"identifiers":2765},"Mori TA, Woodman RJ. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care. 2006;9:95–104.",{"doi":2766},"10.1097\u002F01.mco.0000214566.67439.58",{"id":26,"text":2768,"url":26,"identifiers":2769},"Nestel P, Shige H, Pomeroy S, et al. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr. 2002;76:326–30.",{"doi":2770},"10.1093\u002Fajcn\u002F76.2.326",{"id":26,"text":2772,"url":26,"identifiers":2773},"Woodman RJ, Mori TA, Burke V, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr. 2002;76:1007–15.",{"doi":2774},"10.1093\u002Fajcn\u002F76.5.1007",{"id":26,"text":2776,"url":26,"identifiers":2777},"Conquer JA, Holub BJ. Effect of supplementation with different doses of DHA on the levels of circulating DHA as non-esterified fatty acid in subjects of Asian Indian background. J Lipid Res. 1998;39:286–92.",{"doi":2778},"10.1016\u002FS0022-2275(20)33890-6",{"id":26,"text":2780,"url":26,"identifiers":2781},"Kelley DS, Siegel D, Vemuri M, et al. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr. 2007;86:324–33.",{"doi":2782},"10.1093\u002Fajcn\u002F86.2.324",{"id":26,"text":2784,"url":26,"identifiers":2785},"Stark KD, Holub BJ. Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. Am J Clin Nutr. 2004;79:765–73.",{"doi":2786},"10.1093\u002Fajcn\u002F79.5.765",{"id":26,"text":2788,"url":26,"identifiers":2789},"Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr. 2000;71:1085–94.",{"doi":2790},"10.1093\u002Fajcn\u002F71.5.1085",{"id":26,"text":2792,"url":26,"identifiers":2793},"Sanders TA, Gleason K, Griffin B, et al. Influence of an algal triacylglycerol containing docosahexaenoic acid (22:6 n-3) and docosapentaenoic acid (22:5 n-6) oncardiovascular risk factors in healthy men and women. Br J Nutr. 2006;95:525–31.",{"doi":2794},"10.1079\u002FBJN20051658",{"id":26,"text":2796,"url":26,"identifiers":2797},"Theobald HE, Chowienczyk PJ, Whittall R, et al. LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women. Am J Clin Nutr. 2004;79:558–63.",{"doi":2798},"10.1093\u002Fajcn\u002F79.4.558",{"id":26,"text":2800,"url":26,"identifiers":2801},"Maki KC, Van Elswyk ME, McCarthy D, et al. Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr. 2005;24:189–99.",{"doi":2802},"10.1080\u002F07315724.2005.10719465",{"id":26,"text":2804,"url":26,"identifiers":2805},"Geppert J, Kraft V, Demmelmair H, et al. Microalgal docosahexaenoic acid decreases plasma triacylglycerol in normolipidaemic vegetarians: a randomised trial. Br J Nutr. 2006;95:779–86.",{"doi":2806},"10.1079\u002FBJN20051720",{"id":26,"text":2808,"url":26,"identifiers":2809},"Conquer JA, Holub BJ. Supplementation with an algae source of docosahexaenoic acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects. J Nutr. 1996;126:3032–9.",{"doi":2810},"10.1093\u002Fjn\u002F126.12.3032",{"id":26,"text":2812,"url":26,"identifiers":2813},"Agren JJ, Hänninen O, Julkunen A, et al. Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels. Eur J Clin Nutr. 1996;50:765–71.",{},{"id":26,"text":2815,"url":26,"identifiers":2816},"Wu WH, Lu SC, Wang TF, et al. Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and in vivo oxidative stress in postmenopausal vegetarian women. Eur J Clin Nutr. 2006;60:386–92.",{"doi":2817},"10.1038\u002Fsj.ejcn.1602328",{"id":26,"text":2819,"url":26,"identifiers":2820},"Schaefer EJ, Asztalos IB, Gleason JA, et al. Effects of eicosapentaenoic acid, docosahexaenoic acid, and olive oil on cardiovascular disease risk factors [abstract]. Circulation. 2010;122:A20007.",{},{"id":26,"text":2822,"url":26,"identifiers":2823},"•• Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels: the MARINE trial. Am J Card. 2011;In press. This large placebo-controlled trial of EPA demonstrates a reduction in triglycerides without raising LDL in participants with very high triglyceride levels.",{},{"id":26,"text":2825,"url":26,"identifiers":2826},"Hirano R, Igarashi O, Kondo K, et al. Regulation by long-chain fatty acids of the expression of cholesteryl ester transfer protein in HepG2 cells. Lipids. 2001;36:401–6.",{"doi":2827},"10.1007\u002Fs11745-001-0735-3",{"id":2829,"createTime":2830,"updateTime":2831,"relativeEntities":2832,"slug":2833,"properties":2834,"entityType":760,"verifyStatus":25,"verifyTime":2848,"verifyNote":762,"syncStatus":28,"languages":2849,"translateLanguages":26,"viewCount":36,"primaryUrl":2850,"fullTextUrl":26,"authors":2851,"publicationType":830,"publisherRelationship":2915,"citationCount":2951,"citationInfo":2952,"publishDate":2955,"publishYear":2953,"citationAnalyzeStatus":2956,"lastCitationAnalyze":2957,"indexDatabases":26,"openAccess":26,"references":2958,"isForceReanalyzing":1106},"7be53f17-e8da-4667-8004-2c18221906a6","2024-04-17T17:37:45.076+00:00","2026-05-25T08:02:11.235+00:00",[],"A-Contemporary-Review-of-Epidemiology-Risk-Factors-Etiology-and-Outcomes-of-Premature-Stroke",{"keywords":2835,"openalex":2836,"abstract":2838,"title":2840,"pm":2842,"doi":2844,"gsPaper":2846},{},{"VOID":2837},"W4309010346",{"EN":2839},"\u003Cjats:title>Abstract\u003C\u002Fjats:title>\u003Cjats:sec>\n                \u003Cjats:title>Purpose of Review\u003C\u002Fjats:title>\n                \u003Cjats:p>Recent data identifies increases in young ischemic and hemorrhagic strokes. We provide a contemporary overview of current literature on stroke among young patients or premature stroke along with directions for future investigation.\u003C\u002Fjats:p>\n              \u003C\u002Fjats:sec>\u003Cjats:sec>\n                \u003Cjats:title>Recent Findings\u003C\u002Fjats:title>\n                \u003Cjats:p>Strokes in the young are highly heterogenous and often cryptogenic. Sex distribution and risk factors shift from women among the youngest age groups (< 35) to men over the age of 45, with a coinciding rise in traditional vascular risk factors. Incidence is higher in minority and socioeconomically disadvantaged populations, and the impact of stroke among these communities may be exaggerated by disparities in symptom recognition and access to care. Special diagnostic work-up may be needed, and a lower threshold for diagnosis is warranted as potential misdiagnosis is a concern and may preclude necessary triage and management.\u003C\u002Fjats:p>\n              \u003C\u002Fjats:sec>\u003Cjats:sec>\n                \u003Cjats:title>Summary\u003C\u002Fjats:title>\n                \u003Cjats:p>Although “premature strokes” form a relatively small proportion of total incidence, they vary greatly across subgroups and present an outsized impact on quality of life and productivity.\u003C\u002Fjats:p>\n              \u003C\u002Fjats:sec>",{"EN":2841},"A Contemporary Review of Epidemiology, Risk Factors, Etiology, and Outcomes of Premature Stroke",{"VOID":2843},"36374365",{"VOID":2845},"10.1007\u002Fs11883-022-01067-x",{"VOID":2847},"[\"11938739060777983728\"]","2024-04-30T00:30:15.536+00:00",[102],"https:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11883-022-01067-x",[2852,2875,2898],{"id":2853,"sortIndex":115,"researcher":26,"roles":2854,"affiliations":2855,"properties":2866},"7a133ec9-2cb1-4912-bd40-60a78c6672f8",[],[2856],{"id":2857,"sortIndex":36,"affiliation":2858,"properties":26},"99ddd18e-6290-416a-8595-1849805f422d",{"id":2859,"createTime":2860,"updateTime":2860,"relativeEntities":2861,"slug":2862,"properties":2863,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"3a1b50db-16bb-4b5a-b582-1e0468c98187","2024-04-17T17:37:45.111+00:00",[],"Department-of-Neurosurgery-Houston-Methodist-Josie-Roberts-Administration-Building-4-123-7550-Greenbriar-Drive-Houston-TX-77030-USA",{"title":2864},{"EN":2865},"Department of Neurosurgery, Houston Methodist, Josie Roberts Administration Building, 4.123, 7550 Greenbriar Drive, Houston, TX, 77030, USA",{"openalex":2867,"orcid":2869,"title":2871,"gsAuthor":2873},{"VOID":2868},"A5014557456",{"VOID":2870},"https:\u002F\u002Forcid.org\u002F0000-0003-4022-9267",{"EN":2872},"Jonika Tannous",{"VOID":2874},"[\"ltVCq_MAAAAJ\"]",{"id":2876,"sortIndex":114,"researcher":26,"roles":2877,"affiliations":2878,"properties":2889},"aa393009-62f5-4d5c-ad04-406e4cc1423b",[],[2879],{"id":2880,"sortIndex":36,"affiliation":2881,"properties":26},"578e8f14-49ef-4a74-aa9a-e09ed405887d",{"id":2882,"createTime":2883,"updateTime":2883,"relativeEntities":2884,"slug":2885,"properties":2886,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"2a8aa8be-48e6-4ec1-9955-bc9f3a4e0dda","2024-04-17T17:37:45.125+00:00",[],"Houston-Methodist-Neurological-Institute-Houston-Methodist-Houston-TX-USA",{"title":2887},{"EN":2888},"Houston Methodist Neurological Institute, Houston Methodist, Houston, TX, USA",{"openalex":2890,"orcid":2892,"title":2894,"gsAuthor":2896},{"VOID":2891},"A5053331010",{"VOID":2893},"https:\u002F\u002Forcid.org\u002F0000-0002-3464-2111",{"EN":2895},"Farhaan Vahidy",{"VOID":2897},"[\"JEx2LzgAAAAJ\"]",{"id":2899,"sortIndex":36,"researcher":26,"roles":2900,"affiliations":2901,"properties":2908},"ed0330e5-23f7-467e-88d7-2948eccefd8b",[],[2902],{"id":2903,"sortIndex":36,"affiliation":2904,"properties":26},"38d8bc46-b020-4992-ad32-03e08640bf5d",{"id":2859,"createTime":2860,"updateTime":2860,"relativeEntities":2905,"slug":2862,"properties":2906,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2907},{"EN":2865},{"openalex":2909,"orcid":2911,"title":2913},{"VOID":2910},"A5040524583",{"VOID":2912},"https:\u002F\u002Forcid.org\u002F0000-0001-7884-4172",{"EN":2914},"Thomas Potter",{"url":26,"publisher":2916,"properties":2944},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2917,"slug":663,"properties":2918,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":2922,"manageAffiliations":2923,"indexDatabases":2924,"url":730,"thumbnailPath":26,"statistic":2939,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":2919,"eissn":2920,"title":2921},{"VOID":666},{"VOID":668},{"EN":670},[],[],[2925,2932],{"id":712,"indexDatabase":2926,"url":725,"indexYears":726,"academicFieldIds":2931,"indexDatabaseRanking":729},{"id":714,"createTime":715,"updateTime":716,"relativeEntities":2927,"label":2928,"description":2929,"key":722,"publicationTags":2930,"standard":26},[],{"EN":719,"VI":719},{"EN":719,"VI":721},[724],[728],{"id":693,"indexDatabase":2933,"url":708,"indexYears":26,"academicFieldIds":2938,"indexDatabaseRanking":26},{"id":695,"createTime":696,"updateTime":697,"relativeEntities":2934,"label":2935,"description":2936,"key":704,"publicationTags":2937,"standard":26},[],{"EN":700,"VI":700},{"VI":702,"EN":703},[706,707],[710],{"impactFactor":36,"impactFactorByYear":2940,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":51,"totalPublicationByYear":2941,"totalCitation":36,"totalCitationByYear":2942,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":2943,"hindexLast5Year":36,"hindex":36},{},{"2002":115,"2003":115,"2004":114,"2006":114,"2007":115,"2011":115,"2012":115,"2013":115,"2017":115,"2019":114,"2020":115,"2023":115},{},{},{"volume":2945,"pages":2947,"issue":2949},{"VOID":2946},"24",{"VOID":2948},"939-948",{"VOID":2950},"12",243,{"total":2951,"publishYear":2953,"statisticByYear":2954},2022,{"2022":115,"2023":158,"2024":358,"2025":533,"2026":257},"2022-12-01","DONE_ANALYZE_CITATION","2026-05-25T08:02:11.234+00:00",[2959,2962,2966,2970,2974,2977,2981,2985,2988,2992,2996,3000,3004,3008,3012,3016,3020,3024,3028,3032,3036,3040,3044,3048,3052,3056,3060,3064,3068,3072,3076,3080,3084,3088,3092,3096,3100,3104,3108,3112,3116,3120,3124,3128,3132,3136,3140,3144,3148,3152,3156,3160,3164,3168,3172,3176,3180,3184,3188,3191,3195,3199,3203,3207,3211,3215,3219,3223,3227,3231,3235,3239,3243,3247,3251,3255,3259,3263,3267,3271,3274,3277,3281,3285,3289,3293,3297,3301,3305,3309,3313,3317,3321,3324,3328,3332,3336,3340,3344,3348,3352,3356,3360,3364,3368,3372,3376,3380,3384,3388,3392,3396,3400,3404,3408],{"id":26,"text":2960,"url":26,"identifiers":2961},"GBD. Stroke Collaborators (2021) Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2019;20:795–820.",{},{"id":26,"text":2963,"url":26,"identifiers":2964},"Béjot Y, Delpont B, Giroud M. Rising stroke incidence in young adults: more epidemiological evidence, more questions to be answered. J Am Heart Assoc. 2016;5:e003661.",{"doi":2965},"10.1161\u002FJAHA.116.003661",{"id":26,"text":2967,"url":26,"identifiers":2968},"• Bako AT, Pan A, Potter T, Tannous J, Johnson C, Baig E, Meeks J, Woo D, Vahidy FS. Contemporary trends in the nationwide incidence of primary intracerebral hemorrhage. Stroke. 2022;53:e70–4. Highlights specific temporal and regional trends for young ICH",{"doi":2969},"10.1161\u002FSTROKEAHA.121.037332",{"id":26,"text":2971,"url":26,"identifiers":2972},"•• Boot E, Ekker MS, Putaala J, Kittner S, De Leeuw F-E, Tuladhar AM. Ischaemic stroke in young adults: a global perspective. J Neurol Neurosurg Psychiatry. 2020;91:411–7. Provides a worldwide overview of young stroke and gaps in community assessment",{"doi":2973},"10.1136\u002Fjnnp-2019-322424",{"id":26,"text":2975,"url":26,"identifiers":2976},"Yousufuddin M, Young N. Aging and ischemic stroke Aging (Albany NY). 2019;11:2542–4.",{},{"id":26,"text":2978,"url":26,"identifiers":2979},"Kissela BM, Khoury JC, Alwell K, et al. Age at stroke: temporal trends in stroke incidence in a large, biracial population. Neurol. 2012;79:1781–7.",{"doi":2980},"10.1212\u002FWNL.0b013e318270401d",{"id":26,"text":2982,"url":26,"identifiers":2983},"Chen C-Y, Lin P-T, Wang Y-H, et al. Etiology and risk factors of intracranial hemorrhage and ischemic stroke in young adults. J Chin Med Assoc. 2021;84:930–6.",{"doi":2984},"10.1097\u002FJCMA.0000000000000598",{"id":26,"text":2986,"url":26,"identifiers":2987},"Marini C, Russo T, Felzani G. Incidence of stroke in young adults: a review. Stroke Res Treat. 2010;2011:535672.",{},{"id":26,"text":2989,"url":26,"identifiers":2990},"Madsen TE, Khoury JC, Leppert M, et al. Temporal trends in stroke incidence over time by sex and age in the GCNKSS. Stroke. 2020;51:1070–6.",{"doi":2991},"10.1161\u002FSTROKEAHA.120.028910",{"id":26,"text":2993,"url":26,"identifiers":2994},"Smajlović D. Strokes in young adults: epidemiology and prevention. Vasc Health Risk Manag. 2015;11:157–64.",{"doi":2995},"10.2147\u002FVHRM.S53203",{"id":26,"text":2997,"url":26,"identifiers":2998},"Maaijwee NAMM, Rutten-Jacobs LCA, Schaapsmeerders P, van Dijk EJ, de Leeuw F-E. Ischaemic stroke in young adults: risk factors and long-term consequences. Nat Rev Neurol. 2014;10:315–25.",{"doi":2999},"10.1038\u002Fnrneurol.2014.72",{"id":26,"text":3001,"url":26,"identifiers":3002},"Putaala J, Yesilot N, Waje-Andreassen U, et al. Demographic and geographic vascular risk factor differences in European young adults with ischemic stroke: the 15 cities young stroke study. Stroke. 2012;43:2624–30.",{"doi":3003},"10.1161\u002FSTROKEAHA.112.662866",{"id":26,"text":3005,"url":26,"identifiers":3006},"Putaala J, Metso AJ, Metso TM, Konkola N, Kraemer Y, Haapaniemi E, Kaste M, Tatlisumak T. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke. 2009;40:1195–203.",{"doi":3007},"10.1161\u002FSTROKEAHA.108.529883",{"id":26,"text":3009,"url":26,"identifiers":3010},"Leppert MH, Ho PM, Burke J, Madsen TE, Kleindorfer D, Sillau S, Daugherty S, Bradley CJ, Poisson SN. Young women had more strokes than young men in a large, United States claims sample. Stroke. 2020;51:3352–5.",{"doi":3011},"10.1161\u002FSTROKEAHA.120.030803",{"id":26,"text":3013,"url":26,"identifiers":3014},"Ekker MS, Verhoeven JI, Vaartjes I, van Nieuwenhuizen KM, Klijn CJM, de Leeuw F-E. Stroke incidence in young adults according to age, subtype, sex, and time trends. Neurology. 2019;92:e2444–54.",{"doi":3015},"10.1212\u002FWNL.0000000000007533",{"id":26,"text":3017,"url":26,"identifiers":3018},"Tang M, Yao M, Zhu Y, Peng B, Zhou L, Ni J. Sex differences of ischemic stroke in young adults—a single-center Chinese cohort study. J Stroke Cerebrovasc Dis. 2020;29:105087.",{"doi":3019},"10.1016\u002Fj.jstrokecerebrovasdis.2020.105087",{"id":26,"text":3021,"url":26,"identifiers":3022},"• Leppert MH, Burke JF, Lisabeth LD, et al. Systematic review of sex differences in ischemic strokes among young adults: are young women disproportionately at risk? Stroke. 2022;53:319–27. Important meta analysis of sex disparities in young ischemic stroke",{"doi":3023},"10.1161\u002FSTROKEAHA.121.037117",{"id":26,"text":3025,"url":26,"identifiers":3026},"Trivedi MM, Ryan KA, Cole JW. Ethnic differences in ischemic stroke subtypes in young-onset stroke: the Stroke Prevention in Young Adults Study. BMC Neurol. 2015;15:221.",{"doi":3027},"10.1186\u002Fs12883-015-0461-7",{"id":26,"text":3029,"url":26,"identifiers":3030},"Larrue V, Berhoune N, Massabuau P, Calviere L, Raposo N, Viguier A, Nasr N. Etiologic investigation of ischemic stroke in young adults. Neurol. 2011;76:1983–8.",{"doi":3031},"10.1212\u002FWNL.0b013e31821e5517",{"id":26,"text":3033,"url":26,"identifiers":3034},"Griffiths D, Sturm J (2011) Epidemiology and etiology of young stroke. Stroke Res Treathttps:\u002F\u002Fdoi.org\u002F10.4061\u002F2011\u002F209370",{"doi":3035},"10.4061\u002F2011\u002F209370",{"id":26,"text":3037,"url":26,"identifiers":3038},"Kissela B, Schneider A, Kleindorfer D, et al. Stroke in a biracial population: the excess burden of stroke among blacks. Stroke. 2004;35:426–31.",{"doi":3039},"10.1161\u002F01.STR.0000110982.74967.39",{"id":26,"text":3041,"url":26,"identifiers":3042},"Chong JY, Sacco RL. Epidemiology of Stroke in young adults: race\u002Fethnic differences. J Thromb Thrombolysis. 2005;20:77–83.",{"doi":3043},"10.1007\u002Fs11239-005-3201-9",{"id":26,"text":3045,"url":26,"identifiers":3046},"Aradine EM, Ryan KA, Cronin CA, et al. Black-White differences in ischemic stroke risk factor burden in young adults. Stroke. 2022;53:e66–9.",{"doi":3047},"10.1161\u002FSTROKEAHA.121.034314",{"id":26,"text":3049,"url":26,"identifiers":3050},"Gulli G, Rutten-Jacobs LCA, Kalra L, Rudd AG, Wolfe CDA, Markus HS. Differences in the distribution of stroke subtypes in a UK black stroke population—final results from the South London Ethnicity and Stroke Study. BMC Med. 2016;14:77.",{"doi":3051},"10.1186\u002Fs12916-016-0618-2",{"id":26,"text":3053,"url":26,"identifiers":3054},"Jones EM, Okpala M, Zhang X, et al. Racial disparities in post-stroke functional outcomes in young patients with ischemic stroke. J Stroke Cerebrovasc Dis. 2020;29:104987.",{"doi":3055},"10.1016\u002Fj.jstrokecerebrovasdis.2020.104987",{"id":26,"text":3057,"url":26,"identifiers":3058},"Jacobs BS, Boden-Albala B, Lin I-F, Sacco RL. Stroke in the young in the northern Manhattan stroke study. Stroke. 2002;33:2789–93.",{"doi":3059},"10.1161\u002F01.STR.0000038988.64376.3A",{"id":26,"text":3061,"url":26,"identifiers":3062},"Trimble B, Morgenstern LB. Stroke in minorities. Neurol Clin. 2008;26:1177–90.",{"doi":3063},"10.1016\u002Fj.ncl.2008.05.010",{"id":26,"text":3065,"url":26,"identifiers":3066},"Jafari A, Rajabi A, Gholian-Aval M, Peyman N, Mahdizadeh M, Tehrani H. National, regional, and global prevalence of cigarette smoking among women\u002Ffemales in the general population: a systematic review and meta-analysis. Environ Health Prev Med. 2021;26:5.",{"doi":3067},"10.1186\u002Fs12199-020-00924-y",{"id":26,"text":3069,"url":26,"identifiers":3070},"Sreeramareddy CT, Acharya K. Trends in prevalence of tobacco use by sex and socioeconomic status in 22 sub-Saharan African countries, 2003–2019. JAMA Netw Open. 2021;4:e2137820.",{"doi":3071},"10.1001\u002Fjamanetworkopen.2021.37820",{"id":26,"text":3073,"url":26,"identifiers":3074},"Wasay M, Kaul S, Menon B, et al. Ischemic stroke in young Asian women: risk factors, subtypes and outcome. Cerebrovasc Dis. 2010;30:418–22.",{"doi":3075},"10.1159\u002F000317075",{"id":26,"text":3077,"url":26,"identifiers":3078},"Li F, Yang L, Yang R, Xu W, Chen F-P, Li N, Zhang J-B. Ischemic stroke in young adults of northern China: characteristics and risk factors for recurrence. Eur Neurol. 2017;77:115–22.",{"doi":3079},"10.1159\u002F000455093",{"id":26,"text":3081,"url":26,"identifiers":3082},"Brouwer J, Smaal JA, Emmer BJ, et al. Endovascular thrombectomy in young patients with stroke: a MR CLEAN registry study. Stroke. 2022;53:34–42.",{"doi":3083},"10.1161\u002FSTROKEAHA.120.034033",{"id":26,"text":3085,"url":26,"identifiers":3086},"Kim JS. Moyamoya disease: epidemiology, clinical features, and diagnosis. J Stroke. 2016;18:2–11.",{"doi":3087},"10.5853\u002Fjos.2015.01627",{"id":26,"text":3089,"url":26,"identifiers":3090},"Niu J-W, Gao S, Cui L-Y, Peng B, Zhu Y-C, Ni J, Zhou L-X, Yao M, Xu W-H. Intracranial atherosclerosis in Chinese young adult stroke patients. J Stroke Cerebrovasc Dis. 2014;23:1519–23.",{"doi":3091},"10.1016\u002Fj.jstrokecerebrovasdis.2013.12.030",{"id":26,"text":3093,"url":26,"identifiers":3094},"Yahya T, Jilani MH, Khan SU, et al. Stroke in young adults: current trends, opportunities for prevention and pathways forward. Am J Prev Cardiol. 2020;3:100085.",{"doi":3095},"10.1016\u002Fj.ajpc.2020.100085",{"id":26,"text":3097,"url":26,"identifiers":3098},"van Alebeek ME, Arntz RM, Ekker MS, Synhaeve NE, Maaijwee NA, Schoonderwaldt H, van der Vlugt MJ, van Dijk EJ, Rutten-Jacobs LC, de Leeuw F-E. Risk factors and mechanisms of stroke in young adults: the FUTURE study. J Cereb Blood Flow Metab. 2018;38:1631–41.",{"doi":3099},"10.1177\u002F0271678X17707138",{"id":26,"text":3101,"url":26,"identifiers":3102},"Leys D, Bandu L, Hénon H, Lucas C, Mounier-Vehier F, Rondepierre P, Godefroy O. Clinical outcome in 287 consecutive young adults (15 to 45 years) with ischemic stroke. Neurology. 2002;59:26–33.",{"doi":3103},"10.1212\u002FWNL.59.1.26",{"id":26,"text":3105,"url":26,"identifiers":3106},"Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke. 2009;40:2349–55.",{"doi":3107},"10.1161\u002FSTROKEAHA.109.547828",{"id":26,"text":3109,"url":26,"identifiers":3110},"Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357:2262–8.",{"doi":3111},"10.1056\u002FNEJMoa071422",{"id":26,"text":3113,"url":26,"identifiers":3114},"Divišová P, Šaňák D, Král M, et al. Young cryptogenic ischemic stroke: a descriptive analysis of clinical and laboratory characteristics, outcomes and stroke recurrence. J Stroke Cerebrovasc Dis. 2020;29:105046.",{"doi":3115},"10.1016\u002Fj.jstrokecerebrovasdis.2020.105046",{"id":26,"text":3117,"url":26,"identifiers":3118},"Martinez-Majander N, Artto V, Ylikotila P, et al. Association between migraine and cryptogenic ischemic stroke in young adults. Ann Neurol. 2021;89:242–53.",{"doi":3119},"10.1002\u002Fana.25937",{"id":26,"text":3121,"url":26,"identifiers":3122},"Tatlisumak T, Cucchiara B, Kuroda S, Kasner SE, Putaala J. Nontraumatic intracerebral haemorrhage in young adults. Nat Rev Neurol. 2018;14:237–50.",{"doi":3123},"10.1038\u002Fnrneurol.2018.17",{"id":26,"text":3125,"url":26,"identifiers":3126},"Ruíz-Sandoval JL, Cantu C, Barinagarrementeria F. Intracerebral hemorrhage in young people: analysis of risk factors, location, causes, and prognosis. Stroke. 1999;30:537–41.",{"doi":3127},"10.1161\u002F01.STR.30.3.537",{"id":26,"text":3129,"url":26,"identifiers":3130},"George MG. Risk factors for ischemic stroke in younger adults. Stroke. 2020;51:729–35.",{"doi":3131},"10.1161\u002FSTROKEAHA.119.024156",{"id":26,"text":3133,"url":26,"identifiers":3134},"Parikh NS, Chatterjee A, Díaz I, Merkler AE, Murthy SB, Iadecola C, Navi BB, Kamel H. Trends in active cigarette smoking among stroke survivors in the United States, 1999 to 2018. Stroke. 2020;51:1656–61.",{"doi":3135},"10.1161\u002FSTROKEAHA.120.029084",{"id":26,"text":3137,"url":26,"identifiers":3138},"Markidan J, Cole JW, Cronin CA, Merino JG, Phipps MS, Wozniak MA, Kittner SJ. Smoking and risk of ischemic stroke in young men. Stroke. 2018;49:1276–8.",{"doi":3139},"10.1161\u002FSTROKEAHA.117.018859",{"id":26,"text":3141,"url":26,"identifiers":3142},"Shah RS, Cole JW. Smoking and stroke: the more you smoke the more you stroke. Expert Rev Cardiovasc Ther. 2010;8:917–32.",{"doi":3143},"10.1586\u002Ferc.10.56",{"id":26,"text":3145,"url":26,"identifiers":3146},"Pezzini A, Grassi M, Lodigiani C, et al. Predictors of migraine subtypes in young adults with ischemic stroke: the Italian project on stroke in young adults. Stroke. 2011;42:17–21.",{"doi":3147},"10.1161\u002FSTROKEAHA.110.592246",{"id":26,"text":3149,"url":26,"identifiers":3150},"MacClellan LR, Giles W, Cole J, Wozniak M, Stern B, Mitchell BD, Kittner SJ. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke. 2007;38:2438–45.",{"doi":3151},"10.1161\u002FSTROKEAHA.107.488395",{"id":26,"text":3153,"url":26,"identifiers":3154},"Aigner A, Grittner U, Rolfs A, Norrving B, Siegerink B, Busch MA. Contribution of established stroke risk factors to the burden of stroke in young adults. Stroke. 2017;48:1744–51.",{"doi":3155},"10.1161\u002FSTROKEAHA.117.016599",{"id":26,"text":3157,"url":26,"identifiers":3158},"Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–220.",{"doi":3159},"10.1161\u002FCIR.0b013e318245fac5",{"id":26,"text":3161,"url":26,"identifiers":3162},"• Mszar R, Mahajan S, Valero-Elizondo J, Yahya T, Sharma R, Grandhi GR, Khera R, Virani SS, Lichtman J, Khan SU. Association between sociodemographic determinants and disparities in stroke symptom awareness among US young adults. Stroke. 2020;51:3552–61. Highlights disparities in awareness across age groups and sociodemographic variables",{"doi":3163},"10.1161\u002FSTROKEAHA.120.031137",{"id":26,"text":3165,"url":26,"identifiers":3166},"Bardugo A, Fishman B, Libruder C, et al. Body mass index in 1.9 million adolescents and stroke in young adulthood. Stroke. 2021;52:2043–52.",{"doi":3167},"10.1161\u002FSTROKEAHA.120.033595",{"id":26,"text":3169,"url":26,"identifiers":3170},"Jaakonmäki N, Zedde M, Sarkanen T, et al. Obesity and the risk of cryptogenic ischemic stroke in young adults. J Stroke Cerebrovasc Dis. 2022;31:106380.",{"doi":3171},"10.1016\u002Fj.jstrokecerebrovasdis.2022.106380",{"id":26,"text":3173,"url":26,"identifiers":3174},"Mitchell AB, Cole JW, McArdle PF, Cheng Y-C, Ryan KA, Sparks MJ, Mitchell BD, Kittner SJ. Obesity increases risk of ischemic stroke in young adults. Stroke. 2015;46:1690–2.",{"doi":3175},"10.1161\u002FSTROKEAHA.115.008940",{"id":26,"text":3177,"url":26,"identifiers":3178},"Sultan S, Elkind MSV. The growing problem of stroke among young adults. Curr Cardiol Rep. 2013;15:421.",{"doi":3179},"10.1007\u002Fs11886-013-0421-z",{"id":26,"text":3181,"url":26,"identifiers":3182},"Sarecka-Hujar B, Sordyl J, Małecka-Tendera E, Kopyta I. Levels of lipid parameters in children with arterial ischemic stroke and headache: case-control study and meta-analysis. Brain Sci. 2021;11:417.",{"doi":3183},"10.3390\u002Fbrainsci11040417",{"id":26,"text":3185,"url":26,"identifiers":3186},"Menet R, Bernard M, ElAli A. Hyperlipidemia in stroke pathobiology and therapy: insights and perspectives. Front Physiol. 2018;9:488.",{"doi":3187},"10.3389\u002Ffphys.2018.00488",{"id":26,"text":3189,"url":26,"identifiers":3190},"Talpur MTH, Katbar MT, Shabir KU, Shabir KU, Yaqoob U, Jabeen S, Zia D. Prevalence of dyslipidemia in young adults. Prof Med J. 2020;27:987–93.",{},{"id":26,"text":3192,"url":26,"identifiers":3193},"Ruixing Y, Jinzhen W, Weixiong L, Yuming C, Dezhai Y, Shangling P. The environmental and genetic evidence for the association of hyperlipidemia and hypertension. J Hypertens. 2009;27:251–8.",{"doi":3194},"10.1097\u002FHJH.0b013e32831bc74d",{"id":26,"text":3196,"url":26,"identifiers":3197},"Gialeraki A, Valsami S, Pittaras T, Panayiotakopoulos G, Politou M. Oral contraceptives and HRT risk of thrombosis. Clin Appl Thromb Hemost. 2018;24:217–25.",{"doi":3198},"10.1177\u002F1076029616683802",{"id":26,"text":3200,"url":26,"identifiers":3201},"Li F, Zhu L, Zhang J, He H, Qin Y, Cheng Y, Xie Z. Oral contraceptive use and increased risk of stroke: a dose–response meta-analysis of observational studies. Front Neurol. 2019;10:993.",{"doi":3202},"10.3389\u002Ffneur.2019.00993",{"id":26,"text":3204,"url":26,"identifiers":3205},"Kent DM, Ruthazer R, Weimar C, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurol. 2013;81:619–25.",{"doi":3206},"10.1212\u002FWNL.0b013e3182a08d59",{"id":26,"text":3208,"url":26,"identifiers":3209},"Nedeltchev K, Wiedmer S, Schwerzmann M, Windecker S, Haefeli T, Meier B, Mattle HP, Arnold M. Sex differences in cryptogenic stroke with patent foramen ovale. Am Heart J. 2008;156:461–5.",{"doi":3210},"10.1016\u002Fj.ahj.2008.04.018",{"id":26,"text":3212,"url":26,"identifiers":3213},"Chen L, Deng W, Palacios I, Inglessis-Azuaje I, McMullin D, Zhou D, Lo EH, Buonanno F, Ning M. Patent foramen ovale (PFO), stroke and pregnancy. J Investig Med. 2016;64:992–1000.",{"doi":3214},"10.1136\u002Fjim-2016-000103",{"id":26,"text":3216,"url":26,"identifiers":3217},"Putaala J. Ischemic stroke in the young: current perspectives on incidence, risk factors, and cardiovascular prognosis. Eur Stroke J. 2016;1:28–40.",{"doi":3218},"10.1177\u002F2396987316629860",{"id":26,"text":3220,"url":26,"identifiers":3221},"Mas J-L, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377:1011–21.",{"doi":3222},"10.1056\u002FNEJMoa1705915",{"id":26,"text":3224,"url":26,"identifiers":3225},"Kottoor SJ, Arora RR. Cryptogenic stroke: to close a patent foramen ovale or not to close? J Cent Nerv Syst Dis. 2018;10:1179573518819476.",{"doi":3226},"10.1177\u002F1179573518819476",{"id":26,"text":3228,"url":26,"identifiers":3229},"Kamel H, Okin PM, Elkind MSV, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke. 2016;47:895–900.",{"doi":3230},"10.1161\u002FSTROKEAHA.115.012004",{"id":26,"text":3232,"url":26,"identifiers":3233},"Berthet K, Lavergne T, Cohen A, Guize L, Bousser MG, Le Heuzey JY, Amarenco P. Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke. 2000;31:398–403.",{"doi":3234},"10.1161\u002F01.STR.31.2.398",{"id":26,"text":3236,"url":26,"identifiers":3237},"Morseth B, Geelhoed B, Linneberg A, et al. Age-specific atrial fibrillation incidence, attributable risk factors and risk of stroke and mortality: results from the MORGAM Consortium. Open Heart. 2021;8:e001624.",{"doi":3238},"10.1136\u002Fopenhrt-2021-001624",{"id":26,"text":3240,"url":26,"identifiers":3241},"Šaňák D, Hutyra M, Král M, et al. Atrial fibrillation in young ischemic stroke patients: an underestimated cause? Eur Neurol. 2015;73:158–63.",{"doi":3242},"10.1159\u002F000369793",{"id":26,"text":3244,"url":26,"identifiers":3245},"Kuybu O, Amireh A, Davis D, Kelley RE, Javalkar V. Prevalence of ischemic stroke and atrial fibrillation in young patients with migraine national inpatient sample analysis. J Stroke Cerebrovasc Dis. 2020;29:104972.",{"doi":3246},"10.1016\u002Fj.jstrokecerebrovasdis.2020.104972",{"id":26,"text":3248,"url":26,"identifiers":3249},"Øie LR, Kurth T, Gulati S, Dodick DW. Migraine and risk of stroke. J Neurol Neurosurg Psychiatry. 2020;91:593–604.",{"doi":3250},"10.1136\u002Fjnnp-2018-318254",{"id":26,"text":3252,"url":26,"identifiers":3253},"Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123:416–27.",{"doi":3254},"10.1016\u002Fj.ymgme.2018.02.014",{"id":26,"text":3256,"url":26,"identifiers":3257},"Kolodny E, Fellgiebel A, Hilz MJ, Sims K, Caruso P, Phan TG, Politei J, Manara R, Burlina A. Cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke. 2015;46:302–13.",{"doi":3258},"10.1161\u002FSTROKEAHA.114.006283",{"id":26,"text":3260,"url":26,"identifiers":3261},"Buechner S, Moretti M, Burlina AP, et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry. 2008;79:1249–54.",{"doi":3262},"10.1136\u002Fjnnp.2008.143693",{"id":26,"text":3264,"url":26,"identifiers":3265},"Ghaffari-Rafi A, Ghaffari-Rafi S, Leon-Rojas J. Socioeconomic and demographic disparities of moyamoya disease in the United States. Clin Neurol Neurosurg. 2020;192:105719.",{"doi":3266},"10.1016\u002Fj.clineuro.2020.105719",{"id":26,"text":3268,"url":26,"identifiers":3269},"Burke GM, Burke AM, Sherma AK, Hurley MC, Batjer HH, Bendok BR. Moyamoya disease: a summary. Neurosurg Focus. 2009;26:E11.",{"doi":3270},"10.3171\u002F2009.1.FOCUS08310",{"id":26,"text":3272,"url":26,"identifiers":3273},"Yasaka M, Minematsu K. Stroke in young adults in Japan. Rinsho Shinkeigaku. 2005;45:842–5.",{},{"id":26,"text":3275,"url":26,"identifiers":3276},"Vanakker OM, Hemelsoet D, De Paepe A. Hereditary connective tissue diseases in young adult stroke: a comprehensive synthesis. Stroke Res Treat. 2011;2011:712903.",{},{"id":26,"text":3278,"url":26,"identifiers":3279},"Stack CA, Cole JW. The clinical approach to stroke in young adults. In: Dehkharghani S, editor. Stroke. Brisbane, AU: Exon Publications; 2021. p. 53–78.",{"doi":3280},"10.36255\u002Fexonpublications.stroke.adultstroke.2021",{"id":26,"text":3282,"url":26,"identifiers":3283},"Seshadri S, Beiser A, Pikula A, Himali JJ, Kelly-Hayes M, Debette S, DeStefano AL, Romero JR, Kase CS, Wolf PA. Parental occurrence of stroke and risk of stroke in their children: the Framingham study. Circulation. 2010;121:1304–12.",{"doi":3284},"10.1161\u002FCIRCULATIONAHA.109.854240",{"id":26,"text":3286,"url":26,"identifiers":3287},"Bevan S, Traylor M, Adib-Samii P, et al. Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genomewide associations. Stroke. 2012;43:3161–7.",{"doi":3288},"10.1161\u002FSTROKEAHA.112.665760",{"id":26,"text":3290,"url":26,"identifiers":3291},"Cheng Y-C, Cole JW, Kittner SJ, Mitchell BD. Genetics of ischemic stroke in young adults. Circ Cardiovasc Genet. 2014;7:383–92.",{"doi":3292},"10.1161\u002FCIRCGENETICS.113.000390",{"id":26,"text":3294,"url":26,"identifiers":3295},"MacClellan LR, Mitchell BD, Cole JW, Wozniak MA, Stern BJ, Giles WH, Brown DW, Sparks MJ, Kittner SJ. Familial aggregation of ischemic stroke in young women: the Stroke Prevention in Young Women Study. Genet Epidemiol. 2006;30:602–8.",{"doi":3296},"10.1002\u002Fgepi.20171",{"id":26,"text":3298,"url":26,"identifiers":3299},"Marshall IJ, Wang Y, Crichton S, McKevitt C, Rudd AG, Wolfe CD. The effects of socioeconomic status on stroke risk and outcomes. The Lancet Neurol. 2015;14:1206–18.",{"doi":3300},"10.1016\u002FS1474-4422(15)00200-8",{"id":26,"text":3302,"url":26,"identifiers":3303},"Kamin Mukaz D, Dawson E, Howard VJ, Cushman M, Higginbotham JC, Judd SE, Kissela BM, Safford MM, Soliman EZ, Howard G (2021) Rural\u002Furban differences in the prevalence of stroke risk factors: a cross-sectional analysis from the REGARDS study. J Rural Healthhttps:\u002F\u002Fdoi.org\u002F10.1111\u002Fjrh.12608",{"doi":3304},"10.1111\u002Fjrh.12608",{"id":26,"text":3306,"url":26,"identifiers":3307},"Reshetnyak E, Ntamatungiro M, Pinheiro LC, Howard VJ, Carson AP, Martin KD, Safford MM. Impact of multiple social determinants of health on incident stroke. Stroke. 2020;51:2445–53.",{"doi":3308},"10.1161\u002FSTROKEAHA.120.028530",{"id":26,"text":3310,"url":26,"identifiers":3311},"Salaycik KJ, Kelly-Hayes M, Beiser A, Nguyen A-H, Brady SM, Kase CS, Wolf PA. Depressive symptoms and risk of stroke: the Framingham Study. Stroke. 2007;38:16–21.",{"doi":3312},"10.1161\u002F01.STR.0000251695.39877.ca",{"id":26,"text":3314,"url":26,"identifiers":3315},"Franc D, Šaňák D, Divišová P, et al. Socioeconomic status and lifestyle in young ischaemic stroke patients: a possible relationship to stroke recovery and risk of recurrent event. Cent Eur J Public Health. 2021;29:223–9.",{"doi":3316},"10.21101\u002Fcejph.a6697",{"id":26,"text":3318,"url":26,"identifiers":3319},"Kuruvilla A, Bhattacharya P, Rajamani K, Chaturvedi S. Factors associated with misdiagnosis of acute stroke in young adults. J Stroke Cerebrovasc Dis. 2011;20:523–7.",{"doi":3320},"10.1016\u002Fj.jstrokecerebrovasdis.2010.03.005",{"id":26,"text":3322,"url":26,"identifiers":3323},"León Cejas L, Mazziotti J, Zinnerman A, Nofal P, Fernández Pardal M, Bonardo P, Reisin R. Misdiagnosis of acute ischemic stroke in young patients. Medicina (B Aires). 2019;79:90–4.",{},{"id":26,"text":3325,"url":26,"identifiers":3326},"Singhal AB, Biller J, Elkind MS, Fullerton HJ, Jauch EC, Kittner SJ, Levine DA, Levine SR. Recognition and management of stroke in young adults and adolescents. Neurol. 2013;81:1089–97.",{"doi":3327},"10.1212\u002FWNL.0b013e3182a4a451",{"id":26,"text":3329,"url":26,"identifiers":3330},"Bhattacharya P, Nagaraja N, Rajamani K, Madhavan R, Santhakumar S, Chaturvedi S. Early use of MRI improves diagnostic accuracy in young adults with stroke. J Neurol Sci. 2013;324:62–4.",{"doi":3331},"10.1016\u002Fj.jns.2012.10.002",{"id":26,"text":3333,"url":26,"identifiers":3334},"Jauch EC, Saver JL, Adams HP, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\u002FAmerican Stroke Association. Stroke. 2013;44:870–947.",{"doi":3335},"10.1161\u002FSTR.0b013e318284056a",{"id":26,"text":3337,"url":26,"identifiers":3338},"Markus HS, Levi C, King A, Madigan J, Norris J, Cervical Artery Dissection in Stroke Study (CADISS) Investigators. Antiplatelet therapy vs anticoagulation therapy in cervical artery dissection: the Cervical Artery Dissection in Stroke Study (CADISS) randomized clinical trial final results. JAMA Neurol. 2019;76:657–64.",{"doi":3339},"10.1001\u002Fjamaneurol.2019.0072",{"id":26,"text":3341,"url":26,"identifiers":3342},"van Dongen MME, Aarnio K, Martinez-Majander N, Pirinen J, Sinisalo J, Lehto M, Kaste M, Tatlisumak T, de Leeuw F-E, Putaala J. Use of statins after ischemic stroke in young adults and its association with long-term outcome. Stroke. 2019;50:3385–92.",{"doi":3343},"10.1161\u002FSTROKEAHA.119.026992",{"id":26,"text":3345,"url":26,"identifiers":3346},"Brouwer-Goossensen D, den Hertog HM, Mastenbroek-de Jong MA, van Gemert-Pijnen LJEWC, Taal E. Patient perspectives on health-related behavior change after transient ischemic attack or ischemic stroke. Brain Behav. 2021;11:e01993.",{"doi":3347},"10.1002\u002Fbrb3.1993",{"id":26,"text":3349,"url":26,"identifiers":3350},"Biswas S, Andrianopoulos N, Duffy SJ, et al. Impact of socioeconomic status on clinical outcomes in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2019;12:e004979.",{"doi":3351},"10.1161\u002FCIRCOUTCOMES.118.004979",{"id":26,"text":3353,"url":26,"identifiers":3354},"Bernardo F, Rebordão L, Machado S, Salgado V, Pinto AN. In-hospital and long-term prognosis after spontaneous intracerebral hemorrhage among young adults aged 18–65 years. J Stroke Cerebrovasc Dis. 2019;28:104350.",{"doi":3355},"10.1016\u002Fj.jstrokecerebrovasdis.2019.104350",{"id":26,"text":3357,"url":26,"identifiers":3358},"Balci K, Utku U, Asil T, Celik Y. Ischemic stroke in young adults: risk factors, subtypes, and prognosis. Neurologist. 2011;17:16–20.",{"doi":3359},"10.1097\u002FNRL.0b013e3181f954a7",{"id":26,"text":3361,"url":26,"identifiers":3362},"Khan SU, Khan MZ, Khan MU, et al. Clinical and economic burden of stroke among young, midlife, and older adults in the United States, 2002–2017. Mayo Clin Proc Innov Qual Outcomes. 2021;5:431–41.",{"doi":3363},"10.1016\u002Fj.mayocpiqo.2021.01.015",{"id":26,"text":3365,"url":26,"identifiers":3366},"Rutten-Jacobs LCA, Arntz RM, Maaijwee NAM, Schoonderwaldt HC, Dorresteijn LD, van Dijk EJ, de Leeuw F-E. Long-term mortality after stroke among adults aged 18 to 50 years. JAMA. 2013;309:1136–44.",{"doi":3367},"10.1001\u002Fjama.2013.842",{"id":26,"text":3369,"url":26,"identifiers":3370},"Campo M, Toglia J, Jaywant A, O’Dell MW. Young individuals with stroke in rehabilitation: a cohort study. Int J Rehabil Res. 2021;44:314–22.",{"doi":3371},"10.1097\u002FMRR.0000000000000491",{"id":26,"text":3373,"url":26,"identifiers":3374},"Putaala J, Strbian D, Mustanoja S, Haapaniemi E, Kaste M, Tatlisumak T. Functional outcome in young adult ischemic stroke: impact of lipoproteins. Acta Neurol Scand. 2013;127:61–9.",{"doi":3375},"10.1111\u002Fj.1600-0404.2012.01683.x",{"id":26,"text":3377,"url":26,"identifiers":3378},"Tan E, Gao L, Collier JM, Ellery F, Dewey HM, Bernhardt J, Moodie M. The economic and health burden of stroke among younger adults in Australia from a societal perspective. BMC Public Health. 2022;22:218.",{"doi":3379},"10.1186\u002Fs12889-021-12400-5",{"id":26,"text":3381,"url":26,"identifiers":3382},"Krishnamurthi RV, Moran AE, Feigin VL, et al. Stroke prevalence, mortality and disability-adjusted life years in adults aged 20–64 years in 1990–2013: data from the global burden of disease 2013 study. Neuroepidemiol. 2015;45:190–202.",{"doi":3383},"10.1159\u002F000441098",{"id":26,"text":3385,"url":26,"identifiers":3386},"Jarvis HL, Brown SJ, Price M, Butterworth C, Groenevelt R, Jackson K, Walker L, Rees N, Clayton A, Reeves ND. Return to employment after stroke in young adults: how important is the speed and energy cost of walking? Stroke. 2019;50:3198–204.",{"doi":3387},"10.1161\u002FSTROKEAHA.119.025614",{"id":26,"text":3389,"url":26,"identifiers":3390},"Pinter D, Enzinger C, Gattringer T, et al. Prevalence and short-term changes of cognitive dysfunction in young ischaemic stroke patients. Eur J Neurol. 2019;26:727–32.",{"doi":3391},"10.1111\u002Fene.13879",{"id":26,"text":3393,"url":26,"identifiers":3394},"Schaapsmeerders P, Maaijwee NAM, van Dijk EJ, Rutten-Jacobs LCA, Arntz RM, Schoonderwaldt HC, Dorresteijn LDA, Kessels RPC, de Leeuw F-E. Long-term cognitive impairment after first-ever ischemic stroke in young adults. Stroke. 2013;44:1621–8.",{"doi":3395},"10.1161\u002FSTROKEAHA.111.000792",{"id":26,"text":3397,"url":26,"identifiers":3398},"Maaijwee Na MM, Tendolkar I, Rutten-Jacobs LCA, Arntz RM, Schaapsmeerders P, Dorresteijn LD, Schoonderwaldt HC, van Dijk EJ, de Leeuw FE. Long-term depressive symptoms and anxiety after transient ischaemic attack or ischaemic stroke in young adults. Eur J Neurol. 2016;23:1262–8.",{"doi":3399},"10.1111\u002Fene.13009",{"id":26,"text":3401,"url":26,"identifiers":3402},"Sebastian S, Stein LK, Dhamoon MS. Infection as a stroke trigger. Stroke. 2019;50:2216–8.",{"doi":3403},"10.1161\u002FSTROKEAHA.119.025872",{"id":26,"text":3405,"url":26,"identifiers":3406},"Paganini-Hill A, Lozano E, Fischberg G, Perez Barreto M, Rajamani K, Ameriso SF, Heseltine PNR, Fisher M. Infection and risk of ischemic stroke: differences among stroke subtypes. Stroke. 2003;34:452–7.",{"doi":3407},"10.1161\u002F01.STR.0000053451.28410.98",{"id":26,"text":3409,"url":26,"identifiers":3410},"Qureshi AI, Baskett WI, Huang W, et al. Acute ischemic stroke and COVID-19. Stroke. 2021;52:905–12.",{"doi":3411},"10.1161\u002FSTROKEAHA.120.031786",{"id":3413,"createTime":3414,"updateTime":3415,"relativeEntities":3416,"slug":3417,"properties":3418,"entityType":760,"verifyStatus":25,"verifyTime":3415,"verifyNote":762,"syncStatus":28,"languages":3431,"translateLanguages":26,"viewCount":36,"primaryUrl":3432,"fullTextUrl":26,"authors":3433,"publicationType":830,"publisherRelationship":3530,"citationCount":3563,"citationInfo":3564,"publishDate":3566,"publishYear":3567,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":3568,"isForceReanalyzing":1106},"a3656c76-8a05-4c66-91b2-abcac8bec240","2024-04-18T01:55:51.056+00:00","2024-12-29T10:45:41.675+00:00",[],"The-Different-Facets-of-Dyslipidemia-and-Hypertension-in-Atherosclerosis",{"mag":3419,"keywords":3421,"openalex":3422,"abstract":3424,"title":3425,"pm":3427,"doi":3429},{"VOID":3420},"2554934526",{},{"VOID":3423},"W2554934526",{},{"EN":3426},"The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis",{"VOID":3428},"27822682",{"VOID":3430},"10.1007\u002Fs11883-016-0632-z",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11883-016-0632-z",[3434,3453,3468,3483,3498,3513],{"id":3435,"sortIndex":111,"researcher":26,"roles":3436,"affiliations":3437,"properties":3448},"029fe8b3-965e-4509-8d97-3ffdbf0b1789",[],[3438],{"id":3439,"sortIndex":36,"affiliation":3440,"properties":26},"b1e29eca-2f3a-4bc4-bc5e-1777e64e1f63",{"id":3441,"createTime":3442,"updateTime":3442,"relativeEntities":3443,"slug":3444,"properties":3445,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"bce2359a-4208-4a99-b13b-cea622dc322f","2024-04-18T01:55:51.108+00:00",[],"Department-of-Physiology-University-of-Saskatchewan-College-of-Medicine-107-Wiggins-Road-Saskatoon-SK-S7N-5E5-Canada",{"title":3446},{"EN":3447},"Department of Physiology, University of Saskatchewan College of Medicine, 107 Wiggins Road, Saskatoon, SK, S7N 5E5, Canada",{"openalex":3449,"title":3451},{"VOID":3450},"A5010586620",{"EN":3452},"Daniel Nwabuko",{"id":3454,"sortIndex":115,"researcher":26,"roles":3455,"affiliations":3456,"properties":3463},"2b501ff7-4b84-4537-bab3-ba18d51fecbe",[],[3457],{"id":3458,"sortIndex":36,"affiliation":3459,"properties":26},"5e933f96-226a-4e96-889d-0416f793dbc0",{"id":3441,"createTime":3442,"updateTime":3442,"relativeEntities":3460,"slug":3444,"properties":3461,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3462},{"EN":3447},{"openalex":3464,"title":3466},{"VOID":3465},"A5063906398",{"EN":3467},"Krystie McLellan",{"id":3469,"sortIndex":36,"researcher":26,"roles":3470,"affiliations":3471,"properties":3478},"ccbe0ab2-a1c1-4b4a-9ee7-f630c8b4ae78",[],[3472],{"id":3473,"sortIndex":36,"affiliation":3474,"properties":26},"f9b5993d-682e-4add-91a4-e4f681fcf370",{"id":3441,"createTime":3442,"updateTime":3442,"relativeEntities":3475,"slug":3444,"properties":3476,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3477},{"EN":3447},{"openalex":3479,"title":3481},{"VOID":3480},"A5023769324",{"EN":3482},"Jessica L. Hurtubise",{"id":3484,"sortIndex":162,"researcher":26,"roles":3485,"affiliations":3486,"properties":3493},"494a4420-8e23-4d75-a6da-0e79f8183816",[],[3487],{"id":3488,"sortIndex":36,"affiliation":3489,"properties":26},"11504833-c213-4022-8244-5258e784afb7",{"id":3441,"createTime":3442,"updateTime":3442,"relativeEntities":3490,"slug":3444,"properties":3491,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3492},{"EN":3447},{"openalex":3494,"title":3496},{"VOID":3495},"A5019347906",{"EN":3497},"Joseph Fomusi Ndisang",{"id":3499,"sortIndex":59,"researcher":26,"roles":3500,"affiliations":3501,"properties":3508},"70bfffe2-0776-499f-9fb1-5f888b1b27e9",[],[3502],{"id":3503,"sortIndex":36,"affiliation":3504,"properties":26},"32af94a2-13e6-4cab-8249-e53c6c09e76d",{"id":3441,"createTime":3442,"updateTime":3442,"relativeEntities":3505,"slug":3444,"properties":3506,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3507},{"EN":3447},{"openalex":3509,"title":3511},{"VOID":3510},"A5034154509",{"EN":3512},"Oluwadara Onasanya",{"id":3514,"sortIndex":114,"researcher":26,"roles":3515,"affiliations":3516,"properties":3523},"f7c0a32a-9754-458d-875e-bdf37747802a",[],[3517],{"id":3518,"sortIndex":36,"affiliation":3519,"properties":26},"49fdbd8f-5174-4c03-b5b3-5ae1ab3836a8",{"id":3441,"createTime":3442,"updateTime":3442,"relativeEntities":3520,"slug":3444,"properties":3521,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3522},{"EN":3447},{"openalex":3524,"orcid":3526,"title":3528},{"VOID":3525},"A5064446201",{"VOID":3527},"https:\u002F\u002Forcid.org\u002F0000-0003-3866-0437",{"EN":3529},"Kevin M. Durr",{"url":26,"publisher":3531,"properties":3559},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":3532,"slug":663,"properties":3533,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":3537,"manageAffiliations":3538,"indexDatabases":3539,"url":730,"thumbnailPath":26,"statistic":3554,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":3534,"eissn":3535,"title":3536},{"VOID":666},{"VOID":668},{"EN":670},[],[],[3540,3547],{"id":712,"indexDatabase":3541,"url":725,"indexYears":726,"academicFieldIds":3546,"indexDatabaseRanking":729},{"id":714,"createTime":715,"updateTime":716,"relativeEntities":3542,"label":3543,"description":3544,"key":722,"publicationTags":3545,"standard":26},[],{"EN":719,"VI":719},{"EN":719,"VI":721},[724],[728],{"id":693,"indexDatabase":3548,"url":708,"indexYears":26,"academicFieldIds":3553,"indexDatabaseRanking":26},{"id":695,"createTime":696,"updateTime":697,"relativeEntities":3549,"label":3550,"description":3551,"key":704,"publicationTags":3552,"standard":26},[],{"EN":700,"VI":700},{"VI":702,"EN":703},[706,707],[710],{"impactFactor":36,"impactFactorByYear":3555,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":51,"totalPublicationByYear":3556,"totalCitation":36,"totalCitationByYear":3557,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":3558,"hindexLast5Year":36,"hindex":36},{},{"2002":115,"2003":115,"2004":114,"2006":114,"2007":115,"2011":115,"2012":115,"2013":115,"2017":115,"2019":114,"2020":115,"2023":115},{},{},{"volume":3560,"issue":3562},{"VOID":3561},"18",{"VOID":2950},163,{"total":3563,"publishYear":26,"statisticByYear":3565},{"2017":135,"2018":298,"2019":298,"2020":173,"2021":240,"2022":398,"2023":244,"2024":53},"2016-12-01",2016,[3569,3573,3577,3581,3585,3589,3593,3597,3601,3605,3609,3613,3617,3621,3625,3629,3633,3637,3641,3645,3649,3653,3657,3661,3665,3668,3672,3676,3680,3684,3688,3692,3696,3700,3704,3708,3712,3716,3720,3724,3728,3732,3736,3740,3744,3748,3752,3756,3759,3763,3767,3771,3774,3778,3782,3786,3790,3794,3798,3802,3806,3810,3814,3818,3822,3826,3830,3833,3837,3841,3845,3849,3853,3857,3861,3865,3869,3873,3877,3881,3885,3889,3893,3897,3901,3905,3909,3913,3917,3921,3925,3929,3933,3937,3940,3944,3947,3951],{"id":26,"text":3570,"url":26,"identifiers":3571},"Selvin E, Coresh J, Shahar E, Zhang L, Steffes M, Sharrett AR. Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. The Lancet Neurology. 2005;4(12):821–6.",{"doi":3572},"10.1016\u002FS1474-4422(05)70227-1",{"id":26,"text":3574,"url":26,"identifiers":3575},"Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74.",{"doi":3576},"10.1038\u002Fnature01323",{"id":26,"text":3578,"url":26,"identifiers":3579},"Zarins CK, Giddens DP, Bharadvaj BK, Sottiurai VS, Mabon RF, Glagov S. Carotid bifurcation atherosclerosis. Quantitative correlation of plaque localization with flow velocity profiles and wall shear stress. Circ Res. 1983;53(4):502–14.",{"doi":3580},"10.1161\u002F01.RES.53.4.502",{"id":26,"text":3582,"url":26,"identifiers":3583},"Liu C, Guo Q, Lu M, Li Y. An experimental study on amelioration of dyslipidemia-induced atherosclesis by Clematichinenoside through regulating Peroxisome proliferator-activated receptor-alpha mediated apolipoprotein A-I, A-II and C-III. Eur J Pharmacol. 2015;761:362–74.",{"doi":3584},"10.1016\u002Fj.ejphar.2015.04.015",{"id":26,"text":3586,"url":26,"identifiers":3587},"Ambale Venkatesh B, Volpe GJ, Donekal S, et al. Association of longitudinal changes in left ventricular structure and function with myocardial fibrosis: the Multi-Ethnic Study of Atherosclerosis study. Hypertension. 2014;64(3):508–15.",{"doi":3588},"10.1161\u002FHYPERTENSIONAHA.114.03697",{"id":26,"text":3590,"url":26,"identifiers":3591},"Cochain C, Zernecke A. Macrophages and immune cells in atherosclerosis: recent advances and novel concepts. Basic Res Cardiol. 2015;110(4):34.",{"doi":3592},"10.1007\u002Fs00395-015-0491-8",{"id":26,"text":3594,"url":26,"identifiers":3595},"Atabek ME, Akyurek N, Eklioglu BS, Alp H. Impaired systolic blood dipping and nocturnal hypertension: an independent predictor of carotid intima-media thickness in type 1 diabetic patients. J Diabetes Complicat. 2014;28(1):51–5.",{"doi":3596},"10.1016\u002Fj.jdiacomp.2013.09.007",{"id":26,"text":3598,"url":26,"identifiers":3599},"Pan WH, Bai CH, Chen JR, Chiu HC. Associations between carotid atherosclerosis and high factor VIII activity, dyslipidemia, and hypertension. Stroke. 1997;28(1):88–94.",{"doi":3600},"10.1161\u002F01.STR.28.1.88",{"id":26,"text":3602,"url":26,"identifiers":3603},"Reina SA, Llabre MM, Allison MA, et al. HDL cholesterol and stroke risk: the multi-ethnic study of atherosclerosis. Atherosclerosis. 2015;243(1):314–9.",{"doi":3604},"10.1016\u002Fj.atherosclerosis.2015.09.031",{"id":26,"text":3606,"url":26,"identifiers":3607},"•• Rozanski A, Gransar H, Shaw L, et al. Comparison of the atherosclerotic burden among asymptomatic patients vs matched volunteers. J Nucl Cardiol. 2011;18(2):291–8. This paper underscores problems associated with diagnosis of atherosclerosis, especially in asymptomatic patients. By using coronary artery calcium (CAC) scanning, the authors showed that asymptomatic patients referred for cardiac stress testing manifested some degree of atherosclerosis.",{"doi":3608},"10.1007\u002Fs12350-010-9324-1",{"id":26,"text":3610,"url":26,"identifiers":3611},"Duman S. Rational approaches to the treatment of hypertension: diet. Kidney Int Suppl. 2013;3(4):343–5.",{"doi":3612},"10.1038\u002Fkisup.2013.73",{"id":26,"text":3614,"url":26,"identifiers":3615},"Kim HY, Choi JH. How to utilize coronary computed tomography angiography in the treatment of coronary artery disease. J Cardiovasc Ultrason. 2015;23(4):204–8.",{"doi":3616},"10.4250\u002Fjcu.2015.23.4.204",{"id":26,"text":3618,"url":26,"identifiers":3619},"Niccoli G, Cin D, Scalone G, et al. Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease. Atherosclerosis. 2016;246:214–20.",{"doi":3620},"10.1016\u002Fj.atherosclerosis.2016.01.020",{"id":26,"text":3622,"url":26,"identifiers":3623},"Chung DW, Chen J, Ling M, et al. High density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion. Blood. 2016 127:637–45.",{"doi":3624},"10.1182\u002Fblood-2014-09-599530",{"id":26,"text":3626,"url":26,"identifiers":3627},"Kolski B, Tsimikas S. Emerging therapeutic agents to lower lipoprotein (a) levels. Curr Opin Lipidol. 2012;23(6):560–8.",{"doi":3628},"10.1097\u002FMOL.0b013e3283598d81",{"id":26,"text":3630,"url":26,"identifiers":3631},"Guerra R, Yu Z, Marcovina S, Peshock R, Cohen JC, Hobbs HH. Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study. Circulation. 2005;111(12):1471–9.",{"doi":3632},"10.1161\u002F01.CIR.0000159263.50305.BD",{"id":26,"text":3634,"url":26,"identifiers":3635},"Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90(1):52–60.",{"doi":3636},"10.1172\u002FJCI115855",{"id":26,"text":3638,"url":26,"identifiers":3639},"Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518–28.",{"doi":3640},"10.1056\u002FNEJMoa0902604",{"id":26,"text":3642,"url":26,"identifiers":3643},"Arsenault BJ, Boekholdt SM, Dube MP, et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case–control cohort. Circ Cardiovasc Genet. 2014;7(3):304–10.",{"doi":3644},"10.1161\u002FCIRCGENETICS.113.000400",{"id":26,"text":3646,"url":26,"identifiers":3647},"Utermann G. Genetic architecture and evolution of the lipoprotein(a) trait. Curr Opin Lipidol. 1999;10(2):133–41.",{"doi":3648},"10.1097\u002F00041433-199904000-00007",{"id":26,"text":3650,"url":26,"identifiers":3651},"• Sorokin A, Kotani K. Lipoprotein(a) and arterial stiffness parameters. Pulse. 2015;3(2):148–52. The authors reported a positive association between lipoprotein(a) and arterial stiffness following the measurement of ‘pulse wave velocity’ and ‘cardio-ankle vascular index’, and suggested that lipoprotein(a) could be used a non-invasive bio-marker of atherosclerosis.",{"doi":3652},"10.1159\u002F000438733",{"id":26,"text":3654,"url":26,"identifiers":3655},"Sponder M, Fritzer-Szekeres M, Marculescu R, Litschauer B, Strametz-Juranek J. A new coronary artery disease grading system correlates with numerous routine parameters that were associated with atherosclerosis: a grading system for coronary artery disease severity. Vasc Health Risk Manag. 2014;10:641–7.",{"doi":3656},"10.2147\u002FVHRM.S68919",{"id":26,"text":3658,"url":26,"identifiers":3659},"Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111(25):3481–8.",{"doi":3660},"10.1161\u002FCIRCULATIONAHA.105.537878",{"id":26,"text":3662,"url":26,"identifiers":3663},"Moore RD, Jackson JC, Venkatesh SL, Quarfordt SD, Baxter BW. Revisiting the NIH Stroke Scale as a screening tool for proximal vessel occlusion: can advanced imaging be targeted in acute stroke? J NeuroIntervent Surg. 2016. doi: 10.1136\u002Fneurintsurg-2015-012088 .",{"doi":3664},"10.1136\u002Fneurintsurg-2015-012088",{"id":26,"text":3666,"url":26,"identifiers":3667},"Schainfeld RM. Management of peripheral arterial disease and intermittent claudication. The Journal of the American Board of Family Practice\u002FAmerican Board of Family Practice. 2001;14(6):443–50.",{},{"id":26,"text":3669,"url":26,"identifiers":3670},"Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation. 2002;105(1):15–21.",{"doi":3671},"10.1161\u002Fhc0102.101362",{"id":26,"text":3673,"url":26,"identifiers":3674},"Luczak M, Formanowicz D, Marczak L, et al. Deeper insight into chronic kidney disease-related atherosclerosis: comparative proteomic studies of blood plasma using 2DE and mass spectrometry. J Transl Med. 2015;13:20.",{"doi":3675},"10.1186\u002Fs12967-014-0378-8",{"id":26,"text":3677,"url":26,"identifiers":3678},"Schroeder B, Francis G, Leipsic J, Heilbron B, John Mancini GB, Taylor CM. Early atherosclerosis detection in asymptomatic patients: a comparison of carotid ultrasound, coronary artery calcium score, and coronary computed tomography angiography. Can J Cardiol. 2013;29(12):1687–94.",{"doi":3679},"10.1016\u002Fj.cjca.2013.10.003",{"id":26,"text":3681,"url":26,"identifiers":3682},"Verjans JW, Jaffer FA. Biological imaging of atherosclerosis: moving beyond anatomy. J Cardiovasc Transl Res. 2013;6(5):681–94.",{"doi":3683},"10.1007\u002Fs12265-013-9474-z",{"id":26,"text":3685,"url":26,"identifiers":3686},"Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable\u002Funstable plaque. Arterioscler Thromb Vasc Biol. 2010;30(7):1282–92.",{"doi":3687},"10.1161\u002FATVBAHA.108.179739",{"id":26,"text":3689,"url":26,"identifiers":3690},"Jaffer FA, Vinegoni C, John MC, et al. Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation. 2008;118(18):1802–9.",{"doi":3691},"10.1161\u002FCIRCULATIONAHA.108.785881",{"id":26,"text":3693,"url":26,"identifiers":3694},"Gaemperli O, Saraste A, Knuuti J. Cardiac hybrid imaging. Eur Heart J Cardiovasc Imaging. 2012;13(1):51–60.",{"doi":3695},"10.1093\u002Fejechocard\u002Fjer240",{"id":26,"text":3697,"url":26,"identifiers":3698},"Tarkin JM, Joshi FR, Rudd JH. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol. 2014;11(8):443–57.",{"doi":3699},"10.1038\u002Fnrcardio.2014.80",{"id":26,"text":3701,"url":26,"identifiers":3702},"Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 1986;74(6):1399–406.",{"doi":3703},"10.1161\u002F01.CIR.74.6.1399",{"id":26,"text":3705,"url":26,"identifiers":3706},"Nissen SE, Yock P. Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation. 2001;103(4):604–16.",{"doi":3707},"10.1161\u002F01.CIR.103.4.604",{"id":26,"text":3709,"url":26,"identifiers":3710},"Safar ME. Arterial aging—hemodynamic changes and therapeutic options. Nat Rev Cardiol. 2010;7(8):442–9.",{"doi":3711},"10.1038\u002Fnrcardio.2010.96",{"id":26,"text":3713,"url":26,"identifiers":3714},"Agbor-Etang BB, Setaro JF. Management of hypertension in patients with ischemic heart disease. Curr Cardiol Rep. 2015;17(12):119.",{"doi":3715},"10.1007\u002Fs11886-015-0662-0",{"id":26,"text":3717,"url":26,"identifiers":3718},"Silva PM, Cardoso SM, Ferreira AM. Persistent lipid abnormalities in patients with hypertension and dyslipidemia treated with statins: results of the Portuguese hypertensive subpopulation of the Dyslipidemia International Study (DYSIS). Clin Exp Hypertens. 2015;37(2):116–21.",{"doi":3719},"10.3109\u002F10641963.2014.913605",{"id":26,"text":3721,"url":26,"identifiers":3722},"Huang Q, Qin L, Dai S, et al. AIP1 suppresses atherosclerosis by limiting hyperlipidemia-induced inflammation and vascular endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2013;33(4):795–804.",{"doi":3723},"10.1161\u002FATVBAHA.113.301220",{"id":26,"text":3725,"url":26,"identifiers":3726},"Kassan M, Galan M, Partyka M, et al. Endoplasmic reticulum stress is involved in cardiac damage and vascular endothelial dysfunction in hypertensive mice. Arterioscler Thromb Vasc Biol. 2012;32(7):1652–61.",{"doi":3727},"10.1161\u002FATVBAHA.112.249318",{"id":26,"text":3729,"url":26,"identifiers":3730},"Ndisang JF, Wang R. Novel therapeutic strategies for impaired endothelium-dependent vascular relaxation. Expert Opin Ther Patents. 2002;12(8):1237–47.",{"doi":3731},"10.1517\u002F13543776.12.8.1237",{"id":26,"text":3733,"url":26,"identifiers":3734},"Ndisang JF, Wang R. Alterations in heme oxygenase\u002Fcarbon monoxide system in pulmonary arteries in hypertension. Exp Biol Med. 2003;228(5):557–63.",{"doi":3735},"10.1177\u002F15353702-0322805-27",{"id":26,"text":3737,"url":26,"identifiers":3738},"Ndisang JF, Wang R. Age-related alterations in soluble guanylyl cyclase and cGMP pathway in spontaneously hypertensive rats. J Hypertens. 2003;21(6):1117–24.",{"doi":3739},"10.1097\u002F00004872-200306000-00011",{"id":26,"text":3741,"url":26,"identifiers":3742},"Ndisang JF, Jadhav A. Heme-arginate suppresses phospholipase C and oxidative stress in the mesenteric arterioles of mineralcorticoid-induced hypertensive rats. Hypertens Res. 2010;33(4):338–47.",{"doi":3743},"10.1038\u002Fhr.2010.1",{"id":26,"text":3745,"url":26,"identifiers":3746},"Yang HY, Bian YF, Zhang HP, et al. LOX1 is implicated in oxidized low-density lipoprotein-induced oxidative stress of macrophages in atherosclerosis. Mol Med Rep. 2015;12(4):5335–41.",{"doi":3747},"10.3892\u002Fmmr.2015.4066",{"id":26,"text":3749,"url":26,"identifiers":3750},"Peire MA, Puig-Parellada P. Oxygen-free radicals and nitric oxide are involved in the thrombus growth produced by iontophoresis of ADP. Pharmacol Res. 1998;38(5):353–6.",{"doi":3751},"10.1006\u002Fphrs.1998.0372",{"id":26,"text":3753,"url":26,"identifiers":3754},"Droge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82(1):47–95.",{"doi":3755},"10.1152\u002Fphysrev.00018.2001",{"id":26,"text":3757,"url":26,"identifiers":3758},"Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.",{"doi":2518},{"id":26,"text":3760,"url":26,"identifiers":3761},"Endtmann C, Ebrahimian T, Czech T, et al. Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration. Hypertension. 2011;58(3):394–403.",{"doi":3762},"10.1161\u002FHYPERTENSIONAHA.110.169193",{"id":26,"text":3764,"url":26,"identifiers":3765},"Landmesser U, Drexler H. The clinical significance of endothelial dysfunction. Curr Opin Cardiol. 2005;20(6):547–51.",{"doi":3766},"10.1097\u002F01.hco.0000179821.11071.79",{"id":26,"text":3768,"url":26,"identifiers":3769},"Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering—are they clinically relevant? Eur Heart J. 2003;24(3):225–48.",{"doi":3770},"10.1016\u002FS0195-668X(02)00419-0",{"id":26,"text":3772,"url":26,"identifiers":3773},"Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.",{"doi":2144},{"id":26,"text":3775,"url":26,"identifiers":3776},"de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy. 2004;24(5):584–91.",{"doi":3777},"10.1592\u002Fphco.24.6.584.34738",{"id":26,"text":3779,"url":26,"identifiers":3780},"Nickenig G, Stablein A, Wassmann S, Wyen C, Muller C, Bohm M. Acute effects of ACE inhibition on coronary endothelial dysfunction. J Renin Angiotensin Aldosterone Syst. 2000;1(4):361–4.",{"doi":3781},"10.3317\u002Fjraas.2000.067",{"id":26,"text":3783,"url":26,"identifiers":3784},"Yamamoto K, Ozaki H, Takayasu K, et al. The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. Hypertens Res. 2011;34(3):325–30.",{"doi":3785},"10.1038\u002Fhr.2010.237",{"id":26,"text":3787,"url":26,"identifiers":3788},"Napoli C, Bruzzese G, Ignarro LJ, et al.: Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide\u002Foxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. American Heart Journal 2008, 156(6):1154 e1151-1158.",{"doi":3789},"10.1016\u002Fj.ahj.2008.09.006",{"id":26,"text":3791,"url":26,"identifiers":3792},"Sonoda M, Aoyagi T, Takenaka K, Uno K, Nagai R. A one-year study of the antiatherosclerotic effect of the angiotensin-II receptor blocker losartan in hypertensive patients. A comparison with angiotension-converting enzyme inhibitors. Int Heart J. 2008;49(1):95–103.",{"doi":3793},"10.1536\u002Fihj.49.95",{"id":26,"text":3795,"url":26,"identifiers":3796},"Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101(13):1586–93.",{"doi":3797},"10.1161\u002F01.CIR.101.13.1586",{"id":26,"text":3799,"url":26,"identifiers":3800},"Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131(5):495–502.",{"doi":3801},"10.1161\u002FCIRCULATIONAHA.114.011004",{"id":26,"text":3803,"url":26,"identifiers":3804},"Siracuse JJ, Giles KA, Pomposelli FB, et al. Results for primary bypass versus primary angioplasty\u002Fstent for intermittent claudication due to superficial femoral artery occlusive disease. J Vasc Surg. 2012;55(4):1001–7.",{"doi":3805},"10.1016\u002Fj.jvs.2011.10.128",{"id":26,"text":3807,"url":26,"identifiers":3808},"• McTaggart RA, Marks MP. The case for angioplasty in patients with symptomatic intracranial atherosclerosis. Front Neurol. 2014;5:36. This article describes the role of endovascular treatment of intracranial atherosclerotic disease with primary intracranial angioplasty in selected patients.",{"doi":3809},"10.3389\u002Ffneur.2014.00036",{"id":26,"text":3811,"url":26,"identifiers":3812},"Baur LA, Hazelton B, Shrewsbury VA. Assessment and management of obesity in childhood and adolescence. Nat Rev Gastroenterol Hepatol. 2011;8(11):635–45.",{"doi":3813},"10.1038\u002Fnrgastro.2011.165",{"id":26,"text":3815,"url":26,"identifiers":3816},"Chen MM, O’Halloran EB, Ippolito JA, Choudhry MA, Kovacs EJ. Alcohol potentiates postburn remote organ damage through shifts in fluid compartments mediated by bradykinin. Shock. 2015;43(1):80–4.",{"doi":3817},"10.1097\u002FSHK.0000000000000265",{"id":26,"text":3819,"url":26,"identifiers":3820},"Kumari S, Mittal A, Dabur R. Moderate alcohol consumption in chronic form enhances the synthesis of cholesterol and C-21 steroid hormones, while treatment with Tinospora cordifolia modulate these events in men. Steroids. 2016;114:68–77.",{"doi":3821},"10.1016\u002Fj.steroids.2016.03.016",{"id":26,"text":3823,"url":26,"identifiers":3824},"Solak ZA, Kabaroglu C, Cok G, et al. Effect of different levels of cigarette smoking on lipid peroxidation, glutathione enzymes and paraoxonase 1 activity in healthy people. Clin Exp Med. 2005;5(3):99–105.",{"doi":3825},"10.1007\u002Fs10238-005-0072-5",{"id":26,"text":3827,"url":26,"identifiers":3828},"Sotos-Prieto M, Bhupathiraju SN, Mattei J, et al. Changes in diet quality scores and risk of cardiovascular disease among US men and women. Circulation. 2015;132(23):2212–9.",{"doi":3829},"10.1161\u002FCIRCULATIONAHA.115.017158",{"id":26,"text":3831,"url":26,"identifiers":3832},"Joint WHO\u002FFAO Expert Consultation on Diet NatPoCD: Diet, nutrition and the prevention of chronic diseases. Report of a joint WHO\u002FFAO expert consultation. Geneva, Switzerland 2003, 916:104–117.",{},{"id":26,"text":3834,"url":26,"identifiers":3835},"Jankovic N, Geelen A, Streppel MT, et al. WHO guidelines for a healthy diet and mortality from cardiovascular disease in European and American elderly: the CHANCES project. Am J Clin Nutr. 2015;102(4):745–56.",{"doi":3836},"10.3945\u002Fajcn.114.095117",{"id":26,"text":3838,"url":26,"identifiers":3839},"Ghayur MN, Janssen LJ. A natural way to cardiovascular health. Nat Rev Cardiol. 2010;7(3):1–2.",{"doi":3840},"10.1038\u002Fnrcardio.2009.131-c1",{"id":26,"text":3842,"url":26,"identifiers":3843},"Urpi-Sarda M, Casas R, Chiva-Blanch G, et al. Virgin olive oil and nuts as key foods of the Mediterranean diet effects on inflammatory biomarkers related to atherosclerosis. Pharmacol Res. 2012;65(6):577–83.",{"doi":3844},"10.1016\u002Fj.phrs.2012.03.006",{"id":26,"text":3846,"url":26,"identifiers":3847},"Hansen D, Dendale P, van Loon LJ, Meeusen R. The impact of training modalities on the clinical benefits of exercise intervention in patients with cardiovascular disease risk or type 2 diabetes mellitus. Sports Med. 2010;40(11):921–40.",{"doi":3848},"10.2165\u002F11535930-000000000-00000",{"id":26,"text":3850,"url":26,"identifiers":3851},"Lenk K, Uhlemann M, Schuler G, Adams V. Role of endothelial progenitor cells in the beneficial effects of physical exercise on atherosclerosis and coronary artery disease. J Appl Physiol. 2011;111(1):321–8.",{"doi":3852},"10.1152\u002Fjapplphysiol.01464.2010",{"id":26,"text":3854,"url":26,"identifiers":3855},"Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation. 2003;107(24):3109–16.",{"doi":3856},"10.1161\u002F01.CIR.0000075572.40158.77",{"id":26,"text":3858,"url":26,"identifiers":3859},"Press V, Freestone I, George CF. Physical activity: the evidence of benefit in the prevention of coronary heart disease. QJM: monthly journal of the Association of Physicians. 2003;96(4):245–51.",{"doi":3860},"10.1093\u002Fqjmed\u002Fhcg041",{"id":26,"text":3862,"url":26,"identifiers":3863},"Ndisang JF, Wang R, Vannacci A, et al. Haeme oxygenase-1 and cardiac anaphylaxis. Br J Pharmacol. 2001;134(8):1689–96.",{"doi":3864},"10.1038\u002Fsj.bjp.0704427",{"id":26,"text":3866,"url":26,"identifiers":3867},"Ndisang JF, Mishra M. The heme oxygenase system selectively suppresses the proinflammatory macrophage m1 phenotype and potentiates insulin signaling in spontaneously hypertensive rats. Am J Hypertens. 2013;26(9):1123–31.",{"doi":3868},"10.1093\u002Fajh\u002Fhpt082",{"id":26,"text":3870,"url":26,"identifiers":3871},"Ndisang JF, Chibbar R. Heme oxygenase improves renal function by potentiating podocyte-associated proteins in N omega-nitro-l-arginine-methyl ester (l-NAME)-induced hypertension. Am J Hypertens. 2015;28(7):930–42.",{"doi":3872},"10.1093\u002Fajh\u002Fhpu240",{"id":26,"text":3874,"url":26,"identifiers":3875},"Ndisang JF, Chibbar R, Lane N. Heme oxygenase suppresses markers of heart failure and ameliorates cardiomyopathy in L-NAME-induced hypertension. Eur J Pharmacol. 2014;734:23–34.",{"doi":3876},"10.1016\u002Fj.ejphar.2014.03.026",{"id":26,"text":3878,"url":26,"identifiers":3879},"Ndisang JF, Jadhav A. Upregulating the heme oxygenase system suppresses left ventricular hypertrophy in adult spontaneously hypertensive rats for 3 months. J Card Fail. 2009;15(7):616–28.",{"doi":3880},"10.1016\u002Fj.cardfail.2009.02.003",{"id":26,"text":3882,"url":26,"identifiers":3883},"Ndisang JF, Jadhav A. Heme arginate therapy enhanced adiponectin and atrial natriuretic peptide, but abated endothelin-1 with attenuation of kidney histopathological lesions in mineralocorticoid-induced hypertension. J Pharmacol Exp Ther. 2010;334(1):87–98.",{"doi":3884},"10.1124\u002Fjpet.109.164871",{"id":26,"text":3886,"url":26,"identifiers":3887},"Ndisang JF, Jadhav A. Hemin therapy suppresses inflammation and retroperitoneal adipocyte hypertrophy to improve glucose metabolism in obese rats co-morbid with insulin-resistant type-2 diabetes. Diabetes Obes Metab. 2013;15(11):1029–39.",{"doi":3888},"10.1111\u002Fdom.12130",{"id":26,"text":3890,"url":26,"identifiers":3891},"Ndisang JF, Jadhav A. Hemin therapy improves kidney function in male streptozotocin-induced diabetic rats: role of the heme oxygenase\u002Fatrial natriuretic peptide\u002Fadiponectin axis. Endocrinology. 2014;155(1):215–29.",{"doi":3892},"10.1210\u002Fen.2013-1050",{"id":26,"text":3894,"url":26,"identifiers":3895},"Ndisang JF, Jadhav A, Mishra M. The heme oxygenase system suppresses perirenal visceral adiposity, abates renal inflammation and ameliorates diabetic nephropathy in Zucker diabetic fatty rats. PLoS One. 2014;9(1), e87936.",{"doi":3896},"10.1371\u002Fjournal.pone.0087936",{"id":26,"text":3898,"url":26,"identifiers":3899},"Ndisang JF, Lane N, Jadhav A. The heme oxygenase system abates hyperglycemia in Zucker diabetic fatty rats by potentiating insulin-sensitizing pathways. Endocrinology. 2009;150(5):2098–108.",{"doi":3900},"10.1210\u002Fen.2008-0239",{"id":26,"text":3902,"url":26,"identifiers":3903},"Ndisang JF, Lane N, Jadhav A. Upregulation of the heme oxygenase system ameliorates postprandial and fasting hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2009;296(5):E1029–41.",{"doi":3904},"10.1152\u002Fajpendo.90241.2008",{"id":26,"text":3906,"url":26,"identifiers":3907},"Ndisang JF, Lane N, Syed N, Jadhav A. Up-regulating the heme oxygenase system with hemin improves insulin sensitivity and glucose metabolism in adult spontaneously hypertensive rats. Endocrinology. 2010;151(2):549–60.",{"doi":3908},"10.1210\u002Fen.2009-0471",{"id":26,"text":3910,"url":26,"identifiers":3911},"Jadhav A, Ndisang JF. Treatment with heme arginate alleviates adipose tissue inflammation and improves insulin sensitivity and glucose metabolism in a rat model of Human primary aldosteronism. Free Radic Biol Med. 2012;53(12):2277–86.",{"doi":3912},"10.1016\u002Fj.freeradbiomed.2012.10.529",{"id":26,"text":3914,"url":26,"identifiers":3915},"Jadhav A, Tiwari S, Lee P, Ndisang JF. The heme oxygenase system selectively enhances the anti-inflammatory macrophage-M2 phenotype, reduces pericardial adiposity, and ameliorated cardiac injury in diabetic cardiomyopathy in Zucker diabetic fatty rats. J Pharmacol Exp Ther. 2013;345(2):239–49.",{"doi":3916},"10.1124\u002Fjpet.112.200808",{"id":26,"text":3918,"url":26,"identifiers":3919},"Jadhav A, Ndisang JF. Heme arginate suppresses cardiac lesions and hypertrophy in deoxycorticosterone acetate-salt hypertension. Exp Biol Med (Maywood). 2009;234(7):764–78.",{"doi":3920},"10.3181\u002F0810-RM-302",{"id":26,"text":3922,"url":26,"identifiers":3923},"Tiwari S, Ndisang JF. Heme oxygenase system and hypertension: a comprehensive insight. Curr Pharm Des. 2014;20(9):1354–69.",{"doi":3924},"10.2174\u002F13816128113199990558",{"id":26,"text":3926,"url":26,"identifiers":3927},"Tiwari S, Ndisang JF. The heme oxygenase system and type-1 diabetes. Curr Pharm Design. 2014;20(9):1328–37.",{"doi":3928},"10.2174\u002F13816128113199990552",{"id":26,"text":3930,"url":26,"identifiers":3931},"Fantuzzi G, Mazzone T. Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol. 2007;27(5):996–1003.",{"doi":3932},"10.1161\u002FATVBAHA.106.131755",{"id":26,"text":3934,"url":26,"identifiers":3935},"Keating ST, Plutzky J, El-Osta A. Epigenetic changes in diabetes and cardiovascular risk. Circ Res. 2016;118(11):1706–22.",{"doi":3936},"10.1161\u002FCIRCRESAHA.116.306819",{"id":26,"text":3938,"url":26,"identifiers":3939},"Kwak BR, Back M, Bochaton-Piallat ML, et al. Biomechanical factors in atherosclerosis: mechanisms and clinical implications. Eur Heart J 2014, 35(43):3013–3020, 3020a-3020d.",{},{"id":26,"text":3941,"url":26,"identifiers":3942},"Kusters DM, Vissers MN, Wiegman A, Kastelein JJ, Hutten BA. Treatment of dyslipidaemia in childhood. Expert Opin Pharmacother. 2010;11(5):739–53.",{"doi":3943},"10.1517\u002F14656561003592169",{"id":26,"text":3945,"url":26,"identifiers":3946},"Liu J, Ren Y, Kang L, Zhang L. Overexpression of CCN3 inhibits inflammation and progression of atherosclerosis in apolipoprotein E-deficient mice. PLoS One. 2014;9(4), e94912.",{},{"id":26,"text":3948,"url":26,"identifiers":3949},"Abraham NG, Junge JM, Drummond GS. Translational significance of heme oxygenase in obesity and metabolic syndrome. Trends Pharmacol Sci. 2016;37(1):17–36.",{"doi":3950},"10.1016\u002Fj.tips.2015.09.003",{"id":26,"text":3952,"url":26,"identifiers":3953},"Pechlaner R, Willeit P, Summerer M, et al. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with progressive atherosclerosis and incident cardiovascular disease. Arterioscler Thromb Vasc Biol. 2015;35(1):229–36.",{"doi":3954},"10.1161\u002FATVBAHA.114.304729",{"id":3956,"createTime":3957,"updateTime":3958,"relativeEntities":3959,"slug":3960,"properties":3961,"entityType":760,"verifyStatus":25,"verifyTime":3958,"verifyNote":762,"syncStatus":28,"languages":3976,"translateLanguages":26,"viewCount":36,"primaryUrl":3977,"fullTextUrl":26,"authors":3978,"publicationType":830,"publisherRelationship":4031,"citationCount":4060,"citationInfo":4061,"publishDate":4063,"publishYear":4064,"citationAnalyzeStatus":1203,"lastCitationAnalyze":4065,"indexDatabases":26,"openAccess":26,"references":4066,"isForceReanalyzing":1106},"0c68a45f-813b-4211-8a7f-5c6475da0a15","2024-04-11T16:20:13.463+00:00","2024-12-17T18:41:15.417+00:00",[],"How-Do-We-Improve-Patient-Compliance-and-Adherence-to-Long-Term-Statin-Therapy-",{"mag":3962,"keywords":3964,"pmc":3965,"openalex":3967,"abstract":3969,"title":3970,"pm":3972,"doi":3974},{"VOID":3963},"2053873360",{},{"VOID":3966},"3534845",{"VOID":3968},"W2053873360",{},{"EN":3971},"How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy?",{"VOID":3973},"23225173",{"VOID":3975},"10.1007\u002Fs11883-012-0291-7",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11883-012-0291-7",[3979,3998,4012],{"id":3980,"sortIndex":114,"researcher":26,"roles":3981,"affiliations":3982,"properties":3993},"3153e3f5-a71c-405c-a1a3-2cecf290b405",[],[3983],{"id":26,"sortIndex":36,"affiliation":3984,"properties":26},{"id":3985,"createTime":3986,"updateTime":3987,"relativeEntities":3988,"slug":3989,"properties":3990,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"180f777d-ea40-4f96-a3c8-38ca6c1ca59f","2023-12-30T21:31:40.180+00:00","2025-02-10T16:36:24.085+00:00",[],"The-Rockefeller-University-New-York-USA",{"title":3991},{"VI":3992},"The Rockefeller University, New York, USA",{"openalex":3994,"title":3996},{"VOID":3995},"A5019013528",{"EN":3997},"Jan L. Breslow",{"id":3999,"sortIndex":36,"researcher":26,"roles":4000,"affiliations":4001,"properties":4007},"6805b754-c83e-47c1-8d85-c6cfe46c37fc",[],[4002],{"id":26,"sortIndex":36,"affiliation":4003,"properties":26},{"id":3985,"createTime":3986,"updateTime":3987,"relativeEntities":4004,"slug":3989,"properties":4005,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4006},{"VI":3992},{"openalex":4008,"title":4010},{"VOID":4009},"A5003266391",{"EN":4011},"Patricia Maningat",{"id":4013,"sortIndex":115,"researcher":26,"roles":4014,"affiliations":4015,"properties":4026},"6553df1a-9dc7-4b34-9bc5-d2ebfa7af4a4",[],[4016],{"id":26,"sortIndex":36,"affiliation":4017,"properties":26},{"id":4018,"createTime":4019,"updateTime":4020,"relativeEntities":4021,"slug":4022,"properties":4023,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"04f98ddc-281b-47be-8ba3-b0411408c90d","2024-04-11T16:20:13.479+00:00","2025-06-11T18:11:27.733+00:00",[],"The-Rogosin-Institute-New-York-USA",{"title":4024},{"EN":4025},"The Rogosin Institute, New York, USA",{"openalex":4027,"title":4029},{"VOID":4028},"A5083775927",{"EN":4030},"Bruce R. Gordon",{"url":26,"publisher":4032,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":4033,"slug":663,"properties":4034,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":4038,"manageAffiliations":4039,"indexDatabases":4040,"url":730,"thumbnailPath":26,"statistic":4055,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":4035,"eissn":4036,"title":4037},{"VOID":666},{"VOID":668},{"EN":670},[],[],[4041,4048],{"id":712,"indexDatabase":4042,"url":725,"indexYears":726,"academicFieldIds":4047,"indexDatabaseRanking":729},{"id":714,"createTime":715,"updateTime":716,"relativeEntities":4043,"label":4044,"description":4045,"key":722,"publicationTags":4046,"standard":26},[],{"EN":719,"VI":719},{"EN":719,"VI":721},[724],[728],{"id":693,"indexDatabase":4049,"url":708,"indexYears":26,"academicFieldIds":4054,"indexDatabaseRanking":26},{"id":695,"createTime":696,"updateTime":697,"relativeEntities":4050,"label":4051,"description":4052,"key":704,"publicationTags":4053,"standard":26},[],{"EN":700,"VI":700},{"VI":702,"EN":703},[706,707],[710],{"impactFactor":36,"impactFactorByYear":4056,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":51,"totalPublicationByYear":4057,"totalCitation":36,"totalCitationByYear":4058,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":4059,"hindexLast5Year":36,"hindex":36},{},{"2002":115,"2003":115,"2004":114,"2006":114,"2007":115,"2011":115,"2012":115,"2013":115,"2017":115,"2019":114,"2020":115,"2023":115},{},{},159,{"total":4060,"publishYear":26,"statisticByYear":4062},{"2013":162,"2014":53,"2015":158,"2016":298,"2017":234,"2018":239,"2019":124,"2020":51,"2021":239,"2022":158,"2023":124,"2024":59},"2013-01-01",2013,"2024-04-11T18:59:25.096+00:00",[4067,4071,4075,4079,4083,4087,4091,4095,4099,4103,4106,4109,4112,4115,4119,4122,4126,4129,4133,4136,4139,4143,4147,4151,4155,4159,4163,4167,4171,4175,4179,4183,4186,4190,4194,4198,4202,4205,4209,4213,4217,4221,4225,4229,4233,4237,4241,4245,4249,4253,4257,4261,4265,4268,4271,4275,4279,4283,4287,4290,4294,4298,4302,4306,4310,4314,4318,4322,4325,4329,4333,4337,4341,4345,4349,4353,4357],{"id":26,"text":4068,"url":26,"identifiers":4069},"Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–220.",{"doi":4070},"10.1161\u002FCIR.0b013e31823ac046",{"id":26,"text":4072,"url":26,"identifiers":4073},"Cutler DM, Everett W. Thinking outside the pillbox—medication adherence as a priority for health care reform. N Engl J Med. 2010;362(17):1553–5.",{"doi":4074},"10.1056\u002FNEJMp1002305",{"id":26,"text":4076,"url":26,"identifiers":4077},"Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–7.",{"doi":4078},"10.1001\u002Fjama.288.4.462",{"id":26,"text":4080,"url":26,"identifiers":4081},"•• Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15. This large internet-based survey provides insights into the behavior and attitudes of current and former statin users. More effective dialogue between patients and healthcare providers may increase persistence of statin use, specially when the patient is concerned about adverse events.",{"doi":4082},"10.1016\u002Fj.jacl.2012.03.003",{"id":26,"text":4084,"url":26,"identifiers":4085},"Charland S, Agatep B, Epstein R, et al. Patient knowledge of pharmacogenetic information improves adherence to statin therapy: results of the additional KIF6 risk offers better adherence to statins (AKROBATS) trial. JACC. 2012;59(13):E1848.",{"doi":4086},"10.1016\u002FS0735-1097(12)61849-X",{"id":26,"text":4088,"url":26,"identifiers":4089},"• Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev. 2010;3:CD004371. This review showed that the most promising intervention to increase adherence to lipid lowering drugs includes strategies to remind patients about their medications.",{"doi":4090},"10.1002\u002F14651858.CD004371.pub3",{"id":26,"text":4092,"url":26,"identifiers":4093},"Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC\u002FBHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005–16.",{"doi":4094},"10.1016\u002FS0140-6736(03)13636-7",{"id":26,"text":4096,"url":26,"identifiers":4097},"Downs JR, Clearfield M, Tyroler HA, et al. Air Force\u002FTexas Coronary Atherosclerosis Prevention Study (AFCAPS\u002FTEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol. 2001;87(9):1074–9.",{"doi":4098},"10.1016\u002FS0002-9149(01)01464-3",{"id":26,"text":4100,"url":26,"identifiers":4101},"Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720–32.",{"doi":4102},"10.1016\u002Fj.jacc.2004.07.001",{"id":26,"text":4104,"url":26,"identifiers":4105},"MRC\u002FBHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7–22.",{"doi":2171},{"id":26,"text":4107,"url":26,"identifiers":4108},"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383–1389.",{"doi":2164},{"id":26,"text":4110,"url":26,"identifiers":4111},"Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med 2008.",{"doi":2510},{"id":26,"text":4113,"url":26,"identifiers":4114},"Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–7.",{"doi":2183},{"id":26,"text":4116,"url":26,"identifiers":4117},"• Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90. This meta analysis showed that even in individuals considered to be at low risk for CV disease, LDL cholesterol reduction results in reduction in major vascular events. These individuals would not be treated under present guidelines.",{"doi":4118},"10.1016\u002FS0140-6736(12)60367-5",{"id":26,"text":4120,"url":26,"identifiers":4121},"Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.",{"doi":2144},{"id":26,"text":4123,"url":26,"identifiers":4124},"Superko HR, Roberts R, Agatston A, et al. Genetic testing for early detection of individuals at risk of coronary heart disease and monitoring response to therapy: challenges and promises. Curr Atheroscler Rep. 2011;13(5):396–404.",{"doi":4125},"10.1007\u002Fs11883-011-0198-8",{"id":26,"text":4127,"url":26,"identifiers":4128},"Gotto Jr AM, Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol. 2012;110(1 Suppl):3A–14.",{},{"id":26,"text":4130,"url":26,"identifiers":4131},"Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother. 2008;42(9):1208–15.",{"doi":4132},"10.1345\u002Faph.1L181",{"id":26,"text":4134,"url":26,"identifiers":4135},"Stagnitti M. Trends in Statins Utilization and Expenditures for the U.S. Civilian Noninstitutionalized Population, 2000 and 2005. Statistical Brief #205. In. Edited by Quality AfHRa, vol. 2011. Rockville, MD; 2008.",{},{"id":26,"text":4137,"url":26,"identifiers":4138},"(CDC) CfDCaP: Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol—United States, 1999–2002 and 2005–2008. MMWR Morb Mortal Wkly Rep 2011;60(4):109–114.",{},{"id":26,"text":4140,"url":26,"identifiers":4141},"Spatz ES, Canavan ME, Desai MM. From here to JUPITER: identifying new patients for statin therapy using data from the 1999–2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcome. 2009;2(1):41–8.",{"doi":4142},"10.1161\u002FCIRCOUTCOMES.108.832592",{"id":26,"text":4144,"url":26,"identifiers":4145},"Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011;5(5):338–67.",{"doi":4146},"10.1016\u002Fj.jacl.2011.07.005",{"id":26,"text":4148,"url":26,"identifiers":4149},"Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122(1):198–208.",{"doi":4150},"10.1542\u002Fpeds.2008-1349",{"id":26,"text":4152,"url":26,"identifiers":4153},"AIM-HIGH, Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL\u002Fhigh triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J 2011;161(3):471–477 e472.",{"doi":4154},"10.1016\u002Fj.ahj.2010.12.007",{"id":26,"text":4156,"url":26,"identifiers":4157},"Maningat P, Breslow JL. Needed: pragmatic clinical trials for statin-intolerant patients. N Engl J Med. 2011;365(24):2250–1.",{"doi":4158},"10.1056\u002FNEJMp1112023",{"id":26,"text":4160,"url":26,"identifiers":4161},"Buse JB, Bigger JT, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99(12A):21i–33.",{"doi":4162},"10.1016\u002Fj.amjcard.2007.03.003",{"id":26,"text":4164,"url":26,"identifiers":4165},"Scott R, Best J, Forder P, et al. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol. 2005;4:13.",{"doi":4166},"10.1186\u002F1475-2840-4-13",{"id":26,"text":4168,"url":26,"identifiers":4169},"Ebrahim S, Casas JP. Statins for all by the age of 50 years? Lancet. 2012;380(9841):545–7.",{"doi":4170},"10.1016\u002FS0140-6736(12)60694-1",{"id":26,"text":4172,"url":26,"identifiers":4173},"Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999–2006. JAMA. 2009;302(19):2104–10.",{"doi":4174},"10.1001\u002Fjama.2009.1672",{"id":26,"text":4176,"url":26,"identifiers":4177},"Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410–21.",{"doi":4178},"10.1345\u002Faph.1P150",{"id":26,"text":4180,"url":26,"identifiers":4181},"Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455–61.",{"doi":4182},"10.1001\u002Fjama.288.4.455",{"id":26,"text":4184,"url":26,"identifiers":4185},"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143–3421.",{"doi":2270},{"id":26,"text":4187,"url":26,"identifiers":4188},"Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167(8):847–52.",{"doi":4189},"10.1001\u002Farchinte.167.8.847",{"id":26,"text":4191,"url":26,"identifiers":4192},"Cutrona SL, Choudhry NK, Fischer MA, et al. Targeting cardiovascular medication adherence interventions. J Am Pharm Assoc (2003) 2012;52(3):381–397.",{"doi":4193},"10.1331\u002FJAPhA.2012.10211",{"id":26,"text":4195,"url":26,"identifiers":4196},"Calvert SB, Kramer JM, Anstrom KJ, et al. Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial. Am Heart J 2012;163(4):657–665 e651.",{"doi":4197},"10.1016\u002Fj.ahj.2012.01.019",{"id":26,"text":4199,"url":26,"identifiers":4200},"Gomez Sandoval YH, Braganza MV, Daskalopoulou SS. Statin discontinuation in high-risk patients: a systematic review of the evidence. Curr Pharm Des. 2011;17(33):3669–89.",{"doi":4201},"10.2174\u002F138161211798220891",{"id":26,"text":4203,"url":26,"identifiers":4204},"Aubert RE, Yao J, Xia F, Garavaglia SB. Is there a relationship between early statin compliance and a reduction in healthcare utilization? Am J Manag Care. 2010;16(6):459–66.",{},{"id":26,"text":4206,"url":26,"identifiers":4207},"• Shroufi A, Powles JW. Adherence and chemoprevention in major cardiovascular disease: a simulation study of the benefits of additional use of statins. J Epidemiol Community Health. 2010;64(2):109–13. This is a simulation study showing that improving adherence to statin therapy rather than lowering the CV risk threshold for initiating statin therapy would prevent twice as many additional deaths.",{"doi":4208},"10.1136\u002Fjech.2009.091033",{"id":26,"text":4210,"url":26,"identifiers":4211},"Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203–12.",{"doi":4212},"10.1161\u002FCIRCULATIONAHA.105.505636",{"id":26,"text":4214,"url":26,"identifiers":4215},"Lamberts EJ, Nijpels G, Welschen LM, et al. Discontinuation of statins among patients with type 2 diabetes. Diabetes Metab Res Rev. 2012;28(3):241–5.",{"doi":4216},"10.1002\u002Fdmrr.1293",{"id":26,"text":4218,"url":26,"identifiers":4219},"Bell KJ, Kirby A, Hayen A, Irwig L, Glasziou P. Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data. BMJ. 2011;342:d12.",{"doi":4220},"10.1136\u002Fbmj.d12",{"id":26,"text":4222,"url":26,"identifiers":4223},"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.",{"doi":4224},"10.1056\u002FNEJMra050100",{"id":26,"text":4226,"url":26,"identifiers":4227},"Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–35.",{"doi":4228},"10.1161\u002FCIRCULATIONAHA.108.768986",{"id":26,"text":4230,"url":26,"identifiers":4231},"Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–14.",{"doi":4232},"10.4065\u002Fmcp.2010.0575",{"id":26,"text":4234,"url":26,"identifiers":4235},"Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care. 2010;48(3):196–202.",{"doi":4236},"10.1097\u002FMLR.0b013e3181c132ad",{"id":26,"text":4238,"url":26,"identifiers":4239},"Adams JR, Elwyn G, Legare F, Frosch DL. Communicating with physicians about medical decisions: a reluctance to disagree. Arch Intern Med. 2012;172(15):1184–6.",{"doi":4240},"10.1001\u002Farchinternmed.2012.2360",{"id":26,"text":4242,"url":26,"identifiers":4243},"Ma J, Sehgal NL, Ayanian JZ, Stafford RS. National trends in statin use by coronary heart disease risk category. PLoS Med. 2005;2(5):e123.",{"doi":4244},"10.1371\u002Fjournal.pmed.0020123",{"id":26,"text":4246,"url":26,"identifiers":4247},"Lattry P, Molimard M, Dedieu B: Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study. BMC 2011.",{"doi":4248},"10.1186\u002F1471-2261-11-46",{"id":26,"text":4250,"url":26,"identifiers":4251},"Fung V, Sinclair F, Wang H, et al. Patients' perspectives on nonadherence to statin therapy: a focus-group study. Perm J. 2010;14(1):4–10.",{"doi":4252},"10.7812\u002FTPP\u002F09-090",{"id":26,"text":4254,"url":26,"identifiers":4255},"Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29(7):800–11.",{"doi":4256},"10.1592\u002Fphco.29.7.800",{"id":26,"text":4258,"url":26,"identifiers":4259},"Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373–418.",{"doi":4260},"10.2165\u002F0129784-200808060-00004",{"id":26,"text":4262,"url":26,"identifiers":4263},"Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42.",{"doi":4264},"10.1016\u002FS0140-6736(09)61965-6",{"id":26,"text":4266,"url":26,"identifiers":4267},"FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. In: FDA Drug Safety Communication. 2012.",{},{"id":26,"text":4269,"url":26,"identifiers":4270},"FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. In: FDA Drug Safety Communication. 2011.",{},{"id":26,"text":4272,"url":26,"identifiers":4273},"• Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565–71. Further analysis of the JUPITER study shows that new-onset diabetes develops in the group already at high risk of developing diabetes.",{"doi":4274},"10.1016\u002FS0140-6736(12)61190-8",{"id":26,"text":4276,"url":26,"identifiers":4277},"Standards of medical care in diabetes—2012. Diabetes Care 2012;35 Suppl 1:S11–63.",{"doi":4278},"10.2337\u002Fdc12-s011",{"id":26,"text":4280,"url":26,"identifiers":4281},"Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171(9):814–22.",{"doi":4282},"10.1001\u002Farchinternmed.2010.495",{"id":26,"text":4284,"url":26,"identifiers":4285},"Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation. 2009;119(3):390–7.",{"doi":4286},"10.1161\u002FCIRCULATIONAHA.108.783944",{"id":26,"text":4288,"url":26,"identifiers":4289},"Gossey JT, Whitney SN, Crouch MA, et al. Promoting knowledge of statins in patients with low health literacy using an audio booklet. Patient Prefer Adherence. 2011;5:397–403.",{},{"id":26,"text":4291,"url":26,"identifiers":4292},"Eussen SR, de Jong N, Rompelberg CJ, et al. Effects of the use of phytosterol\u002F-stanol-enriched margarines on adherence to statin therapy. Pharmacoepidemiol Drug Saf. 2010;19(12):1225–32.",{"doi":4293},"10.1002\u002Fpds.2042",{"id":26,"text":4295,"url":26,"identifiers":4296},"Eussen SR, Bouvy ML, Rompelberg CJ, et al. Influence of the use of functional foods enriched with phytosterols\u002F-stanols on adherence to statin therapy. Pharmacoepidemiol Drug Saf. 2011;20(8):830–7.",{"doi":4297},"10.1002\u002Fpds.2168",{"id":26,"text":4299,"url":26,"identifiers":4300},"Iakoubova OA, Tong CH, Rowland CM, et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 2008;51(4):435–43.",{"doi":4301},"10.1016\u002Fj.jacc.2007.05.057",{"id":26,"text":4303,"url":26,"identifiers":4304},"Shiffman D, Chasman DI, Zee RY, et al. A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study. J Am Coll Cardiol. 2008;51(4):444–8.",{"doi":4305},"10.1016\u002Fj.jacc.2007.09.044",{"id":26,"text":4307,"url":26,"identifiers":4308},"Iakoubova OA, Sabatine MS, Rowland CM, et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2008;51(4):449–55.",{"doi":4309},"10.1016\u002Fj.jacc.2007.10.017",{"id":26,"text":4311,"url":26,"identifiers":4312},"• Charland S, Agatep B, Schrader B, et al. Abstract 290: Statin Adherence in Males and Females, and the Impact of Knowledge of a Genetic Test: Results from the AKROBATS Trial. Circulation: Cardiovascular Quality and Outcomes 2012;5(Supplement 1). The utility of pharmacogenetic information to increase adherence was tested, and knowledge of kif6 carrier status increased adherence to statin therapy.",{"doi":4313},"10.1161\u002Fcircoutcomes.5.suppl_1.A290",{"id":26,"text":4315,"url":26,"identifiers":4316},"•• Kalia N, Li D, Budoff M. Statin Therapy Adherence After Visualizing Coronary Calcium by Cardiac Computed Tomography. J Am Coll Cardiol. 2012;59(13s1):E1188. Increased adherence to statin therapy was achieved by having patients view their arteries lined with calcium on cardiac CT scan.",{"doi":4317},"10.1016\u002FS0735-1097(12)61189-9",{"id":26,"text":4319,"url":26,"identifiers":4320},"• Nieuwkerk PT, Nierman MC, Vissers MN, et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. Am J Cardiol. 2012;110(5):666–72. Counseling patients on their CV risk factors improves adherence to statin therapy.",{"doi":4321},"10.1016\u002Fj.amjcard.2012.04.045",{"id":26,"text":4323,"url":26,"identifiers":4324},"Liberman JN, Hutchins DS, Shrank WH, Slezak J, Brennan TA. Adherence to medication under mandatory and voluntary mail benefit designs. Am J Manag Care. 2011;17(7):e260–9.",{},{"id":26,"text":4326,"url":26,"identifiers":4327},"Balu S, Simko RJ, Quimbo RM, Cziraky MJ. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin. 2009;25(11):2765–75.",{"doi":4328},"10.1185\u002F03007990903297741",{"id":26,"text":4330,"url":26,"identifiers":4331},"Kamat SA, Bullano MF, Chang CL, Gandhi SK, Cziraky MJ. Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population. Curr Med Res Opin. 2011;27(5):961–8.",{"doi":4332},"10.1185\u002F03007995.2011.562494",{"id":26,"text":4334,"url":26,"identifiers":4335},"Gaw A, Tolmie E, Lindsay GM. The statin breakthrough—remembering to involve the patient. Cardiovasc Drugs Ther. 2004;18(5):343–4.",{"doi":4336},"10.1007\u002Fs10557-005-5057-9",{"id":26,"text":4338,"url":26,"identifiers":4339},"Yilmaz MB, Pinar M, Naharci I, et al. Being well-informed about statin is associated with continuous adherence and reaching targets. Cardiovasc Drugs Ther. 2005;19(6):437–40.",{"doi":4340},"10.1007\u002Fs10557-005-5202-5",{"id":26,"text":4342,"url":26,"identifiers":4343},"Casebeer L, Huber C, Bennett N, et al. Improving the physician–patient cardiovascular risk dialogue to improve statin adherence. BMC Fam Pract. 2009;10:48.",{"doi":4344},"10.1186\u002F1471-2296-10-48",{"id":26,"text":4346,"url":26,"identifiers":4347},"Lin GA, Trujillo L, Frosch DL. Consequences of not respecting patient preferences for cancer screening: opportunity lost. Arch Intern Med. 2012;172(5):393–4.",{"doi":4348},"10.1001\u002Farchinternmed.2012.58",{"id":26,"text":4350,"url":26,"identifiers":4351},"O'Malley PG. On motivating patients: a picture, even if worth a thousand words, is not enough. Arch Intern Med. 2012;172(4):309–10.",{"doi":4352},"10.1001\u002Farchinternmed.2011.1948",{"id":26,"text":4354,"url":26,"identifiers":4355},"Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf. 2007;30(8):669–75.",{"doi":4356},"10.2165\u002F00002018-200730080-00003",{"id":26,"text":4358,"url":26,"identifiers":4359},"Golomb BA, Yang E, Denenberg J, Criqui MH. Statin-associated adverse effects. Circulation. 2003;107:e7028–9.",{},{"id":4361,"createTime":4362,"updateTime":4363,"relativeEntities":4364,"slug":4365,"properties":4366,"entityType":760,"verifyStatus":25,"verifyTime":4363,"verifyNote":762,"syncStatus":28,"languages":4379,"translateLanguages":26,"viewCount":36,"primaryUrl":4380,"fullTextUrl":26,"authors":4381,"publicationType":830,"publisherRelationship":4423,"citationCount":4459,"citationInfo":4460,"publishDate":4462,"publishYear":4463,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":4464,"isForceReanalyzing":1106},"d879727a-1ac9-47d6-96e9-53b908a730cd","2024-04-20T19:13:17.259+00:00","2025-01-07T04:50:41.904+00:00",[],"Arterial-stiffness-as-a-risk-factor-for-coronary-atherosclerosis",{"mag":4367,"keywords":4369,"openalex":4370,"abstract":4372,"title":4373,"pm":4375,"doi":4377},{"VOID":4368},"1978807721",{},{"VOID":4371},"W1978807721",{},{"EN":4374},"Arterial stiffness as a risk factor for coronary atherosclerosis",{"VOID":4376},"17877923",{"VOID":4378},"10.1007\u002Fs11883-007-0010-y",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11883-007-0010-y",[4382,4403],{"id":4383,"sortIndex":36,"researcher":26,"roles":4384,"affiliations":4385,"properties":4396},"352a4c9c-5251-40dc-a236-5dd5729b3774",[],[4386],{"id":4387,"sortIndex":36,"affiliation":4388,"properties":26},"f0141b9e-cac4-47e7-baed-84c63e44f36d",{"id":4389,"createTime":4390,"updateTime":4390,"relativeEntities":4391,"slug":4392,"properties":4393,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"74e33e7a-7d64-4748-b58e-fcca186f761a","2024-04-20T19:13:17.282+00:00",[],"Cardiovascular-Division-VCRC-Room-270-University-of-Minnesota-Minneapolis-USA",{"title":4394},{"EN":4395},"Cardiovascular Division, VCRC — Room 270, University of Minnesota, Minneapolis, USA",{"openalex":4397,"orcid":4399,"title":4401},{"VOID":4398},"A5075267063",{"VOID":4400},"https:\u002F\u002Forcid.org\u002F0000-0002-0993-6839",{"EN":4402},"Daniel Duprez",{"id":4404,"sortIndex":115,"researcher":26,"roles":4405,"affiliations":4406,"properties":4418},"f4b5adfb-6890-4f6d-a2b6-5f4e18817f0d",[],[4407],{"id":4408,"sortIndex":36,"affiliation":4409,"properties":26},"3bd936e1-0b1d-46bb-8cff-67e2cd68b7da",{"id":4410,"createTime":4411,"updateTime":4412,"relativeEntities":4413,"slug":4414,"properties":4415,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"f54973e1-8196-431e-a1eb-a526ad0adc55","2024-04-20T19:13:17.305+00:00","2025-01-06T10:23:35.667+00:00",[],"Medicine-Cardiology-Division",{"title":4416},{"EN":4417},"Medicine - Cardiology Division",{"openalex":4419,"title":4421},{"VOID":4420},"A5018464718",{"EN":4422},"Jay N. Cohn",{"url":26,"publisher":4424,"properties":4452},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":4425,"slug":663,"properties":4426,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":4430,"manageAffiliations":4431,"indexDatabases":4432,"url":730,"thumbnailPath":26,"statistic":4447,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":4427,"eissn":4428,"title":4429},{"VOID":666},{"VOID":668},{"EN":670},[],[],[4433,4440],{"id":712,"indexDatabase":4434,"url":725,"indexYears":726,"academicFieldIds":4439,"indexDatabaseRanking":729},{"id":714,"createTime":715,"updateTime":716,"relativeEntities":4435,"label":4436,"description":4437,"key":722,"publicationTags":4438,"standard":26},[],{"EN":719,"VI":719},{"EN":719,"VI":721},[724],[728],{"id":693,"indexDatabase":4441,"url":708,"indexYears":26,"academicFieldIds":4446,"indexDatabaseRanking":26},{"id":695,"createTime":696,"updateTime":697,"relativeEntities":4442,"label":4443,"description":4444,"key":704,"publicationTags":4445,"standard":26},[],{"EN":700,"VI":700},{"VI":702,"EN":703},[706,707],[710],{"impactFactor":36,"impactFactorByYear":4448,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":51,"totalPublicationByYear":4449,"totalCitation":36,"totalCitationByYear":4450,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":4451,"hindexLast5Year":36,"hindex":36},{},{"2002":115,"2003":115,"2004":114,"2006":114,"2007":115,"2011":115,"2012":115,"2013":115,"2017":115,"2019":114,"2020":115,"2023":115},{},{},{"volume":4453,"pages":4455,"issue":4457},{"VOID":4454},"9",{"VOID":4456},"139-144",{"VOID":4458},"2",135,{"total":4459,"publishYear":26,"statisticByYear":4461},{"2012":50,"2013":162,"2014":336,"2015":52,"2016":50,"2017":158,"2018":158,"2019":158,"2020":162,"2021":59,"2022":103,"2023":50},"2007-04-01",2007,[4465,4469,4473,4476,4480,4484,4488,4492,4496,4500,4504,4508,4512,4516,4520,4524,4528,4532,4536,4540,4544,4548,4552,4556,4560,4564,4568,4572,4576,4580,4584,4588,4592,4596,4600,4604,4608,4612,4616,4620,4624,4628,4632,4636,4640,4644,4648,4652,4656,4660,4664],{"id":26,"text":4466,"url":26,"identifiers":4467},"Cohn JN: Arterial stiffness, vascular disease and risk of cardiovascular events. Circulation 2006, 113:601–603.",{"doi":4468},"10.1161\u002FCIRCULATIONAHA.105.600866",{"id":26,"text":4470,"url":26,"identifiers":4471},"Duprez D, Cohn JN: Monitoring vascular health beyond blood pressure. Curr Hypertens Rep 2006, 287:287–291.",{"doi":4472},"10.1007\u002Fs11906-006-0066-z",{"id":26,"text":4474,"url":26,"identifiers":4475},"Safar ME, Levy BI, Struijker-Boudier: Current perpectives on arterial stiffness and pulse pressure in hypertension and cardiovascular disease. Hypertension 2003, 107:2864–2869.",{},{"id":26,"text":4477,"url":26,"identifiers":4478},"Davies JI, Struthers AD: Pulse wave analysis and pulse wave velocity: a critical review of their strengths and weakness. J Hypertens 2003, 21:463–472.",{"doi":4479},"10.1097\u002F00004872-200303000-00004",{"id":26,"text":4481,"url":26,"identifiers":4482},"McVeigh GE: Pulse waveform analysis and arterial wall properties. Hypertension 2003, 41:1010–1011.",{"doi":4483},"10.1161\u002F01.HYP.0000069006.98113.22",{"id":26,"text":4485,"url":26,"identifiers":4486},"O’Rourke MF, Staessen JA, Vlachopoulos C, et al.: Clinical applications of arterial stiffness, definitions and reference values. Am J Hypertens 2002, 15:426–444.",{"doi":4487},"10.1016\u002FS0895-7061(01)02319-6",{"id":26,"text":4489,"url":26,"identifiers":4490},"Duprez DA, Kaiser DR, Whitwam W, et al.: Determinants of radial artery pulse wave analysis in asymptomatic individuals. Am J Hypertens 2004, 17:647–653.",{"doi":4491},"10.1016\u002Fj.amjhyper.2004.03.671",{"id":26,"text":4493,"url":26,"identifiers":4494},"Laurent S, Cockroft J, Van Bortel L, et al.: Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588–2605.",{"doi":4495},"10.1093\u002Feurheartj\u002Fehl254",{"id":26,"text":4497,"url":26,"identifiers":4498},"Widlansky ME, Gokce N, Keaney JF Jr, Vita JA: The clinical implications of endothelial dysfunction J Am Coll Cardiol 2003, 42:1149–1160.",{"doi":4499},"10.1016\u002FS0735-1097(03)00994-X",{"id":26,"text":4501,"url":26,"identifiers":4502},"Okumura K, Yasue H, Matsuyama K, et al.: Effect of acetylcholine on the highly stenotic coronary artery: difference between the constrictor response of the infarct-related coronary artery and that of the noninfarct-related artery. J Am Coll Cardiol 1992, 19:752–758.",{"doi":4503},"10.1016\u002F0735-1097(92)90513-M",{"id":26,"text":4505,"url":26,"identifiers":4506},"Ludmer PL, Selwyn AP, Shook TL, et al.: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986, 315:1046–1051.",{"doi":4507},"10.1056\u002FNEJM198610233151702",{"id":26,"text":4509,"url":26,"identifiers":4510},"Cox DA, Vita JA, Treasure CB, et al.: Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation 1989, 80:458–465.",{"doi":4511},"10.1161\u002F01.CIR.80.3.458",{"id":26,"text":4513,"url":26,"identifiers":4514},"Gilani M, Kaiser DR, Bratelli CW, et al.: Role of nitric oxide deficiency and its detection as a risk factor for prehypertension. J Am Soc Hypertens 2007, In press.",{"doi":4515},"10.1016\u002Fj.jash.2006.11.002",{"id":26,"text":4517,"url":26,"identifiers":4518},"Nigam A, Mitchell GF, Lambert J, Tardif JC: Relation between conduit vessel stiffness (assessed by tonometry) and endothelial function (assessed by flow-mediated dilatation) in patients with and without coronary heart disease. Am J Cardiol 2003, 92:395–399.",{"doi":4519},"10.1016\u002FS0002-9149(03)00656-8",{"id":26,"text":4521,"url":26,"identifiers":4522},"Cohn JN, Duprez DA, Grandits GA: Arterial elasticity as part of a comprehensive assessment of cardiovascular risk and drug treatment. Hypertension 2005, 46:217–220.",{"doi":4523},"10.1161\u002F01.HYP.0000165686.50890.c3",{"id":26,"text":4525,"url":26,"identifiers":4526},"Lind L, Fors N, Hall J, et al.: A comparison of three different methods to determine arterial compliance in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. J Hypertension 2006, 24:1083–1088.",{"doi":4527},"10.1097\u002F01.hjh.0000226198.44181.0c",{"id":26,"text":4529,"url":26,"identifiers":4530},"Nurnberger J, Keflioglu-Scheiber A, Opazo Saez AM, et al.: Augmentation index is associated with cardiovascular risk. J Hypertension 2002, 20:2407–2414.",{"doi":4531},"10.1097\u002F00004872-200212000-00020",{"id":26,"text":4533,"url":26,"identifiers":4534},"Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998, 19:1434–1503.",{"doi":4535},"10.1053\u002Feuhj.1998.1243",{"id":26,"text":4537,"url":26,"identifiers":4538},"Simons PC, Algra A, Bots ML, et al.: Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial disease). Circulation 1999, 100:951–957.",{"doi":4539},"10.1161\u002F01.CIR.100.9.951",{"id":26,"text":4541,"url":26,"identifiers":4542},"Hoes AW, Grobbee DE, Valkenburg HA, et al.: Cardiovascular risk and all-cause mortality; a 12 year follow-up study in The Netherlands. Eur J Epidemiol 1993, 9:285–292.",{"doi":4543},"10.1007\u002FBF00146265",{"id":26,"text":4545,"url":26,"identifiers":4546},"Van Trijp MJ, Uiterwaal CS, Bos WJ, et al.: Noninvasive arterial measurements of vascular damage in healthy young adults: relation to coronary heart disease risk. Ann Epidemiol 2006, 16:71–77.",{"doi":4547},"10.1016\u002Fj.annepidem.2005.09.005",{"id":26,"text":4549,"url":26,"identifiers":4550},"Kelly RP, Tunin R, Kass DA: Effect of reduced aortic compliance on cardiac efficiency and contractile function of in situ canine left ventricle. Circ Res 1992, 71:490–502.",{"doi":4551},"10.1161\u002F01.RES.71.3.490",{"id":26,"text":4553,"url":26,"identifiers":4554},"Watanabe H, Ohtsuka S, Kakihana M, Sugishita Y: Coronary circulation in dogs with an experimental decrease in aortic compliance. J Am Coll Cardiol 1993, 21:1497–1506.",{"doi":4555},"10.1016\u002F0735-1097(93)90330-4",{"id":26,"text":4557,"url":26,"identifiers":4558},"Kass DA, Saeki A, Tunin RS, Recchia FA: Adverse influence of systemic vascular stiffening on cardiac dysfunction and adaptation to acute coronary occlusion. Circulation 1996, 93:1533–1541.",{"doi":4559},"10.1161\u002F01.CIR.93.8.1533",{"id":26,"text":4561,"url":26,"identifiers":4562},"Kingwell BA, Waddell TK, Medley TL, et al.: Large artery stiffness predicts ischemic threshold in patients with coronary artery disease. J Am Coll Cardiol 2002, 40:773–779.",{"doi":4563},"10.1016\u002FS0735-1097(02)02009-0",{"id":26,"text":4565,"url":26,"identifiers":4566},"Domanski MJ, Sutton-Tyrrell K, Mitchell GF, et al.: Determinants and prognostic information provided by pulse pressure in patients with coronary artery disease undergoing revascularization. The Balloon Angioplasty Revascularization Trial (BARI). Am J Cardiol 2001, 87:675–679.",{"doi":4567},"10.1016\u002FS0002-9149(00)01482-X",{"id":26,"text":4569,"url":26,"identifiers":4570},"Nakayama Y, Tsumura K, Yamashita N, et al.: Pulsatility of the ascending aortic pressure waveform is a powerful predictor of restenosis after percutaneous transluminal coronary angioplasty. Circulation 2000, 101:470–472.",{"doi":4571},"10.1161\u002F01.CIR.101.5.470",{"id":26,"text":4573,"url":26,"identifiers":4574},"Ueda H, Nakayama Y, Tsumura K, et al.: Inflection point of ascending aortic waveform is a powerful predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Hypertens 2002, 15:823–826.",{"doi":4575},"10.1016\u002FS0895-7061(02)02981-3",{"id":26,"text":4577,"url":26,"identifiers":4578},"Weber T, Auer J, O’Rourke MF, et al.: Increased arterial wave reflections predict severe cardiovascular events in patients undergoing percutaneous coronary interventions. Eur Heart J 2005, 26:2657–2663.",{"doi":4579},"10.1093\u002Feurheartj\u002Fehi504",{"id":26,"text":4581,"url":26,"identifiers":4582},"Chirinos JA, Zambrano JP, Chakko S, et al.: Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. Hypertension 2005, 45:980–985.",{"doi":4583},"10.1161\u002F01.HYP.0000165025.16381.44",{"id":26,"text":4585,"url":26,"identifiers":4586},"Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al.: Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006, 113:664–670.",{"doi":4587},"10.1161\u002FCIRCULATIONAHA.105.579342",{"id":26,"text":4589,"url":26,"identifiers":4590},"Shokawa T, Imazu M, Yamamoto H, et al.: Pulse wave velocity predicts cardiovascular mortality: findings from the Hawaii-Los Angeles-Hiroshima study. Circ J 2005, 69:259–264.",{"doi":4591},"10.1253\u002Fcircj.69.259",{"id":26,"text":4593,"url":26,"identifiers":4594},"Mattace-Raso FU, van der Cammen TJ, Hofman A, et al.: Arterial stiffness and risk of coronary heart disease and stroke. The Rotterdam Study. Circulation 2006, 113:657–663.",{"doi":4595},"10.1161\u002FCIRCULATIONAHA.105.555235",{"id":26,"text":4597,"url":26,"identifiers":4598},"Sutton-Tyrrell K, Najjar SS, Boudreau RM, et al.: Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005, 111:3384–3390.",{"doi":4599},"10.1161\u002FCIRCULATIONAHA.104.483628",{"id":26,"text":4601,"url":26,"identifiers":4602},"Meaume S, Benetos A, Henry OF, et al.: Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol 2001, 21:2046–2050.",{"doi":4603},"10.1161\u002Fhq1201.100226",{"id":26,"text":4605,"url":26,"identifiers":4606},"Stefanadis C, Dernellis J, Tsiamis E, et al.: Aortic stiffness as a risk factor for recurrent acute coronary events in patients with ischaemic heart disease. Eur Heart J 2000, 21:390–396.",{"doi":4607},"10.1053\u002Feuhj.1999.1756",{"id":26,"text":4609,"url":26,"identifiers":4610},"Laurent S, Boutouyrie P, Asmar R, et al.: Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001, 37:1236–1241.",{"doi":4611},"10.1161\u002F01.HYP.37.5.1236",{"id":26,"text":4613,"url":26,"identifiers":4614},"Boutouyrie P, Tropeano AI, Asmar R, et al.: Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002, 39:10–15.",{"doi":4615},"10.1161\u002Fhy0102.099031",{"id":26,"text":4617,"url":26,"identifiers":4618},"Laurent S, Katsahian S, Fassot C, et al.: Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003, 34:1203–1206.",{"doi":4619},"10.1161\u002F01.STR.0000065428.03209.64",{"id":26,"text":4621,"url":26,"identifiers":4622},"Williams B, Lacy PS, Thom SM, et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113:1213–1225.",{"doi":4623},"10.1161\u002FCIRCULATIONAHA.105.606962",{"id":26,"text":4625,"url":26,"identifiers":4626},"Cruickshank K, Riste L, Anderson SG, et al.: Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002, 106:2085–2090.",{"doi":4627},"10.1161\u002F01.CIR.0000033824.02722.F7",{"id":26,"text":4629,"url":26,"identifiers":4630},"Blacher J, Guerin AP, Pannier B, et al.: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999, 99:2434–2439.",{"doi":4631},"10.1161\u002F01.CIR.99.18.2434",{"id":26,"text":4633,"url":26,"identifiers":4634},"Shoji T, Emoto M, Shinohara K, et al.: Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001, 12:2117–2124.",{"doi":4635},"10.1681\u002FASN.V12102117",{"id":26,"text":4637,"url":26,"identifiers":4638},"Safar ME, Blacher J, Pannier B, et al.: Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002, 39:735–738.",{"doi":4639},"10.1161\u002Fhy0202.098325",{"id":26,"text":4641,"url":26,"identifiers":4642},"London GM, Blacher J, Pannier B, et al.: Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001, 38:434–438.",{"doi":4643},"10.1161\u002F01.HYP.38.3.434",{"id":26,"text":4645,"url":26,"identifiers":4646},"Grey E, Bratteli C, Glasser SP, et al.: Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. Am J Hypertension 2003, 16:265–269.",{"doi":4647},"10.1016\u002FS0895-7061(02)03271-5",{"id":26,"text":4649,"url":26,"identifiers":4650},"Blacher J, Pannier B, Guerin AP, et al.: Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998, 32:570–574.",{"doi":4651},"10.1161\u002F01.HYP.32.3.570",{"id":26,"text":4653,"url":26,"identifiers":4654},"Barenbrock M, Kosch M, Joster E, et al.: Reduced arterial distensibility is a predictor of cardiovascular disease in patients after renal transplantation. J Hypertens 2002, 20:79–84.",{"doi":4655},"10.1097\u002F00004872-200201000-00012",{"id":26,"text":4657,"url":26,"identifiers":4658},"Dijk JM, Algra A, van der Graaf Y, et al.; SMART study group: Carotid stiffness and the risk of new vascular events in patients with manifest cardiovascular disease. The SMART study. Eur Heart J 2005, 26:1213–1220.",{"doi":4659},"10.1093\u002Feurheartj\u002Fehi254",{"id":26,"text":4661,"url":26,"identifiers":4662},"Dart AM, Gatzka CD, Kingwell BA, et al.: Brachial blood pressure but not carotid arterial waveforms predict cardiovascular events in elderly female hypertensives. Hypertension 2006, 47:785–790.",{"doi":4663},"10.1161\u002F01.HYP.0000209340.33592.50",{"id":26,"text":4665,"url":26,"identifiers":4666},"Guerin AP, Blacher J, Pannier B, et al.: Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001, 103:987–992.",{"doi":4667},"10.1161\u002F01.CIR.103.7.987"]